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General introduction and aim of the thesis 
In the last decade, the European Commission implemented the REACH 
(Registration, Evaluation, Authorization and restriction of CHemicals) legislation, 
aiming at greater protection of human health and the environment towards the 
adverse eﬀects of industrial chemicals. This REACH legislation aims at the 
harmonization of the testing requirements for so‐called ‘existing’ and ‘new’ 
chemicals, the latter being the chemicals that have been marketed after a change in 
legislation in 1981 (Grindon and Combes, 2006). Since for many of these chemicals 
toxicity data are lacking, the implementation of the REACH legislation will require 
the generation of toxicity data for a large number of chemicals. Currently, these 
toxicity data originate from studies performed with laboratory animals, although 
the REACH legislation stresses the importance of the use of alternative testing 
strategies. It has been estimated that the number of laboratory animals required for 
REACH would amount to 3.9 million if the use of alternative methods would not be 
accepted by regulatory authorities (Van der Jagt et al., 2004). In addition, it was 
estimated that with the expected acceptance scenario for alternative approaches, 
the total number would amount to 2.6 million. Furthermore, it was calculated that 
the majority of the animals will be used for the endpoints developmental toxicity 
(26% of total) and reproduction toxicity (37% of total) (Van der Jagt et al., 2004). 
The developmental and reproductive toxicity testing requirements for chemicals 
under REACH depend on the chemical tonnage levels manufactured or imported in 
the European Union. At tonnage levels of ≥10 metric tons per year, toxicity testing 
according to OECD (Organisation for Economic Co‐operation and Development) 
test guideline 421, describing a reproductive/developmental toxicity screening test 
or 422, describing a combined repeated dose toxicity study with reproductive/
developmental component, should be performed (Scialli, 2008). For the higher 
tonnage levels (≥100 and ≥1000 metric tons per year), data from toxicity studies 
according to OECD test guideline 414, describing a prenatal developmental toxicity 
test, in one or two species are required. Furthermore, a two‐generation 
reproductive toxicity study (not identified by OECD test guideline number in 
REACH, but corresponding to OECD test guideline 416) in one species is required 
at these high tonnage levels. For chemicals manufactured or imported at tonnage 
levels of ≥100 metric tons per year, this study is only required if a 28‐day or 90‐day 
Chapter 1 
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study indicates adverse eﬀects on reproductive organs (Scialli, 2008). According to 
the estimations of Höfer et al. (2004) the total numbers of animals needed for 
REACH would be more than the double amount estimated by Van der Jagt et al. 
(2004) when taking the oﬀspring into account that is produced during these 
developmental toxicity studies. Not only for REACH chemicals, but also for 
pharmaceuticals, food additives and pesticides, regulatory agencies require safety 
studies performed in laboratory animals, including developmental toxicity studies. 
Therefore, the development, validation and application of reliable alternative 
assays for in vivo developmental toxicity studies are urgently needed in the safety 
assessments of REACH chemicals, pharmaceuticals, food additives and pesticides, 
contributing to the replacement, reduction and refinement (3Rs) of animal use in 
toxicological research.  
Several in vitro assays have been reported for developmental toxicity, which may 
be useful in alternative testing strategies for in vivo developmental toxicity studies 
currently carried out in rats and rabbits. In these assays, isolated cells, tissues or 
whole embryos are cultured and exposed to the chemical of interest at increasing 
concentrations, after which the chemical‐induced eﬀects are assessed. The eﬀects 
can be diverse, varying for example from gene or protein expression changes to 
morphological changes. The in vitro developmental toxicity assays reported in the 
literature are described in more detail in chapter 2 of the present thesis. Based on 
the outcomes of the in vitro assays, it is estimated whether developmental toxicity 
will be expected to occur in vivo. 
The translation of in vitro toxicity data into relevant data for the in vivo situation 
is not straightforward. One of the diﬀerences between in vitro and in vivo toxicity 
assays, is that in in vitro assays, concentration‐response curves are obtained, 
whereas in in vivo assays, dose‐response curves are obtained. These dose‐response 
curves are needed in toxicological risk assessment, to set a point of departure to 
derive safe exposure levels for humans. Therefore, in order to use in vitro toxicity 
data for risk assessment, concentration‐response curves obtained in vitro need to 
be translated into in vivo dose‐response curves (Blaauboer, 2010). This translation 
of in vitro concentration‐response curves into in vivo dose‐response curves is at 
present an important bottleneck and challenge for the use of in vitro toxicity assays 
in risk assessment practice. In theory, the translation of in vitro toxicity 
General introduction 
10 
 
concentrations into in vivo doses may be achieved using physiologically based 
kinetic (PBK) modeling using a reverse dosimetry approach (DeJongh et al., 1999; 
Verwei et al., 2006; Forsby and Blaauboer, 2007).  
A PBK model is a set of mathematical equations that together describe the 
absorption, distribution, metabolism and excretion (ADME) characteristics of a 
chemical within an organism on the basis of physiological and anatomical 
parameters, physico‐chemical parameters and kinetic parameters (Krishnan and 
Andersen, 2001). PBK models describe the fate of the chemical (and its metabolite
(s)) in the body in time after a certain dose of the chemical via a certain exposure 
route (e.g. oral or dermal) in a certain species (e.g. rat or human). PBK models can 
be used to translate external dose levels of a chemical into internal blood or tissue 
concentrations of the chemical (and its metabolite(s)). Furthermore, PBK models 
can also be used the other way around, called reverse dosimetry, by translating 
internal blood or tissue concentrations of a chemical (and/or its metabolite(s)) into 
external dose levels of the chemical. Reverse dosimetry is illustrated in Figure 1 
showing a hypothetical example of this approach. In this example a concentration‐
response curve obtained in an in vitro toxicity assay is set as internal 
concentrations in the PBK model (in blood in this case), followed by the 
calculation of the doses needed to reach these internal concentrations using the 
PBK model, resulting in a predicted dose‐response curve for a toxicological 
endpoint.  
The reverse dosimetry approach has been used to translate a single in vitro eﬀect 
concentration (e.g. an EC50 value) into a single in vivo eﬀect dose (e.g. a lowest 
observed adverse eﬀect level (LOAEL)) (DeJongh et al., 1999; Verwei et al., 2006; 
Forsby and Blaauboer, 2007). However, the in vitro eﬀect concentrations and the in 
vivo eﬀect doses were chosen arbitrarily in previous reverse dosimetry work. In 
theory, a complete concentration‐response curve obtained in an in vitro assay 
could be translated into a complete predicted in vivo dose‐response curve, by 
translating all data obtained in the in vitro experiment to the in vivo situation. This 
would enable dose‐response modeling on the predicted in vivo dose‐response data, 
defining a predicted in vivo dose‐response curve, which could be used in the risk 
assessment process to set a point of departure to derive safe exposure levels. 
The aim of the present thesis is to provide the proof‐of‐principle that in vitro 
Chapter 1 
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Figure 1. Example of the reverse dosimetry approach in which an in vivo dose‐response curve 
is predicted for a certain (toxic) endpoint by setting the concentrations of an in vitro 
concentration‐response curve as internal blood concentrations, followed by the calculation 
of the doses needed to reach these internal concentrations using the PBK model. The closed 
symbols represent the data obtained in the in vitro assay (hypothetical data), whereas the 
open symbols represent data from in vivo toxicity studies (hypothetical data), which are used 
to evaluate whether the approach reliably predicts in vivo dose‐response curves. 
liver 
rapidly perfused tissue 
slowly perfused tissue 
fat 
blood 
GI-tract 
oral uptake 
metabolites 
General introduction 
input: in vitro  
concentration-response curve 
output: predicted  
in vivo dose-response curve 
12 
 
concentration‐response curves can be converted into in vivo dose‐response curves 
suitable for risk assessment practice, using PBK modeling as a tool to apply reverse 
dosimetry. The toxicological endpoint for which this proof‐of‐principle will be 
developed is developmental toxicity, because, as outlined above, this type of 
toxicity studies is estimated to require more than one fourth of the animals 
expected to be needed under the REACH legislation. This indicates that reliable 
alternatives for this endpoint would contribute significantly to the 3Rs of animal 
use. The following sections introduce three important factors needed in this study, 
which include 1) an in vitro model to obtain in vitro concentration‐response curves 
for a developmental toxicity endpoint, 2) the selection of chemicals to be studied 
and 3) the development of the PBK models that accurately describe the in vivo 
kinetics, which are needed for reverse dosimetry. 
In vitro model to define in vitro concentration‐response curves for developmental 
toxicity  
An in vitro model is needed that can be used to determine relevant in vitro 
concentration‐response curves to be translated into in vivo dose‐response curves 
for developmental toxicity. The in vitro developmental toxicity assays including 
their readouts reported in the literature are described in more detail in chapter 2 of 
the present thesis. The in vitro assay that was chosen for the studies in the present 
thesis is the embryonic stem cell (ES‐D3 cell) diﬀerentiation assay of the embryonic 
stem cell test (EST). The EST is the only validated in vitro developmental toxicity 
assay that does not require primary animal tissues (Genschow et al., 2002; 
Genschow et al., 2004). The implementation of this assay, when proven to provide 
reliable outcomes in an alternative testing strategy, would therefore result in the 
largest decrease of animal use. Further information on the EST is presented in 
chapter 2. 
Selection of the chemicals to be studied 
The chemicals to be studied in this proof‐of‐principle study needed to fulfill two 
criteria. These criteria were 1) the presence of in vivo kinetic data on the chemical 
in the literature, in order to be able to build and/or evaluate the PBK models 
developed and used for reverse dosimetry and 2) the presence of in vivo 
developmental toxicity data of the chemical in the literature, in order to evaluate 
Chapter 1 
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whether the ultimately predicted dose‐response curves for developmental toxicity 
are in concordance with data obtained in in vivo developmental toxicity studies. 
To select chemicals to be studied in the present thesis, chemicals reported to 
cause in vivo developmental toxicity were assessed for the two above mentioned 
criteria. These chemicals were obtained from the following sources: 1) chemicals 
already used in validation studies of in vitro developmental toxicity assays of the 
European Centre for the Validation of Alternative Methods (ECVAM) (Genschow et 
al., 2002; Genschow et al., 2004; Piersma et al., 2004; Spielmann et al., 2004), 2) a 
list of chemicals developed to be used for such validation studies (Brown et al., 
2002), 3) a list of chemicals developed for the European Framework Program 
project ReProTect which aimed at the development of in vitro test systems for 
reproduction toxicity and developmental toxicity (Pazos et al., 2010) and 4) the 
‘Niet‐limitatieve lijst reprotoxische stoﬀen’ (‘Non‐restrictive list of reproductive 
toxicants’) of the Dutch Ministry of Social Aﬀairs and Employment (Staatscourant, 
2001). The chemicals of these four sources fulfilling the two criteria in order to be 
possibly included in the present thesis are listed in Table 1. When possible, the 
chemicals were grouped in chemical categories sharing structural similarities. From 
this list of chemicals that were appropriate for this proof‐of‐principle study, only 
series of structurally related chemicals were selected. This third criterion enabled 
the assessment of relative diﬀerences within a series of chemicals, thereby 
providing an additional possibility for qualitative evaluation of the predictions 
made. Two series of model compounds were selected, being 1) a group of glycol 
ethers (Figure 2), which need to be bioactivated in order to cause developmental 
toxicity, which are hydrophilic, show low protein binding and have an unspecific 
mode of action and 2) a group of retinoids (Figure 3), containing several members 
that directly act as teratogens without bioactivation, which are hydrophobic, show 
high protein binding and have a specific mode of action. 
Glycol ethers 
Glycol mono‐ethers contain both an ether and an alcohol group, making them 
widely applicable as solvents in cosmetics, printing inks, plastics, household and 
industrial cleaning products and textile dyes. Non‐solvent applications include 
their use as anti‐icing agents in jet fuel and as hydraulic system fluids. Most glycol 
ethers are of low acute toxicity. Glycol ethers are neither genotoxic nor 
General introduction 
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Table 1. Selection of chemicals that are appropriate for the proof‐of‐principle study fulfilling 
the two criteria defined, being 1) the presence of in vivo kinetic data on the chemical in the 
literature, in order to be able to build and/or evaluate the PBK models developed and used 
for reverse dosimetry and 2) the presence of in vivo developmental toxicity data of the 
chemical in the literature, in order to evaluate whether the ultimately predicted dose‐
response curves for developmental toxicity are in concordance with data obtained in in vivo 
developmental toxicity studies. 
carcinogenic (ECETOC, 2005). The short chain ethylene based glycol ethers 
ethylene glycol monomethyl ether (EGME) and ethylene glycol monoethyl ether 
(EGEE) induce systemic toxicity after biotransformation to their alkoxyacetic acid 
metabolites, methoxyacetic acid (MAA) and ethoxyacetic acid (EAA) respectively 
(ECETOC, 2005; Brown et al., 1984; Giavini et al., 1993). MAA and EAA have been 
shown to induce bone marrow depression, testicular atrophy, immunotoxicity and 
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Figure 2. Chemical structures of glycol ethers and their alkoxyacetic acid metabolites studied 
in the present thesis. EGME: ethylene glycol monomethyl ether, EGEE: ethylene glycol 
monoethyl ether, EGBE: ethylene glycol monobutyl ether, EGPE: ethylene glycol 
monophenyl ether, MAA: methoxyacetic acid, EAA: ethoxyacetic acid, BAA: butoxyacetic 
acid, PAA: phenoxyacetic acid. 
developmental toxicity in animals (ECETOC, 2005; Feuston et al., 1990; Hanley et 
al., 1984; Nagano et al., 1981; Wier et al., 1987). The longer chain ethylene based 
glycol ethers ethylene glycol monobutyl ether (EGBE) and ethylene glycol 
monophenyl ether (EGPE) cause red blood cell haemolysis in rat, induced by their 
alkoxyacetic acid metabolites butoxyacetic acid (BAA) and phenoxyacetic acid 
(PAA), respectively (ECETOC, 2005).  
Retinoids 
Chemicals that possess a chemical structure or have functional properties similar 
to retinol (vitamin A) are called retinoids (Figure 3). Retinol is required for 
physiological processes such as vision, reproduction, growth, cell diﬀerentiation, 
immune function and embryonic development (Collins and Mao, 1999). Most of 
the biological activities of the retinoids are believed to be mediated by various 
nuclear receptors of the steroid, thyroid, vitamin D and retinoid superfamily of 
receptors (Collins and Mao, 1999). The most studied retinoid receptors include two 
types of ligand‐dependent transcription factors, the retinoic acid receptors (RARs) 
and the retinoid X receptors (RXRs), existing in diﬀerent subtypes and isoforms. In 
general, the activity of retinoids is mediated by RAR‐RXR heterodimers. For a 
proper physiological function, people require a certain amount of retinol, taken up 
via the diet. Retinol deficiency can lead to xerophthalmia, immunodeficiency and 
weight loss, whereas excessive retinol levels cause toxicity to the central nervous 
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system, liver, bone and skin (Collins and Mao, 1999). Proper levels of vitamin A 
must be maintained for normal embryogenesis. Vitamin A deficiency and high 
retinoid intake induce adverse eﬀects to the developing conceptus (Collins and 
Mao, 1999). People may also be exposed to retinoids via medication. The natural 
retinoids all‐trans‐retinoic acid (ATRA), 13‐cis‐retinoic acid (13‐cis‐RA) and 9‐cis‐
retinoic acid (9‐cis‐RA) are used against acute promyolocytic leukemia (Tallman et 
al., 1997), cystic acne (Kanigsberg and Desgroseilliers, 1983) and Kaposi sarcoma 
(Washenik et al., 2000) respectively, whereas the synthetic retinoids etretinate and 
acitretin are used against psoriasis (Gollnick et al., 1988). These retinoids have been 
shown to be teratogenic in a number of experimental animals, including mice, rats, 
guinea pigs, hamsters, rabbits, dogs, pigs, chickens and monkeys (Collins and Mao, 
1999).  
Development of PBK models  
In order to translate the in vitro concentration‐response curves obtained in the 
ES‐D3 cell diﬀerentiation assay into in vivo dose‐response curves with reverse 
dosimetry, PBK models describing the ADME processes of the chemical of interest 
Chapter 1 
COOH
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Figure 3. Chemical structures of retinoids studied in the present thesis. ATRA: all‐trans‐
retinoic acid, 13‐cis‐RA: 13‐cis‐retinoic acid, 9‐cis‐RA: 9‐cis‐retinoic acid, TTNPB: (E)‐4[2‐
(5,6,7,8‐tetrahydro‐5,5,8,8‐tetramethyl‐2‐naphthalenyl)‐1‐propenyl]benzoic acid. 
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need to be developed. In a tutorial on PBK modeling in molecular nutrition and 
food research, the process of PBK model development has recently been explained 
(Rietjens et al., 2011). The development of a PBK model can be divided in the 
following steps: 1) definition of a conceptual model, 2) translation of the conceptual 
model into a mathematical model by defining mathematical equations, 3) 
obtaining model parameter values, 4) solving the mathematical equations using 
appropriate software and 5) evaluation of model performance. Subsequently the 
PBK model can be applied to make predictions (step 6), such as predictions of 
interspecies diﬀerences in kinetics, enabling extrapolation of animal data to 
humans. The PBK model can also be used for reverse dosimetry, translating in vitro 
concentrations into in vivo doses, as was the application of PBK modeling in the 
present thesis. The six steps are described in more detail in the following sections.  
Step 1: Defining a conceptual model: the basic structure of a PBK model 
The basic structure of a PBK model assumes that an intact organism can be 
described as a set of basic compartments. In a PBK model these basic 
compartments can each be depicted as a single box. In the standard PBK modeling 
approach, it is assumed, as a generally accepted simplification, that a compartment 
is a single region of the body with a uniform chemical concentration. However, 
models using non‐homogenous chemical distribution in compartments exist as 
well. These compartments may be a particular functional or anatomical portion of 
an organ, a single blood vessel with surrounding tissue, an entire discrete organ 
such as the liver or kidney, or a widely distributed tissue type such as fat or skin. As 
a first step in developing a chemical‐specific PBK model one has to decide which 
organs are relevant for the ADME characteristics of that chemical and its biological 
eﬀects. These compartments need to be specifically described, whereas all other 
organs can be lumped together in either a slowly or richly perfused tissue 
compartment. A reason to include a specific organ can be that this organ 
represents the site of uptake or elimination, a major site of metabolism or a target 
organ for the beneficial or adverse eﬀect of the chemical of interest. However, if no 
or little data on the in vivo kinetics of the chemical itself or a structurally related 
chemical is available, one cannot choose beforehand which organs will be relevant 
for the in vivo AMDE characteristics. In that case, a generic PBK model may be 
used, which describes the kinetic processes in all organs of the body using default 
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descriptions of compartments and kinetic processes. To make these generic models 
chemical‐specific, kinetic parameter values for the chemical of interest need to be 
determined (step 3). 
Step 2: Translation of the conceptual model into a mathematical model by defining 
mathematical equations 
The second step in PBK modeling is the translation of the conceptual model into 
a mathematical model, describing the kinetic processes in each compartment by 
diﬀerential equations. As an example, the kinetic processes of a certain chemical in 
the liver can be described as: 
dAL/dt = kuptake * AGI(t) 
  + QL * (CB – CL/PL) 
  ‐ Vmax * CL/PL / (Km + CL/PL) 
This equation describes that the change in the amount of the chemical (A) in the 
liver (L) in time (t), represented as dAL/dt, is a function of 1) the uptake of the 
chemical from the gastrointestinal tract directly into the liver, 2) the exchange of 
the chemical between blood and the liver and 3) the conversion of the chemical 
into its metabolite(s) due to biotransformation. The uptake from the 
gastrointestinal tract can be described by a first‐order process, assuming passive 
absorption from the gastrointestinal tract to the liver compartment. This implies 
that uptake can be described by kuptake * AGI(t), with kuptake (in h‐1) representing the 
first‐order absorption rate constant and AGI(t) (in mol) being the amount of 
chemical remaining at a certain time point in the gastrointestinal tract, with AGI at 
time = 0 being equal to the oral dose. The exchange of the chemical between liver 
tissue and blood, equals the blood flow rate to the liver (QL in L/h) times the 
diﬀerence in chemical concentration between the blood entering the liver (CB) and 
the blood leaving the liver (CVL); thus QL(CB ‐ CVL), assuming a perfusion‐limited 
and not a diﬀusion‐limited process (Krishnan and Andersen, 2001). This implies 
that the exchange of the chemical between liver tissue and blood are dominated by 
blood flow (perfusion) of the liver and not by diﬀusion. This equation is based on 
Fick’s law of simple diﬀusion (dCt/dt = k*dC), which states that the flux of a 
chemical is proportional to its concentration gradient (Krishnan and Andersen, 
2001). Assuming equilibrium between the chemical concentration in the blood 
Chapter 1 
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leaving the liver (CVL) and the blood concentration of the chemical in the liver 
(not bound to liver tissue), CVL in the equation equals CL/PL, with CL 
representing the total chemical concentration in the liver (bound and not bound to 
liver tissue; in mol/L) and PL representing the liver:blood partition coeﬃcient of 
the chemical (Krewski et al., 1994; Krishnan and Andersen, 2001; Clewell and 
Clewell, 2008). The metabolic conversion of the chemical in the liver can be 
modeled by a Michaelis‐Menten equation leading to a contribution equal to ‐ Vmax 
* CL/PL / (Km + CL/PL) with the negative sign reflecting that this contribution 
results in a decrease in the amount of the chemical in the liver and Vmax and Km 
representing the maximum rate and Michaelis–Menten constant for metabolism, 
respectively. The Michaelis–Menten equation expresses the concentration of the 
chemical in the liver as CL/PL, corresponding to the concentration of the chemical 
in the liver that is not bound to liver tissue, being available for metabolism. 
If an available generic PBK model is used as starting‐point for the PBK model 
development for the chemical(s) of interest, the mathematical equations describing 
the kinetic processes in the compartments do not have to be defined (step 2). In 
that case, one can immediately start with obtaining the model parameter values 
(step 3). 
Step 3: Obtaining the model parameter values 
In step 2, based on the basic structure of the PBK model, a set of mathematical 
equations is defined, one set for each compartment. For the further development of 
a PBK model for the chemical(s) of interest, in the next step model parameter 
values need to be obtained. The required model parameter values include values 
for 1) physiological and anatomical parameters (e.g. cardiac output, tissue volumes 
and tissue blood flows), 2) physicochemical parameters (e.g. tissue:blood partition 
coeﬃcients) and 3) other kinetic parameters (e.g. kinetic constants for transport as 
well as for biotransformation reactions of the chemical and/or its metabolites) 
(Krewski et al., 1994; Krishnan and Andersen, 2001; Clewell and Clewell, 2008). The 
values for physiological and anatomical parameters of a species can be obtained 
from the literature. Representative reference physiological parameter values for 
diﬀerent laboratory animals as well as humans can, for instance, be obtained from 
Brown et al. (1997). Physicochemical parameter values (i.e. partition coeﬃcients, 
needed to describe the distribution of the chemical over the body compartments) 
General introduction 
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may be obtained using in vivo data on chemical concentrations in blood and tissues 
of animals exposed to the chemical, or by using in vitro techniques (Gargas et al., 
1989; Artola‐Garicano et al., 2000). Also several in silico tools are described in the 
literature to estimate partition coeﬃcients, based on physicochemical properties 
such as the chemical’s LogP value (DeJongh et al., 1997; Poulin and Theil, 2002; 
Berezhkovskiy, 2004). Values for kinetic parameters to describe absorption, 
metabolism and excretion are often estimated using in vivo kinetic data, by 
choosing these parameter values in such a way that the PBK model predictions fit 
the available in vivo kinetic datasets. However, these parameter values may also be 
obtained using in vitro techniques, such as in vitro incubations with liver enzymes 
in order to determine parameter values for metabolism (Clewell, 1993; Punt et al., 
2009). To limit the use of animals in PBK model development, in vitro and in silico 
approaches are preferred to determine PBK model parameter values. 
Step 4: Solving the mathematical equations using appropriate software 
When the mathematical model has been defined and the parameter values have 
been obtained, the next step involves solving the mass‐balance diﬀerential 
equations and making simulations. Diﬀerent software packages are available for 
the numerical integration of the ordinary diﬀerential equations of the PBK model, 
such as Berkeley Madonna (Macey and Oster, UC Berkeley, CA, USA), acslXtreme 
(AEgis Technologies Group) and MATLAB (The MathWorks). Integration 
algorithms that can be applied are, for instance, the Gear algorithm or Rosenbrock 
algorithm, which are both capable of handling ‘‘stiﬀ’’ sets of diﬀerential equations, 
which most PBK models are (Chiu et al. 2007). 
Step 5: Evaluation of model performance 
When the diﬀerential equations have been solved, thereby calculating the 
concentrations of the chemical and its metabolites in the diﬀerent compartments 
over time, subsequently the evaluation of the model performance against 
experimental in vivo kinetic data needs to be performed. This is important to test 
the validity of the model and thus the reliability of subsequent predictions. 
Furthermore, discrepancies between the model predictions and the experimental 
data may be informative and may for example indicate that an important kinetic 
process has been overlooked or its model parameter value imprecisely incorporated 
Chapter 1 
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in the model. If such situations are encountered, the nature of the discrepancies 
may indicate a new hypothesis and improvements for the model. In case a PBK 
model is developed for a new chemical for which no or limited in vivo kinetic data 
are available, this evaluation cannot be performed. In that case, one should take 
into account that the model predictions may be less certain. 
The evaluation step also includes a sensitivity analysis. This analysis provides a 
quantitative evaluation of how the parameters of the model influence the model 
output. A typical way of performing a sensitivity analysis is the central diﬀerence 
method, which compares the magnitude in model output due to a defined change 
in input parameters. In general, input parameters are changed with 1 or 5%, with 
each parameter being analyzed individually, keeping the other parameters to their 
initial values. This analysis yields normalized sensitivity coeﬃcients that 
correspond to the ratio of change in simulation output (e.g. tissue concentration or 
formation of metabolites) to change in parameter value. A normalized sensitivity 
coeﬃcient of, for instance, 0.8 signifies that 1% change in the numerical value of 
the input parameter will result in 0.8% change in model output. The greater the 
absolute value of the normalized sensitivity coeﬃcient, the more influence the 
parameter has on the model output. The sign of the sensitivity ratio indicates 
whether the model output is directly or inversely related to the parameter. In a 
sensitivity analysis normalized sensitivity coeﬃcients are generally calculated for 
all parameters at selected dose levels, but only parameters that significantly 
influence the model output, having a sensitivity coeﬃcient of, for instance, higher 
than 0.1 in absolute value, are generally regarded as parameters that influence the 
model output to a significant extent (US EPA, 2006; Chiu et al., 2007). Based on the 
results of the sensitivity analysis, requirements to the accuracy of the parameter 
values can be set. 
Step 6: Application of PBK modeling in reverse dosimetry 
Once the performance of the model has been evaluated, simulations and 
predictions can be made. In the present thesis, PBK models were developed for 
reverse dosimetry in order to predict in vivo dose‐response curves for 
developmental toxicity by converting concentration‐response curves from the in 
vitro ES‐D3 cell diﬀerentiation assay into relevant in vivo dose‐response scenarios. 
With reverse dosimetry, the PBK model is used to translate internal blood or tissue 
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concentrations of a chemical (and/or its metabolite(s)) into external dose levels of 
the chemical, enabling in vitro‐in vivo extrapolations (Figure 1). With these in vitro‐
in vivo extrapolations using PBK modeling with reverse dosimetry, the following 
aspects should be considered: 1) the relation between the in vitro toxic eﬀect 
concentration and the predicted in vivo toxic eﬀect dose, 2) the determination of 
the dose metric used to relate exposure to toxicity and 3) diﬀerences in free 
fraction of the chemical in the in vitro assay compared with the in vivo situation. 
1) The relation between the in vitro toxic eﬀect concentration and the predicted in 
vivo toxic eﬀect dose 
With the translation of in vitro concentrations into in vivo doses, diﬀerent 
approaches can be used to relate an in vitro toxic eﬀect to the predicted in vivo 
toxic eﬀect. In previous work on predicting in vivo developmental toxicity by 
translating in vitro developmental toxicity data into in vivo dose levels with reverse 
dosimetry, developmental toxicity dose levels were predicted by translating EC50 
values of the ES‐D3 cell diﬀerentiation assay to the in vivo situation (Verwei et al., 
2006). The obtained predictions for in vivo developmental toxicity were related to 
LOAELs of the chemicals for developmental toxicity, as reported in the literature 
(Verwei et al., 2006). In the present thesis, not a single outcome (such as an EC50 
value) of the in vitro data is translated to the in vivo situation, but complete in vitro 
concentration‐response curves are translated into complete in vivo dose‐response 
curves. This enables the application of benchmark dose (BMD) modeling in the 
assessment of the data, taking into account all data of the in vitro concentration‐
response curve. The resulting predicted BMD values can then be compared with 
BMD values obtained from data on in vivo developmental toxicity reported in the 
literature, in order to evaluate the predictive value of the approach. 
The relation between the readout in the in vitro assay and the predicted in vivo 
eﬀect should be considered as well. In order to be useful to predict in vivo dose‐
response curves, the readout parameter (which is the inhibition of the 
diﬀerentiation of embryonic stem cells into functional cardiomyocytes in the 
present thesis) should be relevant and predictive for the in vivo toxicological 
endpoint (developmental toxicity). It is not intended in the present thesis to 
specifically predict dose levels aﬀecting cardiac development during embryonic 
development. The inhibition of cardiac diﬀerentiation is rather used to represent a 
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sensitive in vitro readout parameter for developmental toxicity (Genschow et al., 
2004), which in the ideal situation could represent the most sensitive in vivo 
developmental toxicity endpoint. 
2) The determination of the dose metric used to relate exposure to toxicity 
Toxic eﬀects of chemicals are related to chemical exposure. Generally, it is 
assumed that the toxic outcome of a chemical is dependent on either the maximal 
concentration (Cmax) to which the in vitro or in vivo system is exposed, or the area 
under the concentration‐time curve (AUC) of the chemical. The toxic eﬀect of 
glycol ethers can be related to the Cmax of the toxic alkoxyacetic acid metabolites 
(Sweeney et al., 2001), whereas the toxic eﬀects of retinoids can be better related to 
the AUC (Tzimas et al., 1997). This asks for diﬀerent reverse dosimetry approaches 
for these chemicals, which are discussed in the present thesis. 
3) Diﬀerences in free fraction of the chemical in the in vitro assay compared with the 
in vivo situation 
When the in vitro concentration‐response curves are set as internal 
concentrations in the PBK model to predict the accompanying in vivo dose levels, 
one must take into account that for some chemicals, the free concentration in the 
culture medium will be higher than the free concentration in the blood (or tissue) 
with equal nominal concentrations. This is the case for protein‐binding chemicals, 
because protein concentrations are higher in blood than in culture medium 
(Gülden et al., 2006; Blaauboer, 2010). Because it is assumed that the available free 
fraction of a chemical causes the toxicity, corrections have to be made to take these 
diﬀerences in availability into account. These corrections made in the present 
thesis in the translation of the in vitro eﬀect concentrations of the retinoid ATRA 
into in vivo doses provide an example of the importance of such a correction for 
protein binding. 
 
Outline of thesis 
In chapter 1 of the thesis, background information on the topic is given and the 
aim of the thesis is presented, being the provision of the proof‐of‐principle that in 
vitro concentration‐response curves can be converted into in vivo dose‐response 
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curves for developmental toxicity, suitable for risk assessment, using PBK modeling 
with a reverse dosimetry approach. To reach this aim, an in vitro model to obtain in 
vitro concentration‐response curves for developmental toxicity is needed, as well as 
the selection of the chemicals to be studied and the development of PBK models. 
Chapter 2 gives an overview of the in vitro assays and readouts for developmental 
toxicity reported in the literature, which could be useful for the reverse dosimetry 
approach to predict in vivo developmental toxicity. It describes how obtained in 
vitro developmental toxicity data may be used to predict in vivo developmental 
toxicity and which factors hamper these in vitro‐in vivo extrapolations. 
Chapters 3, 4 and 5 deal with the first series of chemicals used in the present 
thesis: the glycol ethers. These chemicals are known to cause developmental 
toxicity via their alkoxyacetic acid metabolites. First, in chapter 3 the mode of 
action of these metabolites is investigated by assessing whether developmental 
toxicity of glycol ethers may be caused by a reduction of the intracellular pH (pHi) 
induced by their alkoxyacetic acid metabolites. To this end, mouse embryonic 
fibroblasts (Balb/c‐3T3 cells) and mouse ES‐D3 cells are exposed to increasing 
concentrations of the alkoxyacetic acid metabolites MAA, EAA, BAA and PAA of 
the glycol ethers EGME, EGEE, EGBE and EGPE, respectively (Figure 2). The eﬀect 
concentrations decreasing the pHi are related to eﬀect concentrations inhibiting  
ES‐D3 cell diﬀerentiation and the eﬀect of amiloride, a selective inhibitor of the 
Na+/H+‐antiporter, on sensitivity of the cells to MAA is characterised, to assess 
whether the alkoxyacetic acid‐induced decrease in pHi may be the cause of their 
inhibition of embryonic stem cell diﬀerentiation. Chapter 4 presents the results of 
the exposure of diﬀerentiating ES‐D3 cells to MAA, EAA, BAA and PAA. It also 
compares the in vitro outcomes of these glycol ether alkoxyacetic acid metabolites 
with literature data on the in vivo outcomes of the respective parent glycol ethers 
obtained in mice. In chapter 5 the results are shown for the translation of the in 
vitro concentration‐response curves of MAA, EAA, BAA and PAA obtained in the 
ES‐D3 cell diﬀerentiation assay (Chapter 4) into in vivo dose‐response curves of the 
parent glycol ethers (EGME, EGEE, EGBE and EGPE respectively) in rat and 
human, using the reverse dosimetry approach. To provide the proof‐of principle 
that in vitro concentration‐response curves for developmental toxicity can be 
converted into dose‐response curves for in vivo developmental toxicity, predicted 
dose‐response curves for in vivo developmental toxicity in rats are compared with 
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literature data on glycol ether‐induced in vivo developmental toxicity in rats. 
In chapter 6 and 7 of the thesis, results for the second selected series of 
chemicals, the retinoids, are presented. In chapter 6, the concentration‐response 
curves for a group of retinoids (retinol, ATRA, 13‐cis‐RA, 9‐cis‐RA, acitretin, 
etretinate and TTNPB ((E)‐4[2‐(5,6,7,8‐tetrahydro‐5,5,8,8‐tetramethyl‐2‐
naphthalenyl)‐1‐propenyl]benzoic acid); Figure 3) in the ES‐D3 cell diﬀerentiation 
assay are presented. The outcomes of these studies are compared with literature 
data on concentration‐response eﬀects in two other in vitro assays for 
developmental toxicity (the limb bud micromass test and the rat post implantation 
whole embryo culture test). Furthermore, the outcomes obtained in the ES‐D3 cell 
diﬀerentiation assays are compared with literature data on dose‐response eﬀects of 
these retinoids obtained in rats, mice and rabbits in vivo. Moreover, it is 
investigated whether the retinoid‐induced inhibition of ES‐D3 cell diﬀerentiation is 
mediated via the nuclear retinoic acid receptors, which is the pathway proposed to 
be disturbed in retinoid‐induced developmental toxicity in vivo. In chapter 7 the in 
vitro concentration‐response curve of the retinoid ATRA obtained in the ES‐D3 cell 
diﬀerentiation assay (chapter 6) is translated into in vivo dose‐response curves of 
ATRA in rat and human, using the reverse dosimetry approach. The PBK model 
developed for ATRA is solely based on kinetic parameter values derived using in 
vitro techniques. To assess whether in vivo developmental toxicity could be 
predicted for this chemical with a relatively complex mode of action, using the 
reverse dosimetry approach, predicted dose‐response curves for in vivo 
developmental toxicity in rats are compared with literature data on ATRA‐induced 
in vivo developmental toxicity in rats. 
Finally, chapter 8 summarizes and discusses the results of the present thesis and 
provides future perspectives. It discusses possible implications of the use of the 
reverse dosimetry approach for toxicological risk assessment and gives directions 
for future research in the field. 
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Abstract 
Introduction: Reliable in vitro and in silico assays as alternatives for in vivo 
developmental toxicity studies are urgently needed, for the replacement, reduction 
and refinement (3Rs) of animal use in toxicological research. Therefore, relevant 
biomarkers for in vivo developmental toxicity in in vitro assays are needed. 
Areas covered: The present review gives an overview of alternative assays, as 
described in the literature, for in vivo developmental toxicity, including the eﬀects 
(readouts) assessed in these assays. It is discussed how these data may be used to 
obtain relevant biomarkers for in vivo developmental toxicity, and how in vitro 
eﬀect data can be translated to the in vivo situation using physiologically based 
kinetic (PBK) modeling. 
Expert opinion: Relevance of readouts in in vitro developmental toxicity assays as 
predictive biomarkers for in vivo developmental toxicity should be evaluated by 
comparing the obtained in vitro eﬀect concentrations with in vivo internal 
concentrations at dose levels causing developmental toxicity. Extrapolation of the 
in vitro eﬀect concentrations to in vivo dose levels using PBK modeling (i.e., reverse 
dosimetry) is promising in its use to set points of departure for risk assessment, 
enabling the use of in vitro toxicity data in the safety assessment of chemicals.
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Introduction 
For the registration and safe use of chemicals, information on safety is required. 
It is estimated that more than 25% of the 3.9 million laboratory animals expected 
to be needed for safety testing for industrial chemicals under the European REACH 
(Registration, Evaluation, Authorization and restriction of CHemicals) legislation 
will be used for developmental toxicity studies (Van der Jagt et al., 2004). Also for 
pharmaceuticals, food additives and pesticides, regulatory agencies require safety 
studies performed with laboratory animals, including developmental toxicity 
studies. The use of high numbers of laboratory animals for developmental toxicity 
testing in chemical safety assessment meets increasing ethical and economic 
constraints. Therefore, the development, validation and application of reliable in 
vitro and/or in silico assays as alternatives for in vivo developmental toxicity studies 
are urgently needed, contributing to the replacement, reduction and refinement 
(3Rs) of animal use in toxicological research. According to the test guidelines for 
developmental toxicity testing of the Organisation for Economic Co‐operation and 
Development (OECD guidelines 414, 421, 422 or 426), the preferred rodent and  
non‐rodent species for in vivo developmental toxicity testing are rat and rabbit, 
respectively. Several in vitro alternative assays for developmental toxicity testing 
have been developed, which may be useful in the early phase of drug discovery, in 
the development and early safety testing of new food additives and for setting 
priorities for toxicity testing of chemicals within the REACH framework. However, 
these assays are not capable yet of replacing or reducing the regulatory in vivo 
developmental toxicity studies. Consequently, a large number of laboratory 
animals are still needed for in vivo developmental toxicity testing.  
The present review gives an overview of the alternative test systems for 
developmental toxicity testing that have been described in the literature. It focuses 
on how the readouts of these in vitro assays may serve as predictive biomarkers for 
in vivo developmental toxicity and describes how the data obtained may be used to 
predict the potency of a chemical to induce developmental toxicity in vivo. 
 
Alternative assays for in vivo developmental toxicity testing 
Several in vitro and ex vivo assays have been described in the literature, which 
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evaluate the developmental toxicity potencies of chemicals. Assays have been 
developed to be able to predict developmental toxicity not only for a broad range 
of chemicals covering diverse developmental toxicity endpoints in vivo (e.g., the 
embryonic stem cell test (EST) and the rat postimplantation whole embryo culture 
(WEC) test), but also for chemicals aﬀecting specific phases of development, such 
as the development of the neuronal systems. Several readouts for developmental 
toxicity have been defined in these assays in order to obtain predictive biomarkers 
for the in vivo situation. The term ‘biomarker’ has been defined as ‘a characteristic 
that is objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention’ (Biomarkers definitions working group, 2001). Applying this 
definition specifically to toxicology, Stachlewitz (2007) came up with the definition 
of a biomarker as ‘something that can be objectively measured that will provide a 
reliable signal indicating the chemical being tested is about to have an adverse 
eﬀect on a system’. Identified biomarkers can, for example, range from the level of 
gene expression changes to morphological changes. Many readouts in in vitro 
assays for developmental toxicity have been described in literature that may be 
useful as biomarkers (Tables 1 and 2). However, whether these readouts can be 
used as predictive biomarkers for in vivo developmental toxicity remains to be 
established. 
The assays that have been developed as alternatives for in vivo developmental 
toxicity testing can roughly be divided  into 1) cellular assays, using either primary 
cells or cells from continuous cell lines and 2) WEC assays. 
Cellular assays 
The European Centre for the Validation of Alternative Methods (ECVAM) has 
validated two cellular assays for developmental toxicity including their prediction 
models, which are the rat limb bud micromass (MM) test and the embryonic stem 
cell test (EST) (Genschow et al., 2002). In addition, several other (embryonic stem) 
cell‐based assays have been described in the literature, focusing on diﬀerent in 
vitro readouts for developmental toxicity, which have so far not been validated by 
ECVAM. In the following sections, the cellular assays are discussed in more detail. 
 
Chapter 2 
35 
 
The MM test 
In the MM test, primary cell cultures dissociated from limb buds and/or 
midbrains are used (Flint, 1983; Flint and Orton, 1984; Kistler, 1987). In the 
validated MM test protocol, only limb bud cells are used, which are derived from 
embryos obtained from pregnant rats at gestational day (GD)14. Limb buds are 
dissociated and plated in high density spots (MM cultures), which allows their 
diﬀerentiation into chondrocytes (Genschow et al., 2002; Spielmann et al., 2004). 
After 5 days of exposure to the chemical, the eﬀect on growth and diﬀerentiation of 
limb bud cells is assessed. Only the EC50 values obtained in the diﬀerentiation assay 
are applied in the prediction model for the MM test, because no better predictions 
were made by using either the EC50 values obtained in the proliferation assay or the 
EC50 values for both proliferation and diﬀerentiation (Spielmann et al., 2004). Since 
the strong embryotoxic chemical methotrexate was classified as non‐embryotoxic, 
the MM test was not recommended for screening purposes (Spielmann et al., 
2004). 
The EST 
In the last decade of the previous century, the use of embryonic stem cells for the 
assessment of developmental toxicity potencies of chemicals was introduced 
(Newall and Beedles, 1994; Heuer et al., 1997; Scholz et al., 1999; Genschow et al., 
2000). These initiatives led to the development of the EST, which was validated 
with its prediction model by the ECVAM (Heuer et al., 1997; Scholz et al., 1999; 
Genschow et al., 2004). The EST measures the potency of a chemical to inhibit cell 
growth of embryonic fibroblasts (3T3 cells) and embryonic stem cells (ES‐D3 cells) 
(cell proliferation assays) and the potency of the chemical to inhibit ES‐D3 cell 
diﬀerentiation into contracting cardiomyocytes (ES‐D3 cell diﬀerentiation assay). 
The exposure duration is 10 days, in which the (exposure) medium is renewed two 
times (3 and 5 days after start). The acquired EC50 values in these assays are applied 
in a prediction model to predict the embryotoxic potency (non‐, weak or strong 
embryotoxic) of the chemical. It was concluded in its validation study that the EST 
was ready for consideration for use in assessing the embryotoxic potentials of 
chemicals for regulatory testing (Genschow et al., 2004). 
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Other cellular assays for developmental toxicity testing 
Several in vitro readouts for developmental toxicity have been assessed in 
embryonic stem cell‐based cultures, for example, the expression of specific genes 
for neuronal diﬀerentiation (Stumann et al., 2007; Kuegler et al., 2010; Theunissen 
et al., 2010; Theunissen et al., 2011; Zimmer et al., 2011a; Zimmer et al., 2011b), 
osteoblast diﬀerentiation (Zur Nieden et al., 2010a; Zur Nieden et al., 2010b) or 
endothelial diﬀerentiation (Fesstag et al., 2007). These readouts may be useful 
biomarkers for adverse eﬀects on specific developmental pathways, such as 
neurodevelopment, bone formation, or vasculogenesis and/or angiogenesis, 
respectively. An overview of the studies using diﬀerent in vitro readouts in 
embryonic stem cell‐based test systems, other than the inhibition of ES‐D3 cell 
diﬀerentiation into contracting cardiomyocytes, is presented in Table 1. 
Appearance of a certain eﬀect on exposure to a developmental toxicant does not 
necessarily mean that this eﬀect will be a useful biomarker for developmental 
toxicity. For obtaining useful biomarkers in in vitro assays, it should be carefully 
assessed whether the eﬀect is adverse, whether it is obtained at a relevant 
concentration and whether it is relevant and predictive for the in vivo toxicological 
endpoint.  
In the last decade, the use of toxicogenomics for obtaining biomarkers has gained 
importance (Afshari et al., 2011). Transcriptome analyses in embryonic stem cell 
cultures exposed to varying chemicals have been used to diﬀerentiate teratogens 
from non‐teratogens by analyzing gene expression patterns in control cells, cells 
exposed to teratogens and cells exposed to non‐teratogens (Van Dartel et al., 2010a; 
Van Dartel et al., 2010b; Van Dartel et al., 2011a; Van Dartel et al., 2011b; Van Dartel 
et al., 2011c; Van Dartel and Piersma, 2011). Toxicogenomic approaches have also 
been proven useful to assess whether chemicals share the same mode of action 
(Osman et al., 2010) and whether pathways aﬀected on in vivo exposure are also 
aﬀected in in vitro embryonic cell cultures, in order to demonstrate the predictive 
capacities of the in vitro assays (Stigson et al., 2007).  
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WEC assays 
Of the WEC assays, only the postimplantation rat WEC test, including its 
prediction model, has been validated by the ECVAM (Piersma et al., 2004). Other 
ex vivo embryo culture assays include the frog embryo teratogenesis assay – 
Xenopus (FETAX) and the chicken embryotoxicity screening test (CHEST). 
Furthermore, several studies have described the use of zebrafish embryos for 
developmental toxicity testing. In most studies reported in the literature using 
WECs, morphological examination is used to determine the developmental toxicity 
potency of the chemical tested. However, other readouts, listed in Table 2, may also 
be useful as biomarkers for developmental toxicity in these WEC systems. 
The postimplantation rat WEC test 
Rat WECs have already been used for decades to assess developmental toxicity 
potencies of chemicals (Brown and Fabro, 1981; Schmid et al., 1983; Klug et al., 1985; 
Piersma et al., 1995). This section describes the WEC test procedure as applied in 
the ECVAM validation study (Genschow et al., 2002; Piersma et al., 2004). In the 
WEC test, embryos obtained from pregnant rats at GD10 are cultured in 100% rat 
serum, containing the chemical, for 48 h. After this culture period, heart beat and 
yolk sac circulation are scored and measurements of yolk sac diameter, crown‐
rump length and head length are taken (Genschow et al., 2002; Piersma et al., 
2004). Furthermore, morphological, developmental, functional and growth 
parameters are scored. The number and specificity of malformations are recorded. 
No observed eﬀect concentrations (ICNOEC), 50% eﬀect concentrations (IC50) and 
maximum eﬀect concentrations (ICmax) are determined. In the first prediction 
model developed for the WEC test, the no observed eﬀect concentrations on total 
morphological score (ICNOEC TMS) and the IC50 values for inducing malformations 
(IC50mal) were used for classification, whereas in a second prediction model, the 
ICNOEC TMS values, the ICmax values for malformations and the IC50 values obtained 
in the 3T3 cell proliferation assay of the EST were used for classification (Genschow 
et al., 2000; Genschow et al., 2002; Piersma et al., 2004). The second prediction 
model was demonstrated to be better in predicting the embryotoxicity classes  
(non‐, weak or strong) of the chemicals. It was concluded that the WEC test was 
ready for consideration for use in assessing the embryotoxic potentials of chemicals 
for regulatory testing (Piersma et al., 2004). 
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The FETAX 
The FETAX is a developmental toxicity screening test conducted on Xenopus 
laevis mid‐blastula‐stage eggs over the organogenesis period (Bantle et al., 1999; 
Fort and Paul, 2002; Mouche et al., 2011). The teratogenic potential of a chemical is 
determined after a 96‐h exposure to the chemical, by scoring the mortality and 
malformation rate for the larvae, as well as the larvae length (Mouche et al., 2011). 
Subsequently, a teratogenic index (TI) is determined by dividing the obtained LC50 
(50% embryo lethality) by the EC50, malformation (50% induction of malformed larvae). 
If the TI > 1.2, the chemical will be classified as positive, if the TI < 1.0, it will be 
classified as negative. Chemicals with a TI between 1.0 and 1.2 are classified as 
positive if growth is aﬀected and morphogenesis and/or viability is disturbed, but 
only when the concentration aﬀecting morphogenesis is lower than the 
concentration leading to significant mortality (Mouche et al., 2011).  
An interlaboratory validation study was performed to evaluate the repeatability 
and reliability of the FETAX to evaluate the potential teratogenic hazard for 12 
chemicals. It was concluded that the FETAX proved to yield repeatable and reliable 
data, as long as technicians were adequately trained (Bantle et al., 1999). The data 
from this validation study were later re‐evaluated using characteristic 
malformation criteria, leading to an improved reliability, test endpoint precision 
and predictability (Fort and Paul, 2002). 
The CHEST 
In the CHEST, the developmental toxicity potential of chemicals is evaluated 
using chicken embryos. The method was first described by Jelinek (1977) and more 
recently by Davies and Freeman (1995). In the CHEST, fertilized chicken eggs are 
exposed to diﬀerent doses of the chemical for diﬀerent durations, after which the 
eﬀects are assessed. The number of dead, malformed and growth‐retarded fetuses 
is recorded, on the basis of which the developmental toxicity potency of the 
chemical is determined (Davies and Freeman, 1995). The CHEST protocol is 
divided into two phases: 1) determination of the toxic dose range in early 
administration time (24 h; CHEST I) and 2) determination of the teratogenic dose 
range covering also the late eﬀects on embryo development (days 2, 3 and 4; 
CHEST II) (Davies and Freeman, 1995). Several studies have evaluated the CHEST 
In vitro biomarkers for developmental toxicity 
42 
 
and similar test protocols, and it was concluded that the CHEST is a reproducible 
test system that delivers quantifiable data for evaluation (Adler et al., 2011). The 
CHEST is being used in academia and industry for routine screening purposes and 
mechanistic studies (Adler et al., 2011). 
Developmental toxicity testing using zebrafish embryos 
In recent years, the zebrafish (Danio rero) has gained popularity as a test species 
for developmental toxicity testing. Selderslaghs et al. (2009) determined TI values 
(LC50/EC50, malformation) in zebrafish embryos 24, 48, 72 and 144 h after fertilization 
and chemical exposure, and were able to distinguish four positive from two 
negative chemicals for developmental toxicity. However, separation of positives 
from negatives was not based on TI values, as is the case in the FETAX, but on the 
fact that for the two negative chemicals, no TI values could be determined, as no 
LC50 nor EC50, malformation was reached (Selderslaghs et al., 2009). In a more recent 
study, this zebrafish assay was used to classify a larger group of 27 chemicals based 
on a prediction model using a TI cut‐oﬀ value of 2. When comparing the 
classification obtained in this zebrafish assay with animal data, a sensitivity of 72% 
and a specificity of 100% were obtained for these 27 chemicals (Selderslaghs et al., 
2011). Hermsen et al. (2011b) developed a quantitative evaluation method to assess 
the development of the zebrafish embryo based on specific endpoints in time. In 
their zebrafish embryotoxicity test, the eﬀect of chemicals on zebrafish 
development is assessed using a scoring system for development and teratogenic 
eﬀects (Hermsen et al., 2011b). 
Zebrafish embryos have also been used to assess the neurodevelopmental toxicity 
potential of chemicals, based on locomotor activity studies (Selderslaghs et al., 
2010) and on gene expression patterns of nervous system genes (Fan et al., 2010). 
Demicco et al. (2010) studied the eﬀects of a series of pyrethroid insecticides in 
zebrafish embryos and concluded that the zebrafish might be an appropriate 
alternative model to study the mechanisms of neurodevelopmental toxicity and 
that it might be used to identify chemicals that should be further tested in 
mammalian models. 
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Translation of in vitro obtained developmental toxicity data to the in vivo 
situation 
In order to use in vitro toxicity data for the estimation of in vivo toxic eﬀects, the 
obtained in vitro toxicity data need to be translated to the in vivo situation. In vivo 
developmental toxicity may be predicted in several ways: the in vitro data can be 
used to 1) predict the developmental toxicity class to which a chemical belongs 
(e.g., non‐, weak or strong embryotoxic) using a prediction model, 2) predict the 
relative developmental toxicity potency of a chemical based on the in vitro eﬀect 
concentrations (usually within a group of structurally related chemicals) and 3) 
predict in vivo developmental toxicity dose levels by translating in vitro eﬀect 
concentrations into in vivo eﬀect doses. 
Prediction of developmental toxicity classes using prediction models 
Data from in vitro developmental toxicity studies are often used to divide 
chemicals in embryotoxicity or teratogenicity classes. This is done, for example, in 
the FETAX by separating non‐teratogens from teratogens by deriving TI values 
(Mouche et al., 2011). In the EST, the MM test and the WEC test, chemicals are 
divided into diﬀerent embryotoxicity classes (non‐, weak or strong embryotoxic) 
using prediction models (Genschow et al., 2002). In these assays, the embryotoxic 
potency is predicted by applying the in vitro eﬀect concentrations in prediction 
models. The prediction models of the EST, the MM test and the WEC test were 
developed by linear discriminant analysis, aiming at the creation of rules that 
assign a chemical to a toxicity class, taking into account the endpoints determined 
in the test (Genschow et al., 2002). In the ECVAM validation studies, chemicals 
were correctly classified in 78, 70 and 80% of the experiments, using the in vitro 
data obtained in and the prediction models developed for the EST, the MM test 
and the WEC test, respectively (Genschow et al., 2002). However, using the MM 
test, the strong embryotoxic chemical methotrexate was classified as non‐
embryotoxic. Therefore, the MM test was not recommended for screening purposes 
(Spielmann et al., 2004). The predictability of the EST and the WEC test using their 
prediction models was further evaluated in later studies (Paquette et al., 2008; 
Marx‐Stoelting et al., 2009; Thomson et al., 2011). The usefulness of the prediction 
model of the EST was questioned, since only 2 of 13 chemicals that were tested in 
the European Framework Program project ReProTect were correctly classified 
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using the obtained in vitro data and the prediction model (Marx‐Stoelting et al., 
2009). This might be due to the subjective classification of the chemicals over the 
three diﬀerent embryotoxicity classes, possibly hampering the predictability by the 
prediction models (Marx‐Stoelting et al., 2009). It was suggested that the number 
of toxicity classes should be reduced to two: 1) non‐embryotoxic chemicals and 2) 
embryotoxic chemicals (Marx‐Stoelting et al., 2009). When the WEC test was 
challenged with a group of pharmaceuticals not used in the ECVAM validation 
study, only 24 of 48 chemicals were correctly classified, confirming the concerns 
about the application of the prediction model to a more diverse chemical set than 
that used in the validation study (Thomson et al., 2011). 
If prediction models are to predict the developmental toxicity potencies of a set 
of chemicals, all relevant in vivo kinetic and dynamic characteristics playing a role 
in the developmental toxicity outcome of the chemicals should be addressed by the 
assay and the prediction model. Although some of the dynamic processes playing a 
role in the developmental toxicity outcome might be represented in the in vitro 
assay, important in vivo kinetic characteristics, which might greatly diﬀer between 
the chemicals, are not taken into account. These characteristics include intestinal 
uptake, bioactivation to active metabolites (in the case of proteratogens), 
detoxification to inactive metabolites, placental transfer to the fetus and/or 
excretion into the urine. Since all of these in vivo kinetic processes may play a role 
in the levels of active molecules reaching the embryo, and hence the in vivo 
developmental toxicity potency of a chemical, it is probably impossible to make a 
prediction on the developmental toxicity potency of all chemicals applying in vitro 
eﬀect concentrations obtained in a single prediction model. 
Prediction of relative developmental toxicity potencies of structurally related 
chemicals using in vitro eﬀect concentrations 
The in vivo developmental toxicity potency of a chemical may also be estimated 
by using a so‐called category approach, which may also be used in read‐across 
approaches for developmental toxicity (Fabjan et al., 2006; Enoch et al., 2009). 
Read‐across is based on the concept that data gaps of chemicals can be filled by 
reading across or interpolating or extrapolating (preferably interpolating) missing 
data values, if data exist for chemicals that are structurally related (Scialli, 2008). 
The grouping of chemicals for read‐across may be facilitated by using structure‐
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activity relationship (SAR) models or by in vitro testing (Scialli, 2008). The relative 
in vivo developmental toxicity potencies of chemicals can be estimated, if in vivo 
toxicity data are available for structurally related chemicals, by evaluating the 
relative in vitro developmental toxicity potencies of these chemicals. Furthermore, 
based on the toxicity profile of the chemical with known in vivo toxicity, the most 
appropriate in vitro test could be selected representing the most sensitive 
developmental endpoints for a specific chemical category (Fabjan et al., 2006). 
Recently, the use of quantitative SAR (QSAR) models for reproductive and 
developmental toxicity has been evaluated by the European Commission’s Joint 
Research Centre (Piparo and Worth, 2010). It was concluded that relatively few 
models for this endpoint are present and that those available have limited 
applicability domains (Piparo and Worth, 2010). 
Several studies have assessed the in vitro relative potencies of structurally related 
chemicals using the ES‐D3 cell diﬀerentiation assay of the EST, for example, for a 
series of glycol ether alkoxyacetic acid metabolites (De Jong et al., 2009) (Chapter 
4), valproic acid analogues (De Jong et al., 2011a; Riebeling et al., 2011), retinoids 
(Louisse et al., 2011) (Chapter 6) and 1,2,4‐triazoles (De Jong et al., 2011b). Also the 
WEC test has been used to predict the relative in vivo potencies of structurally 
related chemicals, for example, for a series of glycol ether alkoxyacetic acid 
metabolites (Giavini et al., 1993), phthalates and their metabolites (Janer et al., 
2008) and 1,2,4‐triazoles (De Jong et al., 2011b). The potential of the zebrafish in a 
category approach has been shown for a series of glycol ether alkoxyacetic acid 
metabolites (Hermsen et al., 2011a) and 1,2,4‐triazoles (Hermsen et al., 2011a; De 
Jong et al., 2011b). These studies indicate the potential of these in vitro 
developmental toxicity assays for predicting relative in vivo potencies of 
structurally related chemicals. A disadvantage of this approach is that chemical‐
specific species‐dependent diﬀerences in in vivo kinetics, which may aﬀect the 
relative in vivo potencies, are not taken into account. 
Prediction of in vivo developmental toxicity dose levels by translating in vitro eﬀect 
concentrations into in vivo eﬀect doses 
In vitro toxic eﬀect concentrations that have been obtained in a relevant assay 
can be translated into in vivo doses in order to make predictions for the in vivo 
situation (DeJongh et al., 1999; Verwei et al., 2006; Forsby and Blaauboer, 2007; 
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Louisse et al., 2010 (Chapter 5)). It has previously been shown that in vitro eﬀect 
concentrations obtained in the ES‐D3 cell diﬀerentiation assay can be successfully 
extrapolated to in vivo dose levels causing developmental toxicity, using 
physiologically based kinetic (PBK) modeling (Verwei et al., 2006; Louisse et al., 
2010 (Chapter 5)). A PBK model is a set of mathematical equations that together 
describe the absorption, distribution, metabolism and excretion (ADME) 
characteristics of a chemical within an organism on the basis of physiological and 
anatomical parameters, physicochemical parameters (partition coeﬃcients) and 
other kinetic parameters (Krishnan and Andersen, 2001). PBK models describe the 
fate of the chemical (and its metabolite(s)) in the body in time after a certain dose 
of the chemical via a certain exposure route (e.g., oral or dermal) in a certain 
species (e.g., rat or man). Therefore, PBK models can be used to translate external 
dose levels of a chemical into internal tissue or blood concentrations of the 
chemical (and its metabolite(s)). PBK models can also be used for so‐called reverse 
dosimetry, in which internal concentrations of the chemical (or of one of its 
metabolites) are set and the model is used to calculate which external dose levels 
are needed to reach these internal concentrations. This was done for glycol ethers 
for which in vitro toxicity data of the toxic glycol ether alkoxyacetic acid 
metabolites derived in the ES‐D3 cell diﬀerentiation assay of the EST were used as 
input in the PBK model for the internal blood concentrations to calculate the 
corresponding dose levels of the parent glycol ethers (Louisse et al., 2010) (Chapter 
5). This enables the extrapolation of in vitro concentration‐response curves to 
predicted in vivo dose‐response curves for developmental toxicity (Louisse et al., 
2010). The dose‐response curves that were predicted for rat were found to be in 
concordance with the developmental toxicity dose levels measured in reported in 
vivo rat studies (Figure 1) (Louisse et al., 2010). This example provides a proof‐of‐
principle that PBK modeling can be used to convert in vitro concentration‐response 
curves obtained in in vitro assays into in vivo dose‐response curves for 
developmental toxicity. Reverse dosimetry approaches using PBK modeling are also 
used in the United States Environmental Protection Agency’s ToxCast program and 
the European Framework Program projects ESNATS and ChemScreen to predict in 
vivo eﬀect levels based on in vitro eﬀect concentrations. 
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Figure 1. Extrapolation of in vitro concentration‐response curves for the embryotoxic metabolites 
methoxyacetic acid (MAA) of ethylene glycol monomethyl ether (EGME) and ethoxyacetic acid (EAA) of 
ethylene glycol monoethyl ether (EGEE) in the ES‐D3 cell diﬀerentiation assay to in vivo dose‐response 
curves for developmental toxicity of EGME and EGEE using PBK modeling (Louisse et al., 2010). Circles 
in upper graphs represent in vitro toxicity data of MAA and EAA obtained in the ES‐D3 cell 
diﬀerentiation assay. The curves fitted to these in vitro data were translated into in vivo dose‐response 
curves for developmental toxicity of EGME and EGEE using the PBK model. The circles in the lower 
graphs represent data reported in the literature on the fraction of aﬀected embryos after EGME and 
EGEE exposure. 
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The translation of in vitro obtained eﬀects to the in vivo situation can be 
hampered by several factors, including 1) the lack or the low expression levels of 
biotransformation enzymes in in vitro test systems compared with the in vivo 
situation, 2) the possible lack of relevant cells or tissues in the in vitro test system 
for the in vivo observed eﬀects, 3) the lack of secondary adverse eﬀects resulting 
from maternal or placental toxicity in the in vitro test system and 4) the lack of 
relevant data needed to construct a PBK model that reliably describes the in vivo 
kinetics, for extrapolating in vitro eﬀect concentrations to in vivo eﬀect doses. The 
following sections discuss these factors in more detail. 
The lack or low expression levels of biotransformation enzymes 
Proteratogens, for example cyclophosphamide and valpromide, need to be 
bioactivated in order to give rise to their developmental toxicity eﬀects. In in vitro 
test systems, the expression levels of biotransformation enzymes might be too low 
to bioactivate the parent compounds (Coecke et al., 2006). The addition of a 
bioactivation system might increase the in vitro developmental toxicity potency of 
a proteratogen. Hettwer et al. (2010) showed that the proteratogen 
cyclophosphamide was 70‐fold more potent in the ES‐D3 cell diﬀerentiation assay 
of the EST when the medium with cylophosphamide was pre‐incubated with 
murine hepatocytes (preconditioned medium). However, no increase in the in vitro 
potency was obtained for the proteratogen valpromide, using the same 
experimental procedure, because the levels of the active metabolite (valproic acid) 
in the culture medium were too low to increase the toxicity (Hettwer et al., 2010). 
Furthermore, using preconditioned medium will not increase a proteratogen’s 
potency in a test system, when the toxic bioactivation products are unstable 
(Coecke et al., 2006). 
Bioactivation systems have also been added to WEC test systems, in order to 
improve the predictability for proteratogens. Oglesby et al. (1986) showed that 
cyclophosphamide at concentrations that did not induce embryotoxicity in 
cultured rat embryos induced embryotoxicity when rat embryos were co‐cultured 
with rat, rabbit or hamster hepatocytes. Mitra et al. (1992) showed that the 
embryotoxic eﬀects of ethylene dibromide were increased in a rat WEC test system, 
when purified rat liver glutathione S‐transferases were added to the culture 
medium. In another study, it was shown that the embryotoxic potency of 
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phenytoin was increased in a mouse embryo culture system when embryos were  
co‐cultured with hepatocytes from rats or rabbits, but not from mice (Ozolins et 
al., 1995). The addition of a bioactivation system to the in vitro test system can also 
decrease the potency of proteratogens, as was shown for trichloroethylene and 
tetrachloroethylene in cultured rat embryos (Saillenfait et al., 1995). The addition 
of hepatic microsomal fractions to the culture medium decreased the embryotoxic 
eﬀects of trichloroethylene and tetrachloroethylene, whereas the main metabolites 
dichloro‐ and trichloroacetic acid themselves had a higher potency than the parent 
compounds (Saillenfait et al., 1995). The addition of a biotransformation system has 
also been applied in zebrafish developmental toxicity assays. Busquet et al. (2008) 
showed that on addition of induced rat male microsomes and reduced 
nicotinamide adenine dinucleotide phosphate, the potency of the proteratogens 
cyclophosphamide and ethanol induced abnormalities in the fish embryos whereas 
the proteratogens alone did not show an eﬀect. 
The examples show that the potency of a proteratogen in an in vitro 
developmental toxicity assay does not always increase with the addition of a 
bioactivation system. Whether an increase or a decrease in the potency of a 
proteratogen will be observed with the addition of a bioactivation system, is 
dependent on the overall outcome of bioactivation and detoxification reactions and 
the concentration of the toxic metabolite achieved. Therefore, the in vitro potency 
of a proteratogen does not necessarily increase in a test system to which a 
bioactivation system has been added. This may be dependent on the species from 
which the bioactivation system originates, implicating that the use of human  
tissue‐derived bioactivation systems may be the most relevant for making 
predictions for humans. Furthermore, one must take into account that the addition 
of cellular fractions as a bioactivation system can itself cause toxicity in cellular 
systems (Tan et al., 1982) and WECs (Luijten et al., 2008). 
To investigate whether an unknown chemical could be a proteratogen, the 
metabolites formed could be identified (e.g., using hepatocytes in culture, or liver 
fractions (microsomes, S9) and co‐factors) and tested (e.g., the main metabolites) 
in the in vitro test system. The in vivo formation and internal concentrations of the 
parent compound and its metabolites can then be estimated using PBK modeling. 
Subsequently, estimations of parent compound exposure levels resulting in in vivo 
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developmental toxicity can be made. Although metabolite identification (whether 
or not in combination with metabolite production and testing) is a standard 
procedure in the drug development process, this might be a too expensive and  
time‐consuming process to apply in routine testing strategies for all chemicals. 
The possible lack of relevant cells or tissues in the in vitro test system for the in vivo 
observed eﬀects 
The in vitro assays for developmental toxicity described in the literature have 
varying levels of biological complexity. If the developmental toxicant has an 
adverse eﬀect on specific cell types, the toxicity might not be detected in an in vitro 
test system in which these cells are absent. This would suggest that WEC assays, 
which are closer to the in vivo situation than cellular assays, would be better test 
systems to detect adverse eﬀects of a range of chemicals aﬀecting diﬀerent cell 
types and with diﬀerent modes of action (Piersma, 2004; Piersma, 2006). In 
addition, a battery of cellular assays that would cover the relevant cell types that 
can be aﬀected during development would detect a developmental toxicant that 
might not be detected by a single cellular assay (Piersma, 2006). Instead of using 
cellular assays in which specific cell types are present, embryonic stem cells, which 
can be diﬀerentiated into a mix of relevant cell types, could be used, enabling the 
assessment of eﬀects on diﬀerent cell types, and on the diﬀerentiation into 
diﬀerent cell types, using multiple readouts in one test system. Using 
diﬀerentiating ES‐D3 cells may be a useful tool to accomplish this, because 
although the readout in the classical ES‐D3 cell diﬀerentiation assay is the 
inhibition of ES‐D3 cell diﬀerentiation into contracting cardiomyocytes, cell types 
of all the three germ layers are present in these cultures (Doetschman et al., 1985; 
Toumadje et al., 2003). 
Toxicogenomic tools are useful to get insight into the mechanism of toxicity of 
chemicals (Afshari et al., 2011). These technologies may help to assess whether a 
certain assay contains the relevant cell types to exhibit a specific toxic eﬀect, in 
order to assess the applicability domain of the test system. Van Dartel et al. (2009, 
2010a,b, 2011a‐c) analyzed gene expression patterns for ES‐D3 cells diﬀerentiating 
into cardiomyocytes exposed to chemicals at concentrations aﬀecting 
cardiomyocyte diﬀerentiation. These studies showed the ability to diﬀerentiate 
teratogens from non‐teratogens by analysing gene expression patterns in exposed 
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diﬀerentiating embryonic stem cells. Toxicogenomic approaches are also useful to 
assess whether pathways aﬀected by chemical exposure in the in vivo situation are 
also aﬀected in the in vitro test system, in order to determine its predictive capacity 
(Stigson et al., 2007). However, with the interpretation of toxicogenomic data, one 
must be aware that gene expression changes themselves are not necessarily 
adverse. A change in gene expression may reflect an adaptation of the cell or tissue 
to a situation, not resulting in an adverse eﬀect. Furthermore, a chemical may also 
have an eﬀect on protein levels or interactions in the cell, resulting in adverse 
eﬀects, but not directly in a change in gene expression. Proteomic approaches may 
be useful in assessing eﬀects on protein expression, post‐translational 
modifications and protein interactions (Barrier and Mirkes, 2005). However, the 
low throughput of proteome analyses may be a major limitation. 
The lack of secondary adverse eﬀects resulting from maternal or placental toxicity in 
the in vitro test system 
For some chemicals, developmental toxicity may occur only at dose levels 
causing maternal toxicity (Chernof et al., 1989; Black et al., 1992; Rogers et al., 
2005). Also toxicant‐induced alterations in maternal physiology at doses that do 
not clearly indicate maternal toxicity (such as lethality and/or reduction in 
maternal body weight) may aﬀect the conceptus’s development (Rogers et al., 
2005). Furthermore, chemicals aﬀecting the placenta and hence aﬀecting the 
delivery of oxygen and nutrients to the conceptus may induce developmental 
toxicity (Maranghi et al., 1998). If this maternal and/or placental toxicity occurs at 
lower concentrations than the concentrations that would directly aﬀect the 
conceptus, the chemical’s in vivo developmental toxicity potency would be 
underestimated, if eﬀect data of the in vitro developmental toxicity assay are 
translated to the in vivo situation, without taking the maternal and/or placental 
toxicity eﬀects into account. Since maternally induced developmental toxicity 
eﬀects can be species‐dependent (Rogers et al., 2005), relevant human in vitro 
assays assessing maternal and placental toxicity could help in the prediction of 
secondary developmental toxicity eﬀects of chemicals to humans. 
The lack of relevant data needed to construct a PBK model that reliably describes the 
in vivo kinetics, for extrapolating in vitro eﬀect concentrations to in vivo eﬀect doses 
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For the extrapolation of in vitro eﬀect concentrations to in vivo eﬀect doses, PBK 
models are needed that reliably describe the in vivo kinetics. Definition of these 
PBK models requires robust data for model parameterization. Current PBK models 
often use chemical‐specific parameter values, including tissue:blood partition 
coeﬃcients and other kinetic parameter values, determined using in vivo kinetic 
data (Rietjens et al., 2011). To limit the use of animals, in vitro and in silico 
approaches are preferred to determine these parameter values. However, if 
extrapolations have to be made for many chemicals, the generation of chemical‐
specific parameter values can be a labor‐ and time‐consuming process (Rietjens et 
al., 2011). Furthermore, for some kinetic processes, such as renal clearance, no in 
vitro method is currently available to determine the kinetic parameter values 
(Adler et al., 2011). The use of QSAR approaches in predicting chemical‐specific 
parameter values may be useful to accelerate the process of building PBK models 
and hence the use of PBK models for extrapolating in vitro eﬀect concentrations to 
in vivo eﬀect doses. 
 
Validation processes of in vitro developmental toxicity assays 
In order to be useful as reliable alternatives for in vivo developmental toxicity 
studies, in vitro developmental toxicity assays need to be validated for their 
predictive capacities. The validation processes that have been applied for in vitro 
developmental toxicity assays have been described by Piersma (2004). For 
developmental toxicity, the EST, the MM test and the WEC test have been 
validated according to the criteria of the ECVAM (Genschow et al., 2002). Recently, 
Daston et al. (2010) reported on the limitations of previous approaches for 
validating in vitro assays for developmental toxicity testing and proposed a new 
approach of how screening assays for developmental toxicity should be validated in 
the future. One of the problems that occurred with previous validation studies is 
the categorization of chemicals into ‘positives’ (developmental toxicants) and 
‘negatives’ (non‐developmental toxicants) without notion of the dose (or 
concentration), implying that a non‐developmental toxicant would never cause 
developmental toxicity eﬀects, even at very high dose levels. However, also in 
developmental toxicology, Paracelsus’s concept of dose applies (The dose makes 
the poison), which was restated by Karnofsky (1965) for teratology saying that ‘with 
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the right dose, the right species, and the right timing, any chemical could be shown 
as a teratogen’. Therefore, Daston et al. (2010) defined a developmental toxicant as 
‘an exposure (agent at a stated internal concentration with stated timing) to the 
developing organism that leads to a permanent adverse eﬀect’ and a non‐
developmental toxicant as ‘an exposure that does not cause permanent adverse 
eﬀects’. Using these definitions and the internal concentration as key component 
permits a chemical to be considered as a developmental toxicant at one 
concentration and as a nondevelopmental toxicant at another concentration 
(Daston et al., 2010). Thus, in future validation processes for in vitro developmental 
toxicity assays, a list of internal exposures at which in vivo developmental toxicity 
occurs and a list of internal exposures at which in vivo developmental toxicity does 
not occur should be used (Daston et al., 2010). These ‘values for internal exposure’ 
could be obtained by assessing the in vivo kinetics at dose levels that do not cause 
developmental toxicity (e.g., at no observed adverse eﬀect levels) and assessing the 
in vivo kinetics at dose levels that cause developmental toxicity (e.g., at lowest 
observed adverse eﬀect levels). These data on internal concentrations may be 
acquired in in vivo kinetic studies, but should preferably be estimated by 
developing PBK models for these chemicals. In the validation process, these ‘values 
for internal exposure’ can then be compared with toxic eﬀect concentrations 
obtained in in vitro developmental toxicity assays, to assess the predictive capacity 
of the assays. It must be noted that the concentrations that may cause the 
developmental toxicity may be dependent on the developmental stage of the 
conceptus, because physiological changes that occur during gestation may aﬀect 
chemical availability and/or sensitivity of the conceptus. Therefore, the timing of 
exposure (both in vitro and in vivo) has to be taken into account. A single time 
point measurement may lead to misinterpretation of the obtained data sets. 
Unfortunately, little data are available on the in vivo internal concentrations of 
chemicals at developmentally toxic doses. If the in vivo internal fetal 
concentrations are to be used as the reference concentrations for the evaluation of 
in vitro developmental toxicity assays, the eﬀect concentrations in diﬀerent in vitro 
assays would be roughly the same if they would have the same sensitivity and 
predictive capacity. We evaluated this for the nominal eﬀect concentrations (EC50 
values) for the inhibition of ES‐D3 cell diﬀerentiation and the induction of 
malformations (EC50 values) in the WEC test (Figure 2), reported in the ECVAM 
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validation studies (Genschow et al., 2004; Piersma et al., 2004). Figure 2 shows that 
the ES‐D3 cell diﬀerentiation assay was for most chemicals more sensitive than the 
WEC test, especially for all‐trans‐retinoic acid, 5‐fluorouracil and methylmercury 
chloride, indicated by 80‐, 61‐ and 26‐fold lower EC50 values, respectively. For the 
other chemicals, the EC50 values for both assays diﬀer less than 10‐fold (Figure 2). 
The results presented in Figure 2 indicate that although the EC50 values from the 
ES‐D3 cell diﬀerentiation assay tend to be somewhat lower than those for the WEC 
test, there is a reasonable correlation (r = 0.92). From this it is concluded that the 
ES‐D3 cell diﬀerentiation assay and the WEC test would have roughly the same 
predictive capacity for many of the tested chemicals, but not for all. Diﬀerences in 
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Figure 2. Average EC50 values for chemicals aﬀecting ES‐D3 cell diﬀerentiation (EC50 ES‐D3 cell 
diﬀerentiation) compared with average EC50 values for chemicals inducing malformations in cultured 
rat embryos (EC50 malformations WEC). The short dashed lines indicate EC50 ES‐D3 cell diﬀerentiation 
= EC50 malformations WEC. The long dashed line covers the area in which the EC50 ES‐D3 cell 
diﬀerentiation values do not diﬀer more than 10‐fold from the EC50 malformations WEC values. Average 
EC50 values were calculated from data reported by Genschow et al. (2004) and Piersma et al. (2004). 1: 
All‐trans‐retinoic acid; 2: methotrexate; 3: 5‐fluorouracil 4: methylmercury; 5: 5‐bromo‐2’‐deoxyuridine; 
6: 6‐amino‐nicotinamide; 7: hydroxyurea; 8: diphenhydramine hydrochloride; 9: pentyl‐4‐yn‐valproic 
acid; 10: valproic acid; 11: acrylamide; 12: salicylic acid sodium salt; 13: methoxyacetic acid; 14: boric acid; 
15: lithium chloride. Black circles: chemicals classified as strong embryotoxic in ECVAM validation 
studies. Grey circles: chemicals classified as weak embryotoxic in ECVAM validation studies. White 
circles: chemicals classified as non‐embryotoxic in ECVAM validation studies. 
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the obtained eﬀect concentrations of the same chemical in diﬀerent in vitro test 
systems may be caused by several factors, including the following. 
Diﬀerences in sensitivities of the test systems 
Chemicals may induce developmental toxicity by aﬀecting not only general 
processes, such as cell proliferation, cell viability and/or maintenance of 
intracellular pH, but also specific processes during development, such as neuron 
outgrowth or vasculogenesis. It can be expected that eﬀect concentrations obtained 
in diﬀerent in vitro assays for developmental toxicity will not diﬀer considerably for 
chemicals with a nonspecific mode of action, whereas for chemicals with a more 
complex or specific mode of action, eﬀect concentrations obtained in diﬀerent in 
vitro assays can diﬀer much more. If an in vivo aﬀected process is not represented 
in the in vitro assay, eﬀect concentrations will represent rather nonspecific toxicity 
appearing at higher concentrations than the concentrations that would aﬀect the 
specific process. Thus, if a chemical exerts its eﬀect via a specific mechanism, this 
may not be detected in an oversimplified test system. 
Diﬀerences in exposure characteristics of the test protocols 
In the WEC test, embryos are exposed for 2 days to the chemical, whereas in the 
ES‐D3 cell diﬀerentiation assay, the total period of exposure is 10 days, in which the 
exposure medium is renewed twice. For all‐trans‐retinoic acid, for example, the 
developmental toxicity outcome is reported to be related to the area under the 
concentration‐time curve, and not to the peak concentration (Tzimas et al., 1997). 
Therefore, the longer exposure time in the ES‐D3 cell diﬀerentiation assay might 
play a role in the lower obtained eﬀect concentrations measured in this in vitro 
assay for all‐trans‐retinoic acid. Furthermore, constituents of culture media could 
influence the chemical’s toxic potency. The high sensitivity of the ES‐D3 cell 
diﬀerentiation assay for 5‐fluorouracil could be due to the fact that 5‐fluorouracil 
exerts its toxic eﬀect by the formation of an inhibitory complex with thymidylate 
synthetase and folate, which blocks DNA synthesis, as was discussed before by 
Verwei et al. (2006). Because of the relatively high folate concentrations in ES‐D3 
cell culture medium compared with serum, more inhibitory complexes may be 
formed resulting in a higher potency of 5‐FU in the ES‐D3 cell diﬀerentiation assay 
than in the WEC test and in the in vivo situation (Verwei et al., 2006). 
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Diﬀerences in culture media may also result in diﬀerences in the free 
concentration of the chemical. This will depend on the extent of protein binding of 
the chemicals, which may be species‐dependent, and the diﬀerent amounts of 
proteins present in the test systems (Gülden et al., 2006; Blaauboer, 2010). These 
diﬀerences may also partly explain the higher sensitivity of the ES‐D3 cell 
diﬀerentiation assay for all‐trans‐retinoic acid and methylmercury, compared with 
the WEC test, because the medium used for the WEC test (rat serum) contains 
higher levels of protein than the medium used for the ES‐D3 cell diﬀerentiation 
assay (20% FCS). This also indicates that the use of diﬀerent concentrations of 
serum in assays may lead to interlaboratory diﬀerences in nominal eﬀect 
concentrations obtained. Therefore, free eﬀect concentrations in an in vitro test 
system would preferably be compared with the free in vivo internal concentrations 
at developmental toxicity dose levels, instead of comparing nominal eﬀect 
concentration in the in vitro assay with nominal concentrations in vivo. 
Diﬀerences in biotransformation systems in the in vitro test systems 
The expression of biotransformation enzymes may diﬀer in the diﬀerent test 
systems or may be completely absent. This can lead to diﬀerences in detoxification 
and/or bioactivation between test systems, and, therefore, diﬀerences in eﬀect 
concentrations obtained. 
 
Expert opinion: toward the prediction of relevant in vivo internal toxic 
eﬀect concentrations using in vitro assays for developmental toxicity and 
their subsequent extrapolation to in vivo dose levels 
For the development of in vitro developmental toxicity assays, knowledge on the 
mechanisms underlying developmental toxicity will be helpful to assess whether a 
certain in vitro assay would be suitable to detect a specific toxic eﬀect. The use of 
toxicogenomic approaches is useful to assess whether in the in vitro assay similar 
pathways are aﬀected as compared with the in vivo situation on exposure to a 
developmental toxicant (Stigson et al., 2007). It is unlikely that a single in vitro 
assay can represent all the processes that may be aﬀected by chemicals during in 
vivo developmental processes (Piersma, 2006). Therefore, the combination of a 
group of assays that together represent the processes that can be aﬀected in the 
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developmental process is needed (Piersma, 2006). A chemical that is a 
neurodevelopmental toxicant, for example, may not have an eﬀect at a relevant 
concentration in the ES‐D3 cell diﬀerentiation assay, in which the eﬀect on 
diﬀerentiation into cardiac cells is assessed. Because it is not known for a new 
chemical which developmental process it may aﬀect, it should be tested in a 
battery of assays. The assay in which the lowest eﬀect concentration is obtained for 
that chemical may be the most relevant (the first) process that will be aﬀected in 
vivo. Using PBK modeling, it can then be estimated whether these concentrations 
are expected to be reached in vivo at certain exposure levels. 
In validation processes, it should be evaluated whether the concentrations at 
which toxicity is observed are relevant considering the in vivo internal 
concentrations at developmental toxicity dose levels of the chemicals (Daston et 
al., 2010). This would imply that instead of a list of standard chemicals classified as 
either developmental toxicants (weak or strong) or nondevelopmental toxicants, a 
list of internal exposures should be used in the evaluation and validation of in vitro 
developmental toxicity assays (Daston et al., 2010). The comparison of the eﬀect 
concentrations obtained in the in vitro assays with internal concentrations at 
developmentally toxic dose levels will give insight into which of the assays provide 
the most relevant toxic eﬀect concentrations. Parameters such as dose 
(concentration), timing and duration of exposure should be taken into account in 
these comparisons. If an in vitro developmental toxicity assay proves to predict 
relevant in vitro eﬀect concentrations (e.g., for a certain group of chemicals), its 
applicability domain can be determined and the assay can be used to predict the in 
vivo developmental toxicity potencies of the chemicals by the obtained in vitro 
ranking using a category approach. However, in such a category approach, 
important kinetic considerations, such as diﬀerences in absorption, detoxification 
and excretion, may be overlooked. These kinetic considerations are accounted for 
when the in vitro eﬀect concentrations are translated into in vivo dose levels using 
PBK modeling, enabling the use of in vitro data in a quantitative manner, instead of 
using in vitro data only for hazard identification. The development of PBK models 
may, therefore, become an important factor in the process of the development of 
alternatives to animal experiments in toxicological research. This requires skill 
competence of researchers in programming and modeling, and the development of 
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in vitro or in silico tools that can be used to determine robust kinetic parameter 
values needed to construct these PBK models. With the combined in vitro‐in silico 
approach, in vitro toxicity data may be used to set points of departure for risk 
assessment (like a BMDL10 (lower limit of the 95% confidence interval on the 
benchmark dose at which a benchmark response equivalent to a 10% eﬀect size 
(BMR10) is reached (BMD10)), enabling derivation of safe exposure limits for 
humans using animal‐free approaches. 
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Abstract 
Developmental toxicity of glycol ethers is caused by their alkoxyacetic acid 
metabolites, but the mechanism underlying the developmental toxicity of these 
acid metabolites is so far not known. The present study investigates a possible 
mechanism underlying the developmental toxicity of glycol ether alkoxyacetic acid 
metabolites using the methoxyacetic acid (MAA) metabolite of ethylene glycol 
monomethyl ether as the model compound. The results obtained demonstrate an 
MAA‐induced decrease of the intracellular pH (pHi) of embryonic BALB/c‐3T3 cells 
as well as of embryonic stem cells (ES‐D3 cells), at concentrations that aﬀect ES‐D3 
cell diﬀerentiation. These results suggest a mechanism for MAA‐mediated 
developmental toxicity similar to the mechanism of developmental toxicity of the 
drugs valproic acid and acetazolamide (ACZ), known to decrease the pHi in vivo, 
and therefore used as positive controls. The toxic alkoxyacetic acid metabolites 
ethoxyacetic acid, butoxyacetic acid and phenoxyacetic acid also caused an 
intracellular acidification of BALB/c‐3T3 cells at concentrations that are known to 
inhibit ES‐D3 cell diﬀerentiation. Two other developmentally toxic chemicals, all‐
trans‐retinoic acid and 5‐fluorouracil, did not decrease the pHi of embryonic cells 
at concentrations that aﬀect ES‐D3 cell diﬀerentiation, pointing at a diﬀerent 
mechanism of developmental toxicity of these chemicals. MAA and ACZ induced a 
concentration‐dependent inhibition of ES‐D3 cell diﬀerentiation, which was 
potentiated by amiloride, an inhibitor of the Na+/H+‐antiporter, corroborating an 
important role of the pHi in the mechanism of developmental toxicity of both 
chemicals. Together, the results presented indicate that a decrease of the pHi may 
be the mechanism of developmental toxicity of the alkoxyacetic acid metabolites of 
the glycol ethers. 
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Introduction 
Several members of the chemical group of glycol ethers are known for having 
adverse eﬀects on the developing fetus in mice, rats and rabbits (Hanley et al., 1984; 
Nelson et al., 1984; Wier et al., 1987). Most attention in developmental toxicity 
studies of glycol ethers has gone to ethylene glycol monomethyl ether (EGME), 
being the most potent member of this group of chemicals (Nelson et al., 1984; 
Welsch, 2005). Developmental toxicity eﬀects are not caused by EGME itself, but 
by its metabolite methoxyacetic acid (MAA) (Figure 1) (Brown et al., 1984; Giavini 
et al., 1993).  
Glycol ether-induced decrease of the pHi 
Figure 1. EGME is metabolized to its toxic metabolite MAA by alcohol dehydrogenase (ADH) and 
aldehyde dehydrogenase (ALDH) (Miller et al., 1983). 
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Although being the most potent glycol ether, EGME only causes developmental 
toxicity in rats when MAA plasma levels in the millimolar range are reached 
(Sweeney et al., 2001). Also in in vitro developmental toxicity studies MAA 
concentrations in the millimolar range are needed to obtain adverse eﬀects. For 
example, the BMC5 (Benchmark concentration at which a 5% change occurs 
compared to the control) of MAA for the total morphological score in the whole 
embryo culture is 1.6 mM (Piersma et al., 2008) and the BMC50 for MAA in the 
embryonic stem cell (ES‐D3 cell) diﬀerentiation assay of the Embryonic Stem cell 
Test (EST) is 2.3–2.5 mM (De Jong et al., 2009). Like several other chemicals that 
cause developmental toxicity such as valproic acid (VPA), ethylhexanoic acid and 
boric acid, MAA is a weak acid, suggesting that the acidic nature of MAA and 
related glycol ether alkoxyacetic acid metabolites might play a role in their 
induction of developmental toxicity. Nau and Scott (1986) showed that weak acids 
accumulate in the developing embryo because of its relatively high pH compared to 
maternal blood. They hypothesized that birth defects caused by these acids could 
be due to an alteration of the intracellular pH (pHi) of embryonic cells (Nau and 
Scott, 1986). A decrease of the pHi of embryonic cells by the drugs acetazolamide 
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(ACZ) (Scott et al., 1990) and VPA (Scott et al., 1997) has been linked to their 
induction of developmental toxicity in mice. ACZ inhibits carbonic anhydrase, 
causing indirectly an intracellular acidification (Scott et al., 1990), whereas VPA‐
induced intracellular acidification could be due to the acidic nature of the chemical 
itself, carrying protons directly to the embryo (Scott et al., 1997). When amiloride, 
a blocker of the Na+/H+‐antiporter in the cell membrane, was co‐administered with 
ACZ or VPA, an exacerbation in developmental toxicity was found (Scott et al., 
1990; Scott et al., 1997). This was due to the inhibition of the Na+/H+‐antiporter by 
amiloride, impeding the cells to transport the excess of H+ ions out of the cell when 
being exposed to an acid overload (Scott et al., 1990). The goal of the present study 
was to investigate the possible role of an eﬀect on the pHi in the mechanism of 
developmental toxicity induced by MAA and related glycol ether alkoxyacetic acid 
metabolites. This was done by measuring the changes in the pHi of BALB/c‐3T3 
embryonic fibroblasts exposed to MAA and the alkoxyacetic acid metabolites of 
ethylene glycol monoethyl ether (EGEE), ethylene glycol monobutyl ether (EGBE) 
and ethylene glycol monophenyl ether (EGPE), being ethoxyacetic acid (EAA), 
butoxyacetic acid (BAA) and phenoxyacetic acid (PAA), respectively. Eﬀects on the 
pHi of BALB/c‐3T3 cells by ACZ and VPA, both known to decrease the pHi in vivo, 
were investigated as well. Also, the eﬀect of MAA and ACZ on the pHi of 
undiﬀerentiated, diﬀerentiating and diﬀerentiated ES‐D3 cells was measured. 
Furthermore, the eﬀect of the Na+/H+‐antiporter blocker amiloride on MAA‐
induced inhibition of ES‐D3 cell diﬀerentiation was assessed, using ACZ as a 
positive control. 
 
Materials and methods 
Chemicals 
ACZ, all‐trans‐retinoic acid (ATRA), amiloride, EAA, 5‐fluorouracil (5‐FU) and 
MAA were purchased from Sigma‐Aldrich (Zwijndrecht, the Netherlands). BAA, 
dimethyl sulfoxide (DMSO) and VPA were purchased from Acros Organics (Geel, 
Belgium) and PAA was purchased from Fluka (Zwijndrecht, the Netherlands). 2’,7’‐
Bis‐(2‐carboxyethyl)‐5‐(and‐6)‐carboxyfluorescein (BCECF), BCECF acetoxymethyl 
ester (BCECF‐AM) and nigericin were purchased from Molecular Probes 
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(Invitrogen, Breda, the Netherlands). Ethanol, K2HPO4 and KH2PO4 were obtained 
from Merck (Darmstadt, Germany).  
BALB/c‐3T3 cell culture  
The BALB/c‐3T3 murine embryonic fibroblast cell line was cultured in 75 cm2 cell 
culture flasks (Corning, Schiphol‐Rijk, the Netherlands) at 37 °C in a humidified 
atmosphere of 5% CO2 in Dulbecco's modified Eagle's medium (DMEM) 
(Invitrogen) supplemented with 10% fetal calf serum (HyClone‐Perbio, Etten‐Leur, 
the Netherlands) and 100 U/ml penicillin/100 μg/ml streptomycin (Invitrogen). 
Cells were subcultured three times a week, using trypsin‐EDTA (Invitrogen) to 
detach cells. 
Undiﬀerentiated ES‐D3 cell culture 
The murine ES‐D3 cell line was cultured according to the method described by De 
Smedt et al. (2008). Briefly, cells were cultured in cell culture Petri dishes (35 mm × 
10 mm, Corning) at 37 °C in a humidified atmosphere of 5% CO2 in DMEM 
supplemented with 20% fetal calf serum, 2 mM glutamine (Invitrogen), 50 U/ml 
penicillin/50 μg/ml streptomycin, 1% v/v non‐essential amino acids (Invitrogen) 
and 0.1 mM β‐mercaptoethanol (Sigma‐Aldrich). To keep cells undiﬀerentiated, 
1000 U/ml murine leukemia inhibiting factor (mLIF) (ESGRO®, Chemicon 
International, Amsterdam, The Netherlands) was added to the culture medium. 
Cells were subcultured three times a week, using non enzymatic dissociation buﬀer 
(Sigma‐Aldrich) to detach cells. 
BCECF calibration curves  
To assess the eﬀects of the test chemicals on the pHi, BCECF‐AM was used. 
BCECF‐AM passively diﬀuses through the cell membrane and is cleaved 
intracellularly by cellular esterases, resulting in the free acid BCECF, which is 
trapped inside the cell. BCECF fluorescence at λex=490 nm, λem=535 nm is pH‐
dependent, whereas BCECF fluorescence at λex=440 nm, λem=535 nm is not (Owen, 
1992). The BCECF fluorescence ratio (λex=490 nm, λem=535 nm)/(λex=440 nm, 
λem=535 nm) is a measure for the pHi: the higher the ratio, the higher the pHi. The 
fluorescence ratio measured in the cells can be translated into actual pHi values 
using a BCECF calibration curve. Two types of calibration curves were made: a 
series of calibration curves using increasing concentrations of the free acid BCECF 
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in potassium phosphate of diﬀerent pH values and a calibration curve using BCECF
‐loaded BALB/c‐3T3 cells subsequently incubated with potassium phosphate of 
diﬀerent pH values and 10 μM nigericin to equilibrate the pHi with the extracellular 
pH (Thomas et al., 1979). To obtain calibration curves for the free acid BCECF, 0.1 
M potassium phosphate solutions were prepared with a pH range from 5 to 8 and 
supplemented with BCECF at concentrations ranging from 0.05 to 1 μM. Solutions 
containing BCECF were added to a ViewPlate‐96‐well plate (Perkin Elmer, 
Groningen, the Netherlands; 200 μl/well). BCECF fluorescence at λex=490 nm, 
λem=535 nm and λex=440 nm, λem=535 nm was measured using a Varian Cary Eclipse 
Fluorescent Spectrophotometer (Varian, Middelburg, the Netherlands). To obtain a 
calibration curve for the BCECF‐loaded BALB/c‐3T3 cells, a cell suspension of 
BALB/c‐3T3 cells was made and cells were washed with HBSS. The cells were 
incubated for 30 min with 1 μM BCECF‐AM in HBSS and subsequently washed with 
HBSS. Then, cells were transferred to 0.1 M potassium phosphate of pH values 
ranging from 5 to 8 supplemented with 10 μM nigericin to final cell concentrations 
of 0.5 · 106 cells/ml. From these solutions, 200 μl was transferred to a ViewPlate‐96‐ 
well plate. Subsequently, BCECF fluorescence was measured. The calibration curve 
in BALB/c‐3T3 cells appeared to resemble the curve obtained at 1 μM BCECF (see 
results section), revealing that cellular uptake and hydrolysis of BCECF‐AM appear 
to be eﬃcient. The calibration curve obtained with BALB/c‐3T3 cells was used to 
translate measured fluorescence ratios into actual pHi values. 
pHi measurements in BALB/c‐3T3 and undiﬀerentiated ES‐D3 cells  
A cell suspension of either BALB/c‐3T3 or ES‐D3 cells was made and cells were 
washed with HBSS. Then, the cells were incubated for 30 min with 1 μM BCECF‐
AM in HBSS and subsequently washed with HBSS. Cells were diluted to a 
concentration of 1 · 106 cells/ml in HBSS of which 100 μl was transferred to the inner 
60 wells of a ViewPlate‐96‐well plate. Subsequently, 100 μl exposure medium 
containing the test chemicals, added directly to HBSS (BAA, EAA, MAA), added 
from a 100 times concentrated stock solution in DMSO to HBSS (5‐FU, ACZ, ATRA, 
PAA), or added from a 100 times concentrated stock solution in ethanol (VPA), was 
added to the cells (final solvent concentrations 0.5% v/v). After 30 and 60 min 
incubation, BCECF fluorescence at λex=490 nm, λem=535 nm and λex=440 nm, 
λem=535 nm was measured using a Varian Cary Eclipse Fluorescent 
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Spectrophotometer. Fluorescence measurements of cells exposed to ACZ were also 
performed after 2 and 4 h exposure. 
ES‐D3 cell diﬀerentiation assay  
To study the eﬀects of ACZ and MAA in the presence or absence of amiloride on 
the diﬀerentiation of ES‐D3 cells into contracting cardiomyocytes, the 
diﬀerentiation assay described by De Smedt et al. (2008) was used, with small 
modifications. Briefly, on day 0, droplets of 20 μl cell suspension (3.75 · 104 cells/ml) 
were seeded on the inside of the lid of a 96‐well plate (Corning). Caps of Eppendorf 
tubes were placed at the corners of the well plate to elevate the lid in order to 
prevent direct contact of the hanging drops with the well plate. Wells were filled 
with 250 μl phosphate buﬀered saline (PBS, Invitrogen) to obtain the right 
humidity and to prevent evaporation of the hanging drops. On day 3, cell 
aggregates, called embryoid bodies (EBs), were formed and these were transferred 
to bacteriological petri dishes (Greiner Bio‐one, Alphen a/d Rijn, the Netherlands). 
On day 5, EB structure and size were evaluated using light microscopy. Pictures of 
EBs were taken using an Olympus Color View IIIu camera connected to an 
Olympus CKX41 culture microscope (Olympus Soft Imaging Solutions, Münster, 
Germany). EBs were transferred to 24‐well plates (Corning, 1 EB/well) and were 
incubated for another 5 days. On day 10, the number of wells containing 
contracting cardiomyocytes was determined using light microscopy. Exposure to 
test chemicals, added from 400 times concentrated stock solutions in DMSO to 
culture medium, started at day 0 and lasted for 10 days. Exposure medium was 
refreshed at day 3 and day 5. Solvent controls (0.25% DMSO v/v) were included in 
each experiment. A test was considered valid when at least 21 out of 24 wells of the 
blank (non‐exposed cells) and the solvent control plate contained contracting 
cardiomyocytes. For each plate, the fraction of EBs diﬀerentiated into contracting 
cardiomyocytes was calculated.  
pHi measurements in diﬀerentiating EBs (day 5 EBs) and diﬀerentiated EBs (day 10 
EBs) 
To measure the eﬀect of MAA on the pHi of diﬀerentiating ES‐D3 cells, the ES‐D3 
cell diﬀerentiation assay was carried out as described above with small 
modifications. The eﬀect of ACZ and MAA on the pHi was investigated using 
Glycol ether-induced decrease of the pHi 
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diﬀerentiating EBs (day 5 EBs) and diﬀerentiated EBs (day 10 EBs). Day 5 EBs were 
washed with HBSS and incubated for 30 min with 1 μM BCECF‐AM in HBSS. The 
BCECF‐AM solution was removed after 30 min and EBs were washed with HBSS. 
Subsequently, 20 EBs/well were plated in a ViewPlate‐96‐well plate containing ACZ 
added from a 200 times concentrated stock solution in DMSO to HBSS or MAA 
added directly to HBSS. After 30 min incubation, BCECF fluorescence was 
measured in MAA‐exposed cells and after 1, 2 and 4 h incubation BCECF 
fluorescence was measured in ACZ‐exposed cells. To measure the pHi of day 10 EBs, 
day 5 EBs that had not been used for pHi measurements were plated in a ViewPlate
‐96‐well plate. At day 10, the diﬀerentiated EBs were washed with HBSS and 
incubated for 30 min with 1 μM BCECF‐AM in HBSS. The BCECF‐AM solution was 
removed after 30 min and diﬀerentiated EBs were washed with HBSS. 
Subsequently, the diﬀerentiated EBs were exposed to ACZ added from a 200 times 
concentrated stock solution in DMSO to HBSS or MAA added directly to HBSS. 
After 30 min incubation, BCECF fluorescence was measured in MAA‐exposed cells 
and after 1, 2 and 4 h incubation BCECF fluorescence was measured in ACZ‐
exposed cells.  
Data analysis 
Concentration‐response curve fitting for the ES‐D3 cell diﬀerentiation assay was 
performed using the United States Environmental Protection Agency (US EPA)’s 
benchmark dose software (BMDS) version 2.0. In order to test for significant 
diﬀerences in pHi values of cells exposed to test chemicals compared to the control, 
a one‐way ANOVA followed by a Dunnett's Multiple Comparison Test was used 
(Graphpad Prism 5). To test for significant eﬀects of amiloride on diﬀerentiating EB 
size (day 5 EBs) and the fraction diﬀerentiated EBs (day 10 EBs), one‐tailed 
Student's t‐tests were used (Graphpad Prism 5). 
 
Results 
BCECF calibration curves 
Figure 2 shows the measured fluorescence ratios (λex=490 nm, λem=535 nm/
λex=440 nm, λem=535 nm) obtained with the BCECF concentrations present in 0.1 M 
potassium phosphate with pH values ranging from 5 to 8 and the measured 
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fluorescence ratios of BCECF‐loaded BALB/c‐3T3 cells in 0.1 M potassium 
phosphate with pH values ranging from 5 to 8 and supplemented with 10 μM 
nigericin. A sigmoidal model was fitted to these data points to obtain BCECF 
calibration curves using Sigmaplot 9.01 (Figure 2). Figure 2 shows that pH‐
dependent BCECF calibration curves vary with the BCECF concentration. The 
calibration curve of 1 μM BCECF resembles the calibration curve made in the 
BCECF‐loaded BALB/c‐3T3 cells, revealing that cellular uptake and hydrolysis of 
BCECF‐AM appear to be eﬃcient and suggesting that intracellular BCECF 
concentrations are equivalent to or higher than the extracellular concentration of 1 
μM BCECF‐AM added to upload the cells. The calibration curve made in the 
BCECF‐loaded BALB/c‐3T3 cells was used to translate the measured fluorescence 
ratios obtained in the pHi experiments performed in BALB/c‐3T3 and ES‐D3 cells 
into actual pHi values. 
Glycol ether-induced decrease of the pHi 
Figure 2. BCECF fluorescence ratios ((λex=490 nm, λem=535 nm)/(λex=440 nm, λem=535 nm)) of 
calibration curves obtained using increasing BCECF concentrations added to 0.1 M potassium phosphate 
of pH values ranging from 5 to 8 (closed symbols) and BCECF‐loaded BALB/c‐3T3 cells incubated in 0.1 
M potassium phosphate with pH values ranging from 5 to 8 supplemented with 10 μM nigericin to 
equilibrate the pHi with the extracellular pH (open symbol). The calibration curve made in BCECF‐
loaded BALB/c‐3T3 cells was used to convert measured fluorescence ratios in both BALB/c‐3T3 and ES‐
D3 cells into actual pHi values. 
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ACZ, VPA and the alkoxyacetic acid metabolites of glycol ethers cause a decrease of 
the pHi of BALB/c‐3T3 cells 
Figure 3 shows the concentration‐dependent decrease of the pHi of BALB/c‐3T3 
cells exposed to the developmentally toxic drugs ACZ and VPA. No eﬀect on the 
pHi of ACZ‐exposed BALB/c‐3T3 cells was found after 30 and 60 min exposure. A 
small but significant decrease of the pHi by 5 mM ACZ was found after 2 h exposure 
and by 2 and 5 mM ACZ after 4 h exposure (Figure 3A). For VPA, no diﬀerences in 
eﬀects on the pHi were found between 30 and 60 min exposure (data shown for 30 
min exposure in Figure 3B). A significant decrease of the pHi was measured at VPA 
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Figure 3. Decrease of pHi of BALB/c‐3T3 cells exposed for 1, 2 and 4 h to ACZ (A) and for 30 min to VPA 
(B) indicated by decreasing BCECF fluorescence ratio values (λex=490 nm, λem=535 nm/λex=440 nm, 
λem=535 nm). The fluorescence ratios were converted into pHi values indicated on the Y‐axis on the 
right using the calibration curve made for BCECF‐loaded BALB/c‐3T3 cells of Figure 2. Note that the 
conversion of BCECF fluorescence ratios into pHi values does not follow a linear scale since the 
calibration curve is also non‐linear. *Significantly diﬀerent (p<0.05) from BCECF fluorescence ratio in 
cells of the solvent control. 
concentrations of 2.5 mM and higher (Figure 3B). Also the developmentally toxic 
alkoxyacetic acid metabolites MAA, EAA, BAA and PAA caused a concentration‐
dependent decrease of the pHi of these cells after 30 min exposure (Figure 4), 
which was the same after 60 min exposure (data not shown). Exposure of BALB/c‐
3T3 cells to 5‐FU and ATRA up to concentrations of 10 μM and 1 μM respectively, 
did not change the pHi of BALB/c‐3T3 cells (Figure 5). 
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Figure 4. Decrease of pHi of BALB/c‐3T3 cells exposed for 30 min to MAA, EAA, BAA or PAA indicated 
by decreasing BCECF fluorescence ratio values (λex=490 nm, λem=535 nm/λex=440 nm, λem=535 nm). The 
fluorescence ratios were converted into pHi values indicated on the Y‐axis on the right using the 
calibration curve made for BCECF‐loaded BALB/c‐3T3 cells of Figure 2. Note that the conversion of 
BCECF fluorescence ratios into pHi values does not follow a linear scale since the calibration curve is 
also non‐linear. *Significantly diﬀerent (p<0.05) from BCECF fluorescence ratio in cells of the solvent 
control. 
Figure 5. 5‐FU (A) and ATRA (B) do not change the pHi of BALB/c‐3T3 cells as indicated by BCECF 
fluorescence ratio values (λex=490 nm, λem=535 nm/λex=440 nm, λem=535 nm). The fluorescence ratios 
were converted into pHi values indicated on the Y‐axis on the right using the calibration curve made for 
BCECF‐loaded BALB/c‐3T3 cells of Figure 2. Note that the conversion of BCECF fluorescence ratios into 
pHi values does not follow a linear scale since the calibration curve is also non‐linear. 
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MAA and ACZ cause a decrease of the pHi of diﬀerentiating and diﬀerentiated ES‐D3 
cells 
The eﬀect of ACZ (Figure 6) and MAA (Figure 7) on the pHi of undiﬀerentiated, 
diﬀerentiating and diﬀerentiated ES‐D3 cells was investigated. The concentrations 
of MAA and ACZ used are the same as the ones that were used in the ES‐D3 cell 
diﬀerentiation assay (Figures 8 and 9). Figure 6A shows the results obtained for the 
undiﬀerentiated ES‐D3 cells exposed for 4 h to ACZ and also presents, for 
comparison, the data for the eﬀect of ACZ on the pHi of BALB/c‐3T3 cells. The data 
show that the pHi of undiﬀerentiated ES‐D3 cells is not aﬀected by ACZ, whereas 
ACZ induces a small and significant decrease of the pHi of BALB/c‐3T3 cells (Figure 
6A). ACZ caused a more pronounced decrease of the pHi of diﬀerentiating ES‐D3 
cells (day 5 EBs, Figure 6B), and a small decrease in diﬀerentiated ES‐D3 cells (day 
10 EBs, Figure 6C). In day 5 EBs, a significant decrease of the pHi was found after 2 
and 4 h exposure to 1 and 2.5 mM ACZ (Figure 6B). In day 10 EBs, a significant 
decrease of the pHi was found after 1 and 2 h exposure to 2.5 mM ACZ (Figure 6C).  
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Figure 6. Decrease of pHi of BALB/c‐3T3 and ES‐D3 cells exposed for 4 h to ACZ (A), day 5 
diﬀerentiating (B) and day 10 diﬀerentiated (C) EBs exposed for 1, 2 and 4 h to ACZ indicated by 
decreasing BCECF fluorescence ratio values (λex=490 nm, λem=535 nm/λex=440 nm, λem=535 nm). The 
fluorescence ratios were converted into pHi values indicated on the Y‐axis on the right using the 
calibration curve made for BCECF‐loaded BALB/c‐3T3 cells of Figure 2. Note that the conversion of 
BCECF fluorescence ratios into pHi values does not follow a linear scale since the calibration curve is 
also non‐linear. *Significantly diﬀerent (p<0.05) from BCECF fluorescence ratio in cells of the solvent 
control. 
Figure 7A shows the results obtained for the eﬀects of MAA on the pHi of 
undiﬀerentiated ES‐D3 cells and also presents, for comparison, the data for the 
eﬀect of MAA on the pHi of BALB/c‐3T3 cells. The data show that the decrease of 
the pHi of ES‐D3 cells by MAA is comparable to the MAA‐induced decrease of the 
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pHi of BALB/c‐3T3 cells. MAA also causes a concentration‐dependent decrease of 
the pHi of diﬀerentiating (day 5 EBs, Figure 7B) and diﬀerentiated (day 10 EBs, 
Figure 7C) ES‐D3 cells. In day 5 EBs, a significant decrease of the pHi was found at 
MAA concentrations of 2.8 and 5.6 mM, whereas in day 10 EBs, only a significant 
decrease of the pHi was found at 5.6 mM. 
MAA and ACZ decrease day 5 EB size and inhibit ES‐D3 cell diﬀerentiation, both 
potentiated by the Na+/H+‐antiporter blocker amiloride 
Figure 8 shows the eﬀects of ACZ and MAA in the absence or presence of 100 μM 
amiloride on the structure and size of diﬀerentiating ES‐D3 cells (day 5 EBs). A 
decrease in EB‐size was noticed for all the ACZ concentrations tested. When 100 
μM amiloride was co‐administered with ACZ, the EBs had a granular structure 
(Figure 8). For MAA, a decrease in EB‐size was only noticed at the highest 
concentration tested (5.6 mM), whereas when 100 μM amiloride was co‐
administered with MAA, the EB‐size had already decreased at a concentration of 1.1 
mM (Figure 8).  
The inhibition of ES‐D3 cell diﬀerentiation into contracting cardiomyocytes by 
ACZ and MAA is shown in Figure 9. ACZ, the positive control for inducing 
developmental toxicity by causing intracellular acidification, inhibited ES‐D3 cell 
Glycol ether-induced decrease of the pHi 
Figure 7. Decrease of pHi of BALB/c‐3T3 and ES‐D3 cells (A), day 5 diﬀerentiating (B) and day 10 
diﬀerentiated (C) EBs exposed for 30 min to MAA indicated by decreasing BCECF fluorescence ratio 
values (λex=490 nm, λem=535 nm/λex=440 nm, λem=535 nm). The fluorescence ratios were converted into 
pHi values indicated on the Y‐axis on the right using the calibration curve made for BCECF‐loaded 
BALB/c‐3T3 cells of Figure 2. Note that the conversion of BCECF fluorescence ratios into pHi values does 
not follow a linear scale since the calibration curve is also non‐linear. *Significantly diﬀerent (p<0.05) 
from BCECF fluorescence ratio in cells of the solvent control. 
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diﬀerentiation with a BMC50 of 1.3 mM (BMCL50: 1.2 mM; the lower limit of the 95% 
confidence interval on the BMC50) (Figure 9A), whereas MAA inhibited ES‐D3 cell 
diﬀerentiation with a BMC50 of 2.9 mM (BMCL50: 2.6 mM) (Figure 9B). The eﬀects 
of both ACZ and MAA were potentiated when 100 μM amiloride was co‐
administered, resulting in BMC50 values of 0.20 mM for ACZ (BMCL50: 0.15 mM) 
and 1.3 mM for MAA (BMCL50: 1.2 mM). Exposure to 100 μM amiloride alone did 
not aﬀect ES‐D3 cell diﬀerentiation (Figure 9). 
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Figure 8. Decrease in EB size at day 5 after exposure to ACZ or MAA in the absence (black columns) or 
presence (grey columns) of 100 μM amiloride. C=solvent control. *Significantly smaller diameter 
compared to control (p<0.05). 
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Discussion 
The goal of the present study was to investigate whether the alkoxyacetic acid 
metabolites of glycol ethers, being their proximate developmental toxicants, aﬀect 
the pHi of embryonic cells, providing a hypothesis for the mechanism underlying 
glycol ether‐induced developmental toxicity. The study shows that the glycol ether 
alkoxyacetic acid metabolites MAA, EAA, BAA and PAA, cause a concentration‐
dependent decrease of the pHi of embryonic cells. Furthermore, the results 
obtained show that MAA‐induced inhibition of ES‐D3 cell diﬀerentiation is 
potentiated by the Na+/H+‐antiporter blocker amiloride, impeding the cells to 
remove the excess of H+‐ions when being exposed to the acid overload. These 
results point to a role of the decrease of the pHi in the MAA‐induced inhibition of 
ES‐D3 cell diﬀerentiation. Altogether, the results of the present study indicate that 
a decrease of the pHi of embryonic cells is a possible mechanism by which the 
glycol ether alkoxyacetic acid metabolites induce developmental toxicity. 
The developmental toxicants ACZ and VPA have been shown to induce 
developmental toxicity in vivo by causing a decrease in the pHi of mouse embryos 
(Scott et al., 1990; Scott et al., 1997). The present study shows that these chemicals, 
Glycol ether-induced decrease of the pHi 
Figure 9. Inhibition of EB diﬀerentiation into contracting cardiomyocytes when being exposed to ACZ 
(A, n=3) or MAA (B, n=4) in the absence (black columns) or presence (grey columns) of 100 μM 
amiloride. *Significant diﬀerence (p<0.05) between absence and presence of 100 μM amiloride. 
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which were used as positive controls, also decrease the pHi of embryonic cells in 
vitro. ACZ decreased the pHi of embryonic cells at concentrations that inhibit ES‐
D3 cell diﬀerentiation into contracting cardiomyocytes (Figures 3A and 6, Table 1). 
The decrease of the pHi caused by ACZ was dependent on the exposure time. This 
is probably due to the fact that ACZ is a carbonic anhydrase inhibitor, resulting in 
an indirect eﬀect on the pHi of the cells (Scott et al., 1990). The decrease of the pHi 
caused by ACZ was rather small in the BALB/c‐3T3 cells compared to the decrease 
of the pHi caused by the other positive control VPA. This might be due to the fact 
that ACZ and VPA have diﬀerent mechanisms underlying the pHi decrease, 
proceeding by respectively the inhibition of intracellular carbonic anhydrase (Scott 
et al., 1990) and by carrying protons directly to the cell as suggested by Scott et al. 
(1997). 
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Table 1. Concentrations of chemicals inhibiting ES‐D3 cell diﬀerentiation into contracting 
cardiomyocytes. 
a BMC50: 50% inhibition of diﬀerentiation, determined in present study. 
b ID50: 50% inhibition of diﬀerentiation, determined by Genschow et al. (2004). 
c BMC50: 50% inhibition of diﬀerentiation, determined by De Jong et al. (2009). 
Since no carbonic anhydrase enzyme activity or carbonic anhydrase protein 
expression has been detected in 3T3‐L1 fibroblasts (Lynch et al., 1993), the small 
decrease of the pHi found in Balb/c‐3T3 fibroblasts exposed to ACZ might be due to 
low expression of carbonic anhydrase in these cells. ACZ did not cause a decrease 
in the pHi of undiﬀerentiated ES‐D3 cells at all, pointing at possibly no carbonic 
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anhydrase expression in undiﬀerentiated ES‐D3 cells (Figure 6A). However, a more 
pronounced pHi decrease was found in diﬀerentiating ES‐D3 cells (Figure 6B), 
suggesting that carbonic anhydrase is expressed during the diﬀerentiation of ES‐D3 
cells into cardiomyocytes. This suggestion is further supported by the finding that 
carbonic anhydrase is expressed in the embryonic heart, including the 
myocardium, during mouse development (Vuillemin and Pexieder, 1997). 
A significant decrease of the pHi by VPA was found at concentrations of 2.5 mM 
and higher, approximately 5 times higher than the concentrations that were found 
to inhibit ES‐D3 cell diﬀerentiation into contracting cardiomyocytes (Genschow et 
al., 2004) (Figure 3B, Table 1). Like ACZ, the alkoxyacetic acid metabolites MAA, 
EAA, BAA and PAA caused a decrease of the pHi of embryonic cells at 
concentrations that inhibit the diﬀerentiation of ES‐D3 cells into contracting 
cardiomyocytes (De Jong et al., 2009) (Figure 4, Table 1). 
The two other developmental toxicants that were tested in the present study, 5‐
FU and ATRA, did not change the pHi of embryonic cells, even at concentrations 
more than 10 times higher than those that inhibit the diﬀerentiation of ES‐D3 cells 
into contracting cardiomyocytes (Genschow et al., 2004) (Figure 5, Table 1). These 
results point at a diﬀerent mechanism of developmental toxicity of these 
chemicals, which are suggested to be thymidylate synthetase inhibition by 5‐FU 
(Shuey et al., 1994) and disturbance of retinoid signal transduction pathways by 
ATRA (Collins and Mao, 1999). 
The role of a decrease of the pHi by the glycol ether alkoxyacetic acid metabolites 
on the inhibition of ES‐D3 cell diﬀerentiation was further investigated using MAA 
as a model compound and ACZ as a positive control. Like ACZ, MAA caused a 
decrease of the pHi of diﬀerentiating and diﬀerentiated ES‐D3 cells at similar 
concentrations as was found in BALB/c‐3T3 cells (Figure 7). A decrease of the pHi 
caused by ACZ and MAA in the ES‐D3 cell diﬀerentiation assay occurred at 
concentrations aﬀecting both the diameter size of day 5 EBs (Figure 8) and the ES‐
D3 cell diﬀerentiation into contracting cardiomyocytes (Figure 9), indicating that 
the ACZ‐ and MAA‐induced decrease of the pHi might aﬀect EB formation and ES‐
D3 cell diﬀerentiation. This indication is strengthened by the findings that the  
Na+/H+‐antiporter blocker amiloride potentiates the MAA‐induced decrease in 
diameter size of day 5 EBs (Figure 8) and the ACZ‐ and MAA‐induced inhibition of 
Glycol ether-induced decrease of the pHi 
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ES‐D3 cell diﬀerentiation into contracting cardiomyocytes (Figure 9), since 
amiloride is known for its inhibition of cellular recovery from an acid overload 
(Muallem and Loessberg, 1990; Phillips et al., 2000; Scott et al., 1990). However, 
whether amiloride can potentiate EGME‐induced developmental toxicity in vivo as 
has been shown for both ACZ (Scott et al., 1990) and VPA (Scott et al., 1997) is not 
clear. Nelson et al. (1989) investigated the eﬀects of amiloride on EGME‐induced 
developmental toxicity. No conclusions about a possible potentiation of EGME‐
induced developmental toxicity by amiloride could be drawn, since the number of 
malformations was higher in the group to which amiloride was co‐administered 
with EGME, whereas the number of resorptions was higher in the group that was 
exposed to EGME alone (Nelson et al., 1989). It should be mentioned that amiloride 
was administered via the diet in the EGME study (Nelson et al., 1989), whereas 
amiloride was administered subcutaneously in the ACZ study (Scott et al., 1990). 
Therefore, it is not clear whether in the study of Nelson et al. (1989) amiloride 
plasma levels have been high enough to potentiate EGME‐induced developmental 
toxicity, due to possible diﬀerences in amiloride kinetics upon oral versus 
subcutaneous administration. 
Scott et al. (1994) suggested that the developmental toxicity potential of an acid 
depends on its ‘intrinsic activity’, which can be measured in an in vitro 
developmental toxicity test, and its kinetic properties in vivo, like half‐life values in 
the maternal blood or in the embryo. Methylhexanoic acid and octanoic acid are 
for example rapidly eliminated from the blood and therefore not developmentally 
toxic in vivo, whereas ethylhexanoic acid and VPA are slowly eliminated from the 
blood, resulting in embryo malformations (Scott et al., 1994). Diﬀerences in in vitro 
potencies of the glycol ether alkoxyacetic acid metabolites MAA, EAA, BAA and 
PAA have been observed in rat whole embryo cultures and in the EST (Giavini et 
al., 1993; De Jong et al., 2009), with MAA being the most potent followed by EAA, 
BAA and PAA respectively. Also diﬀerences in in vivo kinetics of MAA, EAA and 
BAA are reported, with BAA being the most rapidly excreted followed by EAA and 
MAA respectively (Ghanayem et al., 1990; Aasmoe et al., 1999). The diﬀerences in in 
vitro potencies and elimination rates of the alkoxyacetic acid metabolites are in 
concordance with the in vivo potency of their parent glycol ethers, with EGME 
being the most potent, followed by EGEE, EGBE and EGPE, respectively (Nagano et 
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al., 1981; Wier et al., 1987; Heindel et al., 1990; De Jong et al., 2009). In vivo 
developmental toxicity eﬀects of these glycol ethers are found at doses that result 
in peak plasma levels of the accompanying alkoxyacetic acid metabolites in the 
millimolar range (EGME/MAA (Sweeney et al., 2001), EGEE/EAA (Doe, 1984; 
Gargas et al., 2000), EGBE/BAA (Sleet et al., 1989; Ghanayem et al., 1990)), similar 
to the concentrations that aﬀect the pHi, as shown in the present study. 
Altogether it is concluded that the alkoxyacetic acid metabolites of glycol ethers 
cause an intracellular acidification of embryonic cells at concentrations that inhibit 
embryonic stem cell diﬀerentiation. Since these concentrations are observed as 
peak plasma levels of animals exposed to developmentally toxic doses of the parent 
glycol ethers, it is suggested that intracellular acidification plays a role in the 
developmental toxicity caused by the alkoxyacetic acid metabolites of glycol ethers. 
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Abstract 
The embryonic stem cell test (EST) has been proposed as an in vitro assay that 
might reduce animal experimentation in regulatory developmental toxicology. So 
far, evaluation of the EST was not performed using chemicals within distinct 
chemical classes. Evaluation within a distinct class of structurally related chemicals 
can define the usefulness of the assay for the chemical class tested. The aim of the 
present study was to evaluate the relative sensitivity of the EST for a selected series 
of homologous chemicals and to compare the data to the relative developmental 
toxicity of the chemicals in vivo. To this end a series of proximate developmentally 
toxic glycol ether alkoxyacetic acid metabolites was tested in the embryonic stem 
cell (ES‐D3 cell) proliferation assay and the ES‐D3 cell diﬀerentiation assay of the 
EST. All glycol ether alkoxyacetic acid metabolites tested showed a concentration‐
dependent inhibition of ES‐D3 cell diﬀerentiation but not in ES‐D3 cell 
proliferation. Methoxyacetic acid was the most potent chemical followed by 
ethoxyacetic acid, butoxyacetic acid and phenoxyacetic acid, respectively. The 
potency ranking of the chemicals in the ES‐D3 cell diﬀerentiation assay 
corresponds with the available in vivo data. The relative diﬀerences between the 
potencies of the chemicals appeared more pronounced in the in vivo studies than 
in the ES‐D3 cell diﬀerentiation assay. A possible explanation for this discrepancy 
could be the diﬀerence in the kinetics of the chemicals in vivo as compared with 
their in vitro kinetics. This study illustrates that the ES‐D3 cell diﬀerentiation assay 
of the EST can be used to set priorities for developmental toxicity testing within 
classes of related chemicals. 
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Introduction 
In the context of the European REACH (Registration, Evaluation, Authorization 
and restriction of CHemicals) legislation the evaluation of the developmental 
toxicity of a large number of chemicals is foreseen. Unfortunately, the current 
regulatory animal tests for the evaluation of developmental toxicity of chemicals 
require a high number of laboratory animals, are time‐consuming and expensive 
(Van der Jagt et al., 2004). Consequently, there is a great need to develop 
alternative approaches and methods (Schaafsma et al., 2009). In vitro alternatives 
could accelerate the process of chemical safety testing compared with classical in 
vivo testing, also reducing costs and animal use. 
Currently three in vitro developmental toxicity assays have been formally 
validated, namely the rat postimplantation whole embryo culture test, the rat limb 
bud micromass test and the embryonic stem cell test (EST) (Genschow et al., 2004). 
Of these three assays, only the last does not require pregnant animals to obtain 
embryonic tissue. Embryonic stem cell lines have been derived from the inner cell 
mass of blastocysts and have the advantage of being able to diﬀerentiate into all 
cell types of the three primary germ layers (Martin, 1981). The EST uses this ability 
to study the eﬀect of chemicals on the diﬀerentiation of embryonic stem cells into 
contracting cardiomyocytes as an indication of developmental toxicity. The assay 
has been validated under the supervision of the European Centre for the Validation 
of Alternative Methods (ECVAM) in four diﬀerent laboratories using 20 diﬀerent 
chemicals resulting in an overall accuracy of 78% (Genschow et al., 2004). 
However, it remains to be answered whether a validation study using 20 chemicals 
of diverse nature is suﬃcient to make a definitive statement on the validity of the 
test system. In addition, the added value of the use of 3T3 cytotoxicity in the 
prediction model has been questioned (Spielmann et al., 2006). The applicability 
domain of the EST in terms of the chemical classes for which the test makes 
reliable predictions is still not suﬃciently defined to allow regulatory 
implementation and may vary with diﬀerent classes of chemicals tested (Hartung 
et al., 2004; Spielmann et al., 2006). Therefore, the applicability of the assay in a so‐
called category approach, which assumes that the in vitro ranking of chemicals of a 
certain chemical category corresponds with the potency ranking of these chemicals 
in vivo, need to be established. Therefore, evaluation of the EST within a distinct 
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class of structurally related chemicals can define the usefulness of the assay for the 
chemical class under study. The aim of the present study was to evaluate the 
performance of the embryonic stem cell (ES‐D3 cell) proliferation and the ES‐D3 
cell diﬀerentiation assay of the EST for a selected series of homologous chemicals. 
To this end a series of glycol ethers and their glycol ether alkoxyacetic acid 
metabolites (Figure 1) was tested in the EST in two independent laboratories.  
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Figure 1. Chemical structure of the glycol ethers (EGME, EGEE), glycol ether alkoxyacetic acid 
metabolites (MAA, EAA, BAA, PAA) and two structural analogues (BuA, TCAA) included in the present 
study. 
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Results were compared among chemicals as well as between laboratories, and 
with available developmental toxicity data from in vivo animal studies. This class of 
chemicals was selected based on the availability of suﬃcient in vivo developmental 
toxicity data in order to allow comparison with the EST data. Also, these chemicals 
showed diﬀerences in embryotoxic potencies among the chemicals within the class, 
which facilitates the in vitro‐in vivo comparison. Glycol ethers are widely used as 
solvents in cosmetics, printing inks, plastics, household and industrial cleaning 
products and textile dyes. Some of them have been shown to cause developmental 
toxicity through several routes of exposure in mice, rats and rabbits (Feuston et al., 
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1990; Hanley et al., 1984; Nagano et al., 1981; Wier et al., 1987). Frequently occurring 
malformations include spina bifida occulta, fused, small or missing digits and 
exencephaly. As the glycol ether alkoxyacetic acid metabolites have been identified 
as the proximate developmental toxicants in animal studies and in whole embryo 
cultures (Brown et al., 1984; Giavini et al., 1993), the glycol ether alkoxyacetic acid 
metabolites methoxyacetic acid (MAA), ethoxyacetic acid (EAA), butoxyacetic acid 
(BAA) and phenoxyacetic acid (PAA) were selected for the present study together 
with the parent glycol ethers of MAA and EAA, being ethylene glycol monomethyl 
ether (EGME) and ethylene glycol monoethyl ether (EGEE), respectively (Figure 1). 
The specificity of the eﬀects of the glycol ether metabolites in the EST was further 
studied by comparison with the eﬀects of two structurally similar non‐glycol ether 
organic acids, butyric acid (BuA) and trichloroacetic acid (TCAA) (Figure 1).  
To determine the applicability of the ES‐D3 cell proliferation and ES‐D3 cell 
diﬀerentiation assay of the EST for glycol ethers, the inhibition concentration‐
response data obtained for several glycol ether alkoxyacetic acid metabolites were 
compared with in vivo developmental toxicity data of their parent compounds 
reported in the literature, using the benchmark dose (BMD) approach. In the BMD 
approach a dose‐response curve is fitted to determine the BMD for in vivo data and 
the benchmark concentration (BMC) for in vitro data, corresponding to the dose or 
concentration at which a certain benchmark response (BMR) is reached (Crump, 
1984). The method has several principal advantages above the classical No 
Observed Adverse Eﬀect Level (NOAEL) approach, as discussed elsewhere (Slob, 
2002). One of the uncertainties in the BMD approach, as with any type of dose‐
response modeling, lies in the model chosen to mimic the ‘‘true’’ dose‐response 
curve. The choice of the model fitted could influence the BMC values calculated 
and thereby influence the obtained ranking of the chemicals. Therefore, multiple 
models were used in the analysis to address this uncertainty. Another issue is the 
choice of the BMR used to determine the BMC values for the potency ranking. 
When concentration‐response curves are not of a similar shape, diﬀerent response 
levels could lead to a diﬀerence in the ranking of the chemicals based on the BMCs 
derived in vitro. This study investigated these uncertainties by deriving BMC values 
for multiple BMR values and with multiple types of dose‐response models based on 
ES‐D3 cell diﬀerentiation assay data for the glycol ether alkoxyacetic acid 
metabolites as the selected chemical class. In addition, the eﬀect of interlaboratory 
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variation on chemical ranking was addressed by testing the same chemical set in 
two independent laboratories. Finally, the resultant ranking was compared with in 
vivo data to assess the predictive value of the EST for the developmental toxicity of 
glycol ethers. 
 
Materials and methods 
Cell line and culture conditions  
The mouse embryonic stem cell line D3 (ATCC, Rockville, MD) was grown in 
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Breda, The 
Netherlands) at 37 oC and 5% CO2 and routinely passaged three times per week. 
Culture medium was supplemented with 20% fetal calf serum (Hyclone, Thermo‐
Fisher Scientific, Etten‐Leur, The Netherlands), 2 mM glutamine (Invitrogen), 50 
U/ml penicillin (Invitrogen), 50 µg/ml streptomycin (Invitrogen), 1% non‐essential 
amino acids (Invitrogen), 0.1 mM β‐mercaptoethanol (Sigma‐Aldrich, Zwijndrecht, 
The Netherlands) and 1000 U/ml murine leukemia inhibiting factor (mLIF) 
(ESGRO®, Chemicon International, Amsterdam, The Netherlands).  
Chemicals tested  
All chemicals were obtained from Sigma‐Aldrich unless stated otherwise. The 
glycol ether alkoxyacetic acid metabolites MAA, EAA, BAA (Tokyo Chemical 
Industries, Zwijndrecht, Belgium) and PAA were selected (Figure 1). Other test 
chemicals included the structural analogues TCAA and BuA and the parent glycol 
ethers EGME and EGEE. All chemicals were dissolved and diluted in DMSO (0.1% 
v/v final concentration in culture medium) with the exception of MAA, EAA, 
EGME and EGEE which were dissolved and diluted directly in culture medium. 5‐
Fluorouracil, dissolved in phosphate buﬀered saline (PBS, Invitrogen), was used as 
a positive control in the ES‐D3 cell diﬀerentiation assay (Genschow et al., 2004). 
ES‐D3 cell proliferation assay 
The ES‐D3 cell proliferation assay was carried out in Lab 1. To determine the 
potencies of the chemicals in inducing inhibition of ES‐D3 cell proliferation, ES‐D3 
cells were seeded in 96‐well plates at 500 cells per well in routine culture medium 
and allowed to attach for 2 h before chemical exposure at equal concentrations as 
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used in the diﬀerentiation assay. The cells were subsequently cultured for 5 days at 
37 oC and 5% CO2, with a medium renewal containing the corresponding chemical 
for exposure on day 3. On day 5, CellTiter‐blue (Promega, Leiden, The 
Netherlands) was added to each well and incubated for 2 h. After the incubation 
period the fluorescence was measured using a FLUOstar spectrofluorometer 
(FLUOstar Optima, BMG Labtech, de Meeren, The Netherlands) at λexcitation = 544 
nm and λemission = 590 nm. Three independent experiments were performed for 
each chemical.  
ES‐D3 cell diﬀerentiation assay 
The ES‐D3 cell diﬀerentiation assay for cardiac diﬀerentiation was carried out in 2 
labs as previously described using culture medium in the absence of mLIF 
(Genschow et al., 2004; De Smedt  et al., 2008). Briefly, on day 0 of the assay, 
droplets of 20 µl of an ES‐D3 cell suspension (3.75 · 104 cells/ml) were placed onto 
the inner side of the lid of a 10‐cm Petri dish (Greiner Bio‐one, Alphen a/d Rijn, the 
Netherlands) containing 5 ml of phosphate buﬀered saline (PBS, Invitrogen) and 
incubated at 37 oC and 5% CO2 for three days, in lab 1. In lab 2, droplets of 20 µl of 
an ES‐D3 cell suspension (3.75 · 104 cells/ml) were seeded on the inside of the lid of 
a 96‐well plate (Corning, Schiphol‐Rijk, the Netherlands). Caps of Eppendorf tubes 
were placed at the corners of the well plate to elevate the lid in order to prevent 
direct contact of the hanging drops with the well plate. Wells were filled with 250 
μl PBS to obtain the right humidity and to prevent evaporation of the hanging 
drops. On day 3, the resulting embryoid bodies (EBs) were transferred to 
bacteriological Petri dishes (Greiner). On day 5, the EBs were transferred to 24‐well 
plates (lab 1: TPP, Trasadingen, Switzerland; lab 2: Corning). On day 10, the number 
of wells containing contracting cardiomyocytes was determined by light 
microscopy. For each plate, the fraction of EBs diﬀerentiated into contracting 
cardiomyocytes was calculated. Cells were exposed to the test chemical in 
concentrations up to 1 mg/ml from day 0 onwards with a medium renewal 
containing the corresponding chemical for exposure on day 3 and day 5. Solvent 
controls were included in each experiment. Tests were accepted for further analysis 
if the solvent control plate contained at least 21 wells containing contracting 
cardiomyocytes out of 24 EBs incubated. Three independent experiments were 
done for each of the chemicals.  
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BMC and BMD derivation 
In vitro data. The results from the EST were analyzed using the BMD approach, 
meaning that a concentration‐response curve was fitted to determine the 
concentration associated with a predefined BMR. For each of the chemicals a 50% 
change in the number of contracting cardiomyocytes was selected as the BMR to 
calculate the benchmark concentrations for the diﬀerentiation (BMCd50). BMD 
values at a BMR of 25 and 10% were also determined to study the eﬀect of the 
choice of the response level on the ranking of the chemicals within the chemical 
class. For the concentration‐response curves for chemical‐induced inhibition of ES‐
D3 cell proliferation, a 50% inhibition of cell proliferation was selected as the BMR 
to calculate the benchmark concentrations for inhibition of cell proliferation 
(BMCp50). For the continuous data from this assay a model was selected according 
to the procedure previously described by Slob (2002) in which a family of 
concentration‐response models are fitted together. The goodness‐of‐fit was 
determined by the log‐likelihoods of each model. The final model selected was the 
model with the lowest number of parameters which gave the best significant fit. 
For the quantal data from the diﬀerentiation assay several models with a 
statistically equal goodness‐of‐fit for the data were used to determine the eﬀect of 
the model choice on the results. Models fitted included Logistic, Probit, Weibull 
and Gamma. The BMC calculations were performed using PROAST software (Slob, 
2002). 
In vivo data. For each of the chemicals a literature search was performed for in 
vivo developmental toxicity of the parent glycol ethers and their alkoxyacetic acid 
metabolites. For the glycol ether alkoxyacetic acid metabolites, which are 
considered as the proximate toxicants (Brown et al., 1984; Giavini et al., 1993), no 
relevant in vivo studies were available. Search terms included the chemical name 
together with combinations of the search terms teratogen, teratogenic, 
teratogenicity, development, developmental toxicity, malformation and 
embryotoxicity. Only studies containing multiple exposure times, multiple doses, 
and an oral exposure route were included in the data analysis for each of the glycol 
ethers. Fetal body weight and incidence of malformations were selected as the in 
vivo endpoints. The BMDs were calculated using dose‐response modeling as done 
with the in vitro dataset for continuous data. When required, dose‐response 
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modeling using constrained fit parameters was applied. The BMR for the BMD for 
each chemical was defined as a 10% decrease in fetal weight and a 10% additional 
incidence of malformations. These eﬀect levels were selected because they could be 
estimated within each of the selected studies and could be distinguished from the 
background variation. This approach has previously been used by Piersma et al. 
(2008). The BMD calculations were performed using PROAST software (Slob, 
2002). 
 
Results 
ES‐D3 cell proliferation assay 
ES‐D3 cell proliferation assays were performed to evaluate the potencies of the 
chemicals on the inhibition of ES‐D3 cell proliferation (Figure 2). The 
concentration‐response curves obtained were used to calculate the BMCp50 values 
corresponding to a 50% inhibition of ES‐D3 cell proliferation (Table 1). MAA was 
the most potent of the glycol ether alkoxyacetic acid metabolites, reducing the ES‐
D3 cell proliferation with a BMCp50 of 6.7 mM. The non‐glycol ethers TCAA and 
BuA resulted in lower BMCp50 values of 4.9 mM and 0.9 mM, respectively, 
reflecting higher toxic potencies of these chemicals than of the glycol ether 
alkoxyacetic acid metabolites tested. The alkoxyacetic acid metabolite BAA and the 
parent compounds EGME and EGEE did not cause an inhibition of ES‐D3 cell 
proliferation. 
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Table 1. BMCp50 values for inhibition of ES‐D3 cell proliferation by four glycol ether alkoxyacetic acid 
metabolites and two structural analogues. 
The 90% confidence interval is given between brackets. 
n.d.: not detected. 
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Figure 2. Concentration‐dependent eﬀects of glycol ether alkoxyacetic acid metabolites and two 
structural analogues on ES‐D3 cell proliferation in lab 1 (‐‐‐‐‐‐) and on ES‐D3 cell diﬀerentiation into 
contracting cardiomyocytes in lab 1 (——) and lab 2   (— —). 
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The results show that all the glycol ether alkoxyacetic acid metabolites exert a 
concentration‐dependent inhibition of ES‐D3 cell diﬀerentiation into contracting 
cardiomyocytes. MAA was the most potent of the four glycol ether alkoxyacetic 
acid metabolites followed by EAA, BAA and PAA, respectively (Table 2). In both 
laboratories, BuA had a strong eﬀect on the diﬀerentiation of ES cells into 
contracting cardiomyocytes with a BMCd50 value four times lower than the most 
potent glycol ether alkoxyacetic acid metabolite MAA. Unlike the glycol ether 
alkoxyacetic acid metabolites, both parent compounds tested (EGME and EGEE) 
did not inhibit diﬀerentiation (data not shown), corroborating that the metabolites 
are the proximate developmental toxicants in vivo after exposure to the parent 
compounds. Therefore, the potency of the glycol ether alkoxyacetic acid 
metabolites in the EST was compared with in vivo toxicity data of the glycol ethers. 
For all chemicals, the ES‐D3 cell diﬀerentiation assay was more sensitive than the 
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Table 2. BMCd25 and BMCd50 values for inhibition of ES‐D3 cell diﬀerentiation by four glycol ether 
alkoxyacetic acid metabolites and two structural analogues. 
The 90% confidence interval is given between brackets. BMCd25 = 25% reduction of the fraction of wells 
containing contracting cardiomyocytes; BMCd50 = 50% reduction of the fraction of wells containing 
contracting cardiomyocytes. 
ES‐D3 cell diﬀerentiation assay 
The eﬀect of each of the chemicals on the diﬀerentiation of ES‐D3 cells into 
contracting cardiomyocytes was evaluated in two independent laboratories (Figure 
2). The Weibull model gave the best fit for the dataset obtained, based on the log‐
likelihood of the fitted curves and was used to determine the BMCd50 values for 
both labs corresponding to a 50% decline in the fraction of contracting 
cardiomyocytes in comparison to the solvent control (Table 2). 
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ES‐D3 cell proliferation assay. This is indicated by the diﬀerences between the 
BMCp50 and the BMCd50 values, which amount to 2.9‐fold for MAA, 4.1‐fold for 
EAA, ≥ 2‐fold for BAA, 2.1‐fold for PAA, 1.5‐fold for BuA and 1.3‐fold for TCAA. 
Because all alkoxyacetic acid metabolites were active in the ES‐D3 cell 
diﬀerentiation assay, but not in the ES‐D3 proliferation assay, at the concentrations 
tested, the data obtained in the ES‐D3 cell diﬀerentiation were used for comparison 
with in vivo toxicity data of the parent glycol ethers. 
The interlaboratory reproducibility of the results was determined by comparing 
the BMCd50 values obtained at the two labs (Figure 3). Interlaboratory variation is 
represented by the R2, where the R2 can range between 0 (no correlation) and 1 
(equal values). The R2 of 0.89 indicates a good correlation between the two 
laboratories whereas the BMCd50 values were on average about 1.3‐fold higher in 
Lab 2 than in Lab 1. 
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Figure 3. Scatter plot for the interlaboratory comparison of BMCd50 values of MAA, EAA, BAA, PAA, 
BuA and TCAA in the ES‐D3 cell diﬀerentiation assay of the EST. 
Choice of BMR and dose‐response model  
For the in vitro data set a 50% decline in diﬀerentiated EBs was arbitrarily selected 
as the BMR for the BMCd derivation to compare the results of the diﬀerent 
chemicals. The ranking of the diﬀerent chemicals might diﬀer with the magnitude 
of the BMR chosen. This possibility was investigated by also calculating the BMCd25 
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values for each of the chemicals at both labs (Table 2). The choice for BMCd25 
instead of BMCd50 values did not aﬀect the ranking within the group of chemicals. 
Furthermore, using an even lower BMR of 10% and using the BMCd10 values for 
comparison did also not aﬀect the ranking of the chemicals (data not shown). In 
addition, the eﬀect of the choice of the fitted model was evaluated by calculating 
the BMCd50 values with diﬀerent models for each of the chemicals (Table 3). For 
the BMCd50 values it was shown that the choice of model did not significantly 
aﬀect the values obtained. Furthermore, the ranking of the chemicals was not 
aﬀected when using diﬀerent models. Similarly, the choice of model did not 
significantly aﬀect the BMCd25 or BMCd10 values and did not modify their ranking 
(data not shown).  
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Table 3. Eﬀect of fitted model on BMCd50 values for inhibition of ES‐D3 cell diﬀerentiation by four glycol 
ether alkoxyacetic acid metabolites and two structural analogues in two laboratories. 
The 90% confidence interval is given between brackets. 
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BMD derivation from in vivo data  
Table 4 provides the details of the animal studies used to establish the BMD 
values. Studies were selected to represent the most uniform study design available 
between the diﬀerent studies with respect to the animal species used, exposure 
route and exposure duration. For all chemicals a mouse developmental toxicity 
study with the parent glycol ethers was available with exposure from gestational 
day (GD) 7 or 8 to GD14 by oral exposure with the exception of ethylene glycol 
monophenyl ether (EGPE). For EGPE, a mouse study with exposure from 
premating day 7 to birth was available, which was included in the present study. 
BMD values were determined that correspond with a 10% reduction in fetal body 
weight and with a 10% additional incidence of malformations. EGME was the most 
potent embryotoxic chemical followed by EGEE. Ethylene glycol monobutyl ether 
(EGBE) exposure led to an increase in malformations and a reduction of fetal body 
weight with BMD values slightly higher than those of EGEE. However, these eﬀects 
occurred only at EGBE doses that were maternally toxic, and thus they may be in 
part secondary to maternal toxicity. In the available in vivo study for EGPE, a slight 
decrease in fetal weight only occurred after exposure to a relatively high dose of 4 
g/kg bw/day indicating that this glycol ether has the lowest developmental toxicity 
potency within the series. 
 
Discussion 
The aim of the present study was to assess the usefulness of the ES‐D3 cell 
proliferation assay and the ES‐D3 cell diﬀerentiation assay of the EST in category 
approaches to predict in vivo developmental toxicity within series of glycol ethers 
and their glycol ether alkoxyacetic acid metabolites. The present study showed that 
not all glycol ether alkoxyacetic acid metabolites inhibited ES‐D3 cell proliferation 
at the concentrations tested, whereas all inhibited the diﬀerentiation of ES‐D3 cells 
into contracting cardiomyocytes in a concentration‐dependent manner. MAA 
appeared to be the most potent ES‐D3 cell diﬀerentiation‐inhibiting chemical, 
followed by EAA, BAA and PAA, respectively. Because all alkoxyacetic acid 
metabolites were active in the ES‐D3 cell diﬀerentiation assay, but not in the ES‐D3 
proliferation assay, at the concentrations tested, the BMCd50 values obtained in the 
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ES‐D3 cell diﬀerentiation were compared with in vivo developmental toxicity data 
for the corresponding parent glycol ethers, based on the BMD10 values for fetal 
weight and malformations derived from the in vivo data for the parent glycol 
ethers. 
The in vitro potency ranking of the glycol ether alkoxyacetic acid metabolites was 
found to be the same as the in vivo potency ranking based on the BMD10 values of 
the parent glycol ethers. However, the relative diﬀerences between the in vitro 
BMCd50 levels of the four chemicals were smaller than the relative diﬀerences in 
BMD10 levels of the chemicals found in vivo. In view of the observed eﬀects on 
malformations in the animal studies, EGME (the parent compound of MAA) is 17‐
fold more potent than EGEE (the parent compound of EAA). In contrast, there was 
only a 1.4‐fold diﬀerence between MAA and EAA in the in vitro study. In addition, 
the BMCd50 values for BAA were twofold higher in the in vitro ES‐D3 cell 
diﬀerentiation assay compared with those for MAA, whereas in the in vivo animal 
studies there is about a 19‐fold diﬀerence between the BMD10 values for EGME and 
EGBE (the parent compounds of MAA and BAA, respectively). With respect to the 
in vivo BMD10 values it should be mentioned that EGBE only induced 
malformations at maternally toxic doses. EGBE has been shown to induce severe 
hemolytic anemia following gavage and dermal exposure (Ghanayem et al., 2001). 
In general, a possible role of maternal toxicity in the mediation of developmental 
eﬀects should be kept in mind, but a useful in vitro correlate is not easily defined.  
The diﬀerences between the relative potencies in vitro and in vivo may be 
explained by diﬀerences in the kinetics of these chemicals in the in vivo model as 
compared with the in vitro model system. Diﬀerences in in vivo kinetics of the 
glycol ethers and their metabolites are reflected by their half‐life values. After 
intravenous injection MAA was shown to have a low elimination rate with a half‐
life in blood ranging between 14 and 19 h, whereas EAA and BAA displayed a 
shorter half‐life ranging between 7.6 and 10 h for EAA and ranging between 1.5 and 
3.2 h for BAA (Aasmoe and Aarbakke, 1997; Aasmoe et al., 1999; Ghanayem et al., 
1990). This indicates that MAA is eliminated more slowly than EAA and BAA, 
resulting in higher plasma levels, which may explain the relatively higher 
embryotoxic potency of its parent glycol ether in vivo. The in vitro system does not 
simulate the in vivo kinetic processes and, therefore, the in vitro levels should be 
extrapolated to in vivo levels by integrating information on in vivo kinetics of the 
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chemicals. To overcome these issues, physiologically based kinetic modeling may 
prove to be a way to ultimately link the in vitro BMCd50 values to BMD10 values 
from in vivo studies (Piersma et al., 2008; Verwei et al., 2006). Work on such in 
vitro‐in silico models for the developmental toxicity of glycol ethers is presented in 
chapter 5. 
The two structurally related non‐glycol ether chemicals, TCAA and BuA, also 
caused a concentration‐dependent inhibition of ES‐D3 cell diﬀerentiation into 
cardiomyocytes. These obtained eﬀect concentrations, however, were close to the 
obtained eﬀect concentrations for the inhibition of ES‐D3 cell proliferation, 
indicating that the eﬀect on proliferation and diﬀerentiation may have been caused 
by a cytotoxic eﬀect of the chemicals. This observation demonstrates that it is 
informative to compare BMCd50 values with BMCp50 values of the test chemicals for 
the interpretation of results obtained with the EST. 
In the present study possible sources of uncertainties influencing the results were 
investigated as well. First, we have studied interlaboratory variation. The high 
correlation between the BMCd50 values of the two laboratories with an R2 of 0.89 
demonstrates the interlaboratory reproducibility of the ES‐D3 cell diﬀerentiation 
assay. The 1.3‐fold diﬀerence in the sensitivity of the ES‐D3 cell diﬀerentiation assay 
observed between laboratories in BMCd50 values may be due to subtle diﬀerences 
in culture conditions. However, we show that this diﬀerence did not interfere with 
the overall conclusions in regard to the relative potency of the glycol ether 
metabolites. Furthermore, the results have shown that the selection of diﬀerent 
models for the curve fitting did not aﬀect the overall outcome. Finally, changing 
the arbitrarily chosen in vitro BMR of a 50% decline in the number of contracting 
cardiomyocytes to a 25 or 10% decline did not aﬀect the overall ranking of the 
potency of the chemicals either. These findings could be expected on the basis of 
the data structure in our experiments, because with an adequate distribution of 
test concentrations over the entire concentration‐response range, the 
concentration‐response models will deliver similar fits and BMCd50 values, as 
illustrated here. 
In conclusion, the ES‐D3 cell diﬀerentiation assay of the EST is a useful tool for 
the identification of the relative embryotoxic potencies of glycol ethers as a 
chemical class, by testing their alkoxyacetic acid metabolites. However, the 
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diﬀerent kinetic processes in the ES‐D3 cell diﬀerentiation assay as compared with 
the kinetic processes in the in vivo situation may aﬀect the interpretation and 
should be taken into account in the quantitative extrapolation of the in vitro results 
to the in vivo situation. Combining the obtained concentration‐response curves 
with a physiologically based kinetic model describing the in vivo kinetics of the 
glycol ethers could lead to a more accurate link of the in vitro results from the EST 
to the data from the in vivo studies. To the best of our knowledge this is the first 
study to evaluate the EST for embryotoxic potencies within a series of related 
chemicals. This study shows that the ES‐D3 cell diﬀerentiation assay of the EST can 
be used to set priorities for developmental toxicity testing within series of related 
chemicals. Prior knowledge on major metabolites of the parent compound of 
interest can focus the choice of derivatives to be tested in the EST. A similar 
approach could be applied to other chemical classes to further define the 
applicability domain of the EST in terms of the groups of chemicals for which the 
test can be used and to set priorities in future animal testing for developmental 
toxicity. This approach can be useful in regulatory settings such as the European 
chemicals legislation REACH, which anticipates significant additional animal 
testing while at the same time promoting the use of alternatives wherever 
appropriate (Van der Jagt et al., 2004). 
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Abstract 
At present, regulatory assessment of systemic toxicity is almost solely carried out 
using animal models. The European Commission’s REACH legislation stimulates 
the use of animal‐free approaches to obtain information on the toxicity of 
chemicals. In vitro toxicity tests provide in vitro concentration‐response curves for 
specific target cells, whereas in vivo dose‐response curves are regularly used for 
human risk assessment. The present study shows an approach to predict in vivo 
dose‐response curves for developmental toxicity by combining in vitro toxicity data 
and in silico kinetic modeling. A physiologically based kinetic (PBK) model was 
developed, describing the kinetics of four glycol ethers and their developmentally 
toxic alkoxyacetic acid metabolites in rat and human. In vitro toxicity data of these 
metabolites derived in the embryonic stem cell test were used as input in the PBK 
model to translate in vitro concentration‐response curves into predicted in vivo 
dose‐response curves for developmental toxicity of the parent glycol ethers in rat 
and human. The predicted dose‐response curves for rat were found to be in 
concordance with the developmental toxicity dose levels measured in reported in 
vivo rat studies. Therefore, predicted dose‐response curves for rat could be used to 
set a point of departure for deriving safe exposure limits in human risk assessment. 
Combining the in vitro toxicity data with a human PBK model allows the prediction 
of dose‐response curves for human developmental toxicity. This approach could 
therefore provide a means to reduce the need for animal testing in human risk 
assessment practices. 
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Introduction 
The implementation of the European REACH (Registration, Evaluation, 
Authorization and restriction of CHemicals) legislation will lead to the evaluation 
of the toxicity of a large number of chemicals. The European Commission 
estimated the number of laboratory animals required for REACH to amount to 3.9 
million if the use of alternative methods is not accepted by regulatory authorities. 
In addition, they indicated that with the expected acceptance scenario for 
alternative approaches, the total number will amount to 2.6 million (Van der Jagt et 
al., 2004). Taking into account the oﬀspring produced during the studies, a number 
of 9 million laboratory animals was estimated (Höfer et al., 2004). Hartung and 
Rovida (2009) calculated an even higher number of laboratory animals required for 
REACH, which was contradicted by the European Chemical Agency (ECHA, 2009). 
Irrespective of the actual number of laboratory animals required for REACH, the 
development of validated and accepted in vitro and in silico approaches is urgently 
needed. Because it is expected that more than 25% of the laboratory animals 
needed for REACH will be used for developmental toxicity studies (Van der Jagt et 
al., 2004), in vitro and in silico alternatives for developmental toxicity studies could 
contribute substantially to the reduction of animal use. 
Three alternative methods for in vivo developmental toxicity tests have been 
scientifically validated so far by the European Centre for the Validation of 
Alternative Methods (ECVAM), which are the rat post implantation whole‐embryo 
culture test, the rat limb bud micromass test and the embryonic stem cell test 
(EST) (Genschow et al., 2002). Only the EST does not require live animals because 
a mouse embryonic stem cell line is used. De Jong et al. (2009) showed that the 
embryonic stem cell (ES‐D3 cell) diﬀerentiation assay of the EST, which assesses 
the eﬀects of chemicals on the diﬀerentiation of mouse embryonic stem cells into 
contracting cardiomyocytes, can be used to rank the potency of chemicals within a 
series of alkoxyacetic acid metabolites formed from glycol ethers. The alkoxyacetic 
acid metabolites of the glycol ethers, and not the parent glycol ethers themselves, 
have been identified as the proximate developmental toxicants of these chemicals 
(Brown et al., 1984; Giavini et al., 1993). The in vitro potencies of the 
developmentally toxic glycol ether alkoxyacetic acid metabolites, as measured in 
the ES‐D3 cell diﬀerentiation assay, were found to correspond with the 
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developmental toxicity potency of the corresponding glycol ethers in vivo (De Jong 
et al., 2009). However, the ES‐D3 cell diﬀerentiation assay provides in vitro 
concentration‐response curves, whereas for human risk assessment in vivo dose‐
response curves are often required. These in vitro data should therefore be 
translated into in vivo data by taking into account in vivo kinetics (Verwei et al., 
2006). 
The goal of the present study was to integrate in vitro toxicity data and in silico 
kinetic modeling as an approach to predict dose‐response curves for developmental 
toxicity in both rat and human, thereby providing a basis for the use of in vitro 
toxicity data in human risk assessment. To this end, four glycol ethers (ethylene 
glycol monomethyl ether (EGME), ethylene glycol monoethyl ether (EGEE), 
ethylene glycol monobutyl ether (EGBE) and ethylene glycol monophenyl ether 
(EGPE)) were used as model chemicals belonging to one chemical class, but 
showing diﬀerences in in vivo developmental toxicity potencies. To take the in vivo 
kinetics into consideration, the in vitro data derived from the ES‐D3 cell 
diﬀerentiation assay were used as input in a physiologically based kinetic (PBK) 
model, translating in vitro eﬀect concentrations into predicted in vivo 
developmental toxicity dose levels, as described by Verwei et al. (2006). 
The predicted developmental toxicity dose levels are based on the assumption 
that concentrations of the toxic alkoxyacetic acid metabolites that cause an 
inhibition of embryonic stem cell diﬀerentiation in vitro will also cause toxic eﬀects 
in the developing embryo in vivo. By using the ES‐D3 cell diﬀerentiation assay data 
as input for the blood concentration in the PBK model, the model allows the 
calculation of the in vivo dose levels of the parent glycol ethers that will lead to 
these blood concentrations of the toxic alkoxyacetic acid metabolites in vivo. By 
calculating this dose level for each concentration tested in the ES‐D3 cell 
diﬀerentiation assay, in vitro concentration‐response curves for the toxic 
alkoxyacetic acid metabolites can be converted into predicted in vivo dose‐response 
curves for the parent glycol ethers. This dose‐response curve could be used to set a 
point of departure, like a BMDL10 (lower limit of the 95% confidence interval on the 
benchmark dose at which a benchmark response equivalent to a 10% eﬀect size 
(BMR10) is reached (BMD10)), for deriving safe exposure levels for humans. 
Therefore, the combined in vitro‐in silico approach provides a platform to use in 
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vitro toxicity data for risk assessment practices, thereby contributing to the 
reduction of animal use in chemical risk assessment for developmental toxicity 
endpoints. 
 
Materials and methods 
Chemicals 
EGPE, ethylene glycol monopropyl ether, HCl and phenoxyacetic acid (PAA) were 
purchased from Sigma‐Aldrich (Zwijndrecht, the Netherlands). Ethyl acetate and 
methanol were obtained from Biosolve (Valkenswaard, the Netherlands) and 
sodium sulfate (Na2SO4) from Merck (Darmstadt, Germany). Ammonium formate 
was purchased from Fluka (Zwijndrecht, the Netherlands). 
In vitro‐in silico approach to predict dose‐response curves for in vivo developmental 
toxicity in rat and human 
The in vitro‐in silico approach to predict developmental toxicity dose levels in 
rats, as proposed by Verwei et al. (2006), was used to estimate dose‐response 
curves for the in vivo developmental toxicity of the glycol ethers EGME, EGEE, 
EGBE and EGPE in both rat and human. To this end the following steps were 
followed in the present study, which are described in more detail in the following 
sections: 1) development of a PBK model for in vivo glycol ether kinetics in rat and 
human, 2) evaluation of the PBK model, 3) determination of in vitro eﬀect 
concentrations in the ES‐D3 cell diﬀerentiation assay to be used as input for the 
PBK model, 4) PBK model‐based prediction of dose‐response curves for in vivo 
developmental toxicity in rat and human and 5) evaluation of the potential of the 
in vitro‐in silico approach to predict dose‐response curves for in vivo developmental 
toxicity in the rat. 
Development of a PBK model for in vivo glycol ether kinetics in rat and human 
A generic PBK model describing the kinetics of the glycol ethers EGME, EGEE, 
EGBE and EGPE and their alkoxyacetic acid metabolites methoxyacetic acid 
(MAA), ethoxyacetic acid (EAA), butoxyacetic acid (BAA) and PAA, respectively, in 
rat and human was developed, using the model of EGME and MAA of Gargas et al. 
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(2000a) as starting point. A schematic representation of the model is shown in 
Figure 1. 
Chapter 5 
Figure 1. Schematic representation of the PBK model of glycol ethers and their alkoxyacetic acid 
metabolites in rat and human. The PBK model is based on the PBK model of EGME and MAA described 
by Gargas et al. (2000a). GI tract: gastrointestinal tract. 
Physiological parameter values for the rat and human model describing in vivo 
kinetics after inhalation exposure were taken from Gargas et al. (2000a) (Table 1) 
and represent the physiological parameter values at the beginning of pregnancy. In 
the present study, the PBK model was adjusted to also describe in vivo kinetics 
after oral exposure. Oral uptake of the glycol ethers was described by an oral 
absorption constant (ka) fitted to the in vivo plasma concentrations of EGME (Hays 
et al., 2000) and EGPE (present study) in rats that were orally dosed. Partition 
coeﬃcients of the glycol ethers and their alkoxyacetic acid metabolites for rat and 
human tissues were estimated using the equation described by Berezhkovskiy 
(2004) (Table 2). Biotransformation kinetics of EGME, EGEE and EGBE determined 
in rat and human hepatocytes by Green et al. (1996) were scaled to a whole liver by 
assuming a number of 128 · 106 hepatocytes/g rat liver (Seglen, 1976) and 99 · 106 
hepatocytes/g human liver (Barter et al., 2007).  
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Table 1. Physiological parameter values used in the PBK model for glycol ethers taken from Gargas et al. 
(2000a). 
No data on the biotransformation kinetics of EGPE to PAA are available in the 
literature. Because the biotransformation kinetics of EGME, EGEE and EGBE are 
alike, it is expected that they are close to those of EGPE. Because the properties 
that might describe the biotransformation kinetics of EGPE, such as logP and 
VanderWaals volume (Chang et al., 2009; Soﬀers et al., 2001), are closest to those of 
EGBE (Table 3), the biotransformation kinetics of EGBE were used in the EGPE 
PBK model. Literature studies describing the kinetics of EGME (Gargas et al., 
2000a; Hays et al., 2000), EGEE acetate (EGEEA) (Gargas et al., 2000b) and EGBE 
(Ghanayem et al., 1990) in rats were used to obtain the parameter values for urinary 
excretion of MAA, EAA and BAA, respectively, in rats by using a urinary excretion 
constant (Kex) in the model fitted to the in vivo plasma concentrations of the 
alkoxyacetic acid metabolites (Table 2). Because no in vivo EGPE kinetic study in 
rats was found in the literature, an in vivo kinetic study with a limited number of 
rats was carried out to determine the parameter values for urinary excretion of PAA 
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in rats. Model parameter values for urinary excretion of MAA, EAA and BAA in 
human were estimated using in vivo kinetic studies of EGME (Groeseneken et al., 
1989), EGEE (Groeseneken et al., 1986) and EGBE (Jones and Cocker, 2003; Kezic et 
al., 2004), respectively, in human, by using a Kex in the model fitted to the in vivo 
urinary excretion rates of the alkoxyacetic acid metabolites (Table 2). Because no 
study on human EGPE kinetics is described in the literature, the urinary excretion 
of PAA was determined by fitting the Kex to in vivo plasma concentrations of 2,4‐
dichlorophenoxyacetic acid (2,4‐D) of human orally exposed to 2,4‐D (Sauerhoﬀ et 
al., 1977) (Table 2). The present study shows that PAA’s plasma half‐life in the rat is 
almost equal to 2,4‐D’s plasma half‐life in rat (see the ‘‘Discussion’’ section). 
Therefore, it was assumed that PAA’s plasma half‐life in human will be the same as 
2,4‐D’s plasma half‐life in human, making it possible to use the in vivo kinetic data 
for 2,4‐D in human to estimate the Kex, which is directly related to the plasma half‐
life, for the human PAA model. 
Evaluation of the PBK model 
To evaluate the PBK model describing in vivo kinetics of the glycol ethers, in vivo 
kinetic studies for rat and human reported in literature were used (Table 4). The 
doses, exposure routes and exposure duration used in the studies were applied in 
the PBK model simulation, to evaluate the model (Table 4). For the rat EGEE 
model, an in vivo kinetic study with EGEEA was used. No in vivo kinetic studies of 
EGPE were present in the literature. Therefore, in vivo EGPE kinetics in rats were 
determined in the present study, as described in the following. No kinetic data of 
EGPE in human were available, so for the human EGPE PBK model no evaluation 
could be carried out. 
Reverse dosimetry glycol ethers 
Table 3. LogP values and VanderWaals volumes of glycol ethers. 
a LogP values calculated using ChemBioDraw Ultra 12.0. 
b VanderWaals volumes calculated using Spartan 04 for Windows version 1.0.3. 
118 
 
 
Chapter 5 
Ta
bl
e 
4.
 P
ub
lis
he
d 
ki
ne
ti
c 
st
ud
ie
s 
us
ed
 to
 b
ui
ld
 a
nd
/o
r e
va
lu
at
e 
th
e 
PB
K
 m
od
el
. 
119 
 
EGPE kinetic study in rat. The experimental protocol of the EGPE kinetic study 
was approved by the Animal Welfare Committee of the National Institute of Public 
Health and the Environment (RIVM). Female Sprague‐Dawley rats (254.4 ± 5.2 g) at 
approximately 13 weeks of age were obtained from Harlan Laboratories (Horst, the 
Netherlands). Rats were maintained in a temperature‐, humidity‐ and light cycle‐
controlled facility for 1 week prior to exposure. Feed (SDS, Witham, Essex, UK) and 
water were provided ad libitum. Two groups of 4 rats per group were exposed to 
either 1.1 mmol · kg body weight (bw)‐1 EGPE or 3.3 mmol · kg bw‐1 EGPE by oral 
gavage. Blood samples of 150 µl were taken from the tail vein prior to EGPE 
exposure and at 5, 15 and 30 min and 1, 2, 4, 6, 8 and 24 h after dosing and were 
stored in heparin‐coated tubes (Sarstedt, Nümbrecht, Germany). Samples were 
centrifuged at 1300 g for 10 min. The acquired serum samples were stored at ‐20 oC. 
EGPE and PAA analysis of plasma samples using gas chromatography‐mass 
spectrometry and liquid chromatography‐mass spectrometry. To determine the 
EGPE and PAA plasma concentrations, 20 µl plasma was added to 20 µl of a 0.5% 
(v/v) HCl solution. Then, 1 ml ethyl acetate, containing the internal standard 
ethylene glycol monopropyl ether, was added and samples were vortexed 
thoroughly. Sodium sulfate was added as a drying agent, after which samples were 
vortexed and centrifuged. The supernatant was used for EGPE analysis using gas 
chromatography‐mass spectrometry (GC‐MS) and PAA analysis using liquid 
chromatography‐mass spectrometry (LC‐MS).  
EGPE was analyzed with an Agilent HP 5972 GC‐MS system (Hewlett‐Packard, 
Palo Alto, CA) equipped with a 60 m × 0.25 mm × 0.5 µm Stabilwax‐DA column 
(Restek; Interscience B.V., Breda, the Netherlands). The oven temperature was 
initially maintained for 5 min at 60 oC after injection and then increased in steps of 
15 oC · min‐1 to 250 oC, which was held for 15 min. Samples of 1 µl were injected 
using a programmed temperature vaporization splitless mode and helium as carrier 
gas with a constant flow rate of 1.5 ml · min‐1. A positive electron ionization method 
was used for EGPE and ethylene glycol monopropyl ether (internal standard) 
detection. The ratio of EGPE (m/z = 94) and ethylene glycol monopropyl ether (m/
z = 73) was used for quantification. 
LC‐MS analysis was carried out with an HP Agilent 1100 system (Hewlett‐Packard) 
equipped with a Waters Atlantis C18 T3 5‐µm column, 150 × 3.0 mm (Waters,  
Reverse dosimetry glycol ethers 
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Etten‐Leur, the Netherlands), coupled to a Waters Quattro Premier XE mass 
spectrometer (Waters). Aliquots of 5 µl were injected. The flow rate was 0.3 ml · 
min‐1. A gradient was made using a 5 mM ammonium formate in methanol/H2O 
(20/80, v/v) solution (solution A) and a 5 mM ammonium formate in methanol/
H2O (90/10, v/v) solution (solution B). A linear gradient was applied from 0 to 100% 
solution B over 5 min, after which solution B was kept at 100% for another 5 min, 
lowered to 0% in 0.5 min, and equilibrated at these initial conditions for 8.5 min. A 
positive electrospray ionization mode was used for mass spectrometrical analysis. 
Sample analysis was carried out by the multiple reaction monitoring scan mode. 
The m/z transition 150.77 → 92.60 was used for PAA quantification. 
Data analysis of EGPE kinetic study in rats. The plasma concentrations of EGPE 
and PAA determined in the EGPE kinetic study were used to calculate EGPE’s and 
PAA’s half‐lives in plasma after oral dosing of 1.1 or 3.3 mmol EGPE · kg bw‐1, using 
Kinetica 4.2. 
Sensitivity analysis. A sensitivity analysis was carried out to identify the key 
parameters highly influencing the model output (peak blood concentrations of 
alkoxyacetic acid metabolites). The eﬀect of a 5% increase in parameter value was 
evaluated by calculating normalized sensitivity coeﬃcients (SC = (C’ ‐ C)/(P’ ‐ P) · 
(P/C)) as was done by Evans and Andersen (2000) (C = initial value of model 
output, C’ =  value of model output resulting from 5% increase in parameter value, 
P = initial parameter value, P’ = 5% increased parameter value). This 5% change in 
parameter value is theoretical and does not necessarily reflect realistic variations. 
Sensitivity analyses were carried out for the rat and human models using a single 
oral exposure of 1 mmol · kg bw‐1 and an 8‐h inhalation exposure of 50 ppm. 
Determination of in vitro eﬀect concentrations in the ES‐D3 cell diﬀerentiation assay 
The in vitro developmental toxicity eﬀect data derived in two diﬀerent labs in our 
previous study (De Jong et al., 2009) were used to calculate benchmark 
concentrations (BMCs) at which 1‐99% (BMC1 to BMC99) of the embryoid bodies 
(aggregations of embryonic stem cells) did not diﬀerentiate into contracting 
cardiomyocytes, using United States Environmental Protection Agency (EPA)’s 
benchmark dose software (BMDS) version 2.0 (Weibull model). These data were 
used as input in the PBK model to predict dose‐response curves for in vivo 
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developmental toxicity of the glycol ethers in rat and human, based on the in vitro 
ES‐D3 cell diﬀerentiation assay data of both  labs. 
PBK model‐based prediction of dose‐response curves for in vivo developmental 
toxicity in rat and human 
To predict the dose‐response curves for in vivo developmental toxicity of the 
glycol ethers, derived BMCs for the inhibition of embryonic stem cell 
diﬀerentiation by the alkoxyacetic acids were used as input for the peak blood 
concentrations in the PBK model (Figure 1). The model was then used to calculate 
the corresponding dose levels of the parent glycol ethers leading to these 
concentrations in the blood, resulting in the predicted dose‐response curves for in 
vivo developmental toxicity. For rat, dose‐response curves were predicted using 
identical exposure regimens (route of exposure and exposure duration) in the PBK 
model simulations as applied in the in vivo developmental toxicity studies (Table 
5). For human, dose‐response curves were predicted for single‐ and repeated‐
exposure regimens, to investigate the eﬀect of repeated dosing. For repeated 
dosing, a 5‐day exposure regimen was used (8 h · day‐1 for inhalation exposure), 
representing a working week exposure. 
Evaluation of the potential of the in vitro‐in silico approach to predict dose‐response 
curves for in vivo developmental toxicity in rat 
To evaluate the potential of the in vitro‐in silico approach to predict dose‐
response curves for in vivo developmental toxicity, the predicted dose‐response 
curves for the rat were compared with data obtained in in vivo developmental 
toxicity studies listed in the ECETOC Technical Report 095 (ECETOC, 2005). 
Developmental toxicity endpoints described include resorptions, malformations, 
fetal deaths and decrease in fetal bw. The in vivo data were used to derive BMDL10 
values on the basis of dose‐response analyses (BMDS version 2.0), which can be 
used as points of departure in human risk assessment practices (Barlow et al., 
2009). These BMDL10 values derived from in vivo data were compared to predicted 
BMDL10 values, which were acquired by translating the in vitro BMCL10 (lower limit 
of the 95% confidence interval on the BMC10) values into dose levels using the rat 
PBK model. No human glycol ether developmental toxicity data were available. 
Consequently, predicted dose‐response curves for developmental toxicity in human 
Reverse dosimetry glycol ethers 
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could not be compared with data on developmental toxicity of glycol ethers in 
human. 
 
Results 
Development of a PBK model for in vivo glycol ether kinetics in rat and human 
The parameter values for oral uptake (ka) were fitted to in vivo kinetic data for 
EGME and EGPE, as described in the ‘‘Materials and Methods’’ section, and were 
found to be 4 h‐1 in both cases. Therefore, in all models, a ka of 4 h‐1 was used for 
oral uptake of the parent glycol ethers. The parameter values for urinary excretion 
of the alkoxyacetic acid metabolites (Kex), obtained by fitting these parameter 
values to in vivo kinetic data as described in the ‘‘Materials and Methods’’ section, 
are shown in Table 2. For the rat model, the Kex value is the lowest for MAA, 
followed by that for EAA, BAA and PAA, respectively. For the human model, the 
Kex value is the lowest for MAA, followed by that for EAA, PAA and BAA, 
respectively. 
Evaluation of the PBK model 
Figure 2 shows the PBK‐model predicted plasma concentrations of EGME/MAA 
(Figures 2A and 2B), EGEE/EAA (Figure 2C), EGBE/BAA (Figure 2D) and EGPE/
PAA (Figure 2E) in the rat and the measured plasma levels from in vivo rat kinetic 
studies. The plasma concentrations of EGPE and PAA after EGPE exposure were 
measured in the present study. The results of the PBK simulations show that the 
predicted plasma concentrations are close to the measured plasma concentrations 
of the four glycol ethers and their alkoxyacetic metabolites measured in rat. Figures 
3A‐C show the PBK‐model predicted urinary excretion rates of MAA (Figure 3A), 
EAA (Figure 3B) and BAA (Figure 3C) in human and the measured urinary 
excretion rates from in vivo human kinetic studies. Figure 3D shows the prediction 
of the EGBE plasma concentrations in human and the measured EGBE plasma 
concentrations as measured in an in vivo human kinetic study. The results show 
that the model predicted urinary excretion rates and the predicted EGBE plasma 
levels are within a factor of  10 compared with the measured urinary excretion rates 
of MAA, EAA and BAA and the EGBE plasma concentrations measured in human. 
Chapter 5 
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Figure 2. Measured and PBK‐model predicted plasma concentrations of parent glycol ethers and 
alkoxyacetic acid metabolites in rats exposed to EGME (A, B), EGEE (C), EGBE (D) and EGPE (E). The 
main graphs show the plasma alkoxyacetic acid concentrations (open symbols), whereas the insets show 
the plasma parent glycol ether concentrations (closed symbols). The curves represent the PBK model 
predictions and the symbols with error bars (= SD) the measured in vivo data. (A) Oral exposure to 3.3 
mmol EGME · kg bw‐1 (Hays et al., 2000); (B) 5 days (6 h · day‐1) of inhalation exposure to 10 (triangles) 
or 50 (circles) ppm EGME (Gargas et al., 2000a). Thick lines on x‐axis indicate time interval of glycol 
ether exposure. Plasma concentrations were determined on days 5, 6 and 7; (C) 5 days (6 h · day‐1) of 
inhalation exposure to 50 (circles) or 100 (triangles) ppm EGEE (Gargas et al., 2000b). Thick lines on x‐
axis indicate time interval of glycol ether exposure. Plasma concentrations were determined on days 5, 6 
and 7; (D) intravenous exposure to 0.26 (circles), 0.53 (triangles), or 1.1 (diamonds) mmol EGBE · kg bw‐1 
(Ghanayem et al., 1990); (E) oral exposure to 1.1 (circles) or 3.3 (triangles) mmol EGPE · kg bw‐1 (present 
study). 
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In general, prediction of in vivo kinetics of the glycol ethers by the PBK models was 
found to be somewhat better in rat than in human (Figures 2 and 3). 
EGPE kinetics in rat. The plasma concentrations of EGPE and PAA in rats exposed 
to 1.1 and 3.3 mmol EGPE · kg bw‐1 are shown in Figure 2E. Maximum EGPE plasma 
concentrations measured were already reached 5 min after exposure, and were 0.4 
mM after exposure to 1.1 mmol EGPE · kg bw‐1 and 0.5 mM after exposure to 3.3 
mmol EGPE · kg bw‐1. The maximum PAA plasma concentration of 1.2 mM 
obtained upon exposure to 1.1 mmol EGPE · kg bw‐1, was reached 30 min after 
Chapter 5 
Figure 3. Measured and PBK‐model predicted urinary excretion rates of MAA (A), EAA (B) and BAA (C) 
in human after inhalation exposure to EGME, EGEE and EGBE, respectively, and measured and 
predicted EGBE plasma concentrations (D) in human after inhalation exposure to EGBE. The curves 
represent the PBK model predictions and the symbols with error bars (= SD) the measured in vivo data. 
(A) 4‐h inhalation exposure to 5 ppm EGME (Groeseneken et al., 1989); (B) 4‐h inhalation exposure to 3 
(circles), 6 (triangles), or 9 (squares) ppm EGEE (Groeseneken et al., 1986); (C) 2‐h inhalation exposure 
to 20 ppm EGBE (Jones and Cocker, 2003; circles) and 0.5‐h inhalation exposure to 19 ppm EGBE (Kezic 
et al., 2004; triangles); (D) 0.5‐h inhalation exposure to 19 ppm EGBE (Kezic et al., 2004). Thick lines on 
x‐axis indicate time interval of glycol ether exposure. 
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exposure, whereas the maximal PAA plasma concentration of 2.6 mM obtained 
upon exposure to 3.3 mmol EGPE · kg bw‐1, was reached 60 min after exposure. 
EGPE was not detected in the plasma 4 h after exposure to both doses. The half‐
lives of EGPE in plasma were 0.4 and 0.9 h after exposure to 1.1 and 3.3 mmol EGPE 
· kg bw‐1, respectively. PAA was not detected 4 h after exposure to 1.1 mmol EGPE · 
kg bw‐1 and 24 h after exposure to 3.3 mmol EGPE · kg bw‐1. The half‐life of PAA in 
the plasma was 1.0 h in the rats that were exposed to 1.1 mmol EGPE · kg bw‐1 and 
2.6 h in the rats that were exposed to 3.3 mmol EGPE · kg bw‐1. 
Sensitivity analysis. Figure 4 shows the normalized sensitivity coeﬃcients of the 
most sensitive model parameters for peak blood concentrations of the alkoxyacetic 
acids in the rat and human PBK model for EGME/MAA (single exposure). The 
results of the sensitivity analyses for the PBK models for the other glycol ethers 
were similar to those of the EGME PBK models (data not shown). The sensitivity 
analysis revealed that the most sensitive physiological parameters for peak blood 
Reverse dosimetry glycol ethers 
Figure 4. Sensitivity of the predicted peak MAA plasma concentrations to diﬀerent model parameters of 
the rat (A) and human (B) PBK models for EGME and MAA, after oral exposure to 1 mmol EGME · kg  
bw‐1 (grey bars) or inhalation exposure of 8 h to 50 ppm EGME (white bars). All model parameters with 
normalized sensitivity coeﬃcients smaller than ‐0.03 or larger than 0.03 are shown. Dose: oral or 
inhaled dose EGME; bw: body weight; QP: alveolar ventilation rate; V RP: volume richly perfused tissue; 
V SP: volume slowly perfused tissue; QPV: blood flow through portal vein; PC SP EGME: partition 
coeﬃcient EGME slowly perfused tissue:blood; PC RP MAA: partition coeﬃcient MAA rapidly perfused 
tissue:blood; PC SP MAA: partition coeﬃcient MAA slowly perfused tissue:blood; PC L MAA: partition 
coeﬃcient MAA liver:blood; Km MAA formation: Michaelis‐Menten constant for biotransformation of 
EGME to MAA; Vmax MAA formation: maximum rate of MAA formation; Kex: MAA excretion rate. 
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concentrations of the alkoxyacetic acids are the alveolar ventilation rate (QP; with 
inhalation exposure), the blood flow through the portal vein (QPV) and the volume 
of the slowly perfused tissue compartment (V SP). The most sensitive chemical‐
specific parameters for peak blood concentrations of the alkoxyacetic acids 
appeared to be the slowly perfused tissue:blood partition coeﬃcient of MAA (PC SP 
MAA) and the Kex. All SCs for the remaining model parameters are between ‐0.2 
and 0.2. 
Comparison of predicted and observed dose‐response curves for in vivo 
developmental toxicity in rat 
Figure 5 shows the predicted dose‐response curves of the glycol ethers EGME, 
EGEE, EGBE and EGPE in rat, presenting also the measured developmental toxicity 
data as derived from literature. The in vitro concentration‐response curves (at 
BMC1 to BMC99 values) for the alkoxyacetic acid metabolites in the ES‐D3 cell 
diﬀerentiation assay of the EST (De Jong et al., 2009) translated into in vivo dose‐
response curves are shown in Figure 5A (EGME), Figure 5B (EGEE) and Figure 5C 
(EGBE) for oral exposure; in Figure 5D (EGPE) for subcutaneous exposure; and in 
Figure 5E (EGME), Figure 5F (EGEE), Figure 5G (EGBE) and Figure 5H (EGPE) for 
inhalation exposure. Each figure shows two predicted dose‐response curves, 
derived from the in vitro ES‐D3 cell diﬀerentiation assay data obtained in each of 
the labs in our previous study (De Jong et al., 2009). The individual data points in 
the graphs (Figure 5) represent developmental toxicity data from in vivo rat studies 
as reported in the literature (for studies used, see Table 5). For the predicted dose‐
response curves, the dose regimens used in the corresponding in vivo studies were 
applied in the PBK model simulations. In Figures 5E‐G, in vivo data of inhalation 
studies are shown in which diﬀerent exposure regimens have been used, that is, 
diﬀerences in the number of exposure days and diﬀerences in exposure duration 
per day (either 6 or 7 h · day‐1). Predicted dose‐response curves in these figures are 
shown for the studies using a 7 h · day‐1 exposure regimen (Figures 5E‐H). When 
applying a 6 h · day‐1 exposure regimen in the PBK model simulations, predicted 
dose‐response curves are slightly shifted to the right (data not shown). The 
developmental toxicity data from reported in vivo rat studies were used to derive 
BMDL10 values that could be used for deriving safe exposure limits for human risk 
assessment. These BMDL10 values derived from in vivo data are presented in Table 
Chapter 5 
129 
 
 
Reverse dosimetry glycol ethers 
130 
 
5, together with the predicted BMDL10 values, which were acquired by translating 
the in vitro BMCL10 values into in vivo dose levels using the rat PBK model. When 
comparing in vivo‐derived and in vivo‐predicted BMDL10 values for each of the 
chemicals studied, diﬀerences in the range of 0.2‐ to 6‐fold were found (Table 5). 
No BMDL10 value for developmental toxicity could be derived for the EGBE 
inhalation exposure study in rats. However, when comparing the individual data 
points of the in vivo studies and the predicted dose‐response curve (Figure 5G), a 
somewhat larger discrepancy between the predicted dose‐response curve and the 
reported developmental toxicity dose levels was found. In rats exposed to 200 ppm 
EGBE, 47% of the fetuses died (Tyl et al., 1984) (Figure 5G), whereas the predicted 
BMD47 value for developmental toxicity amounted to 1300 (predicted dose‐
response curve 1) and 1900 (predicted dose‐response curve 2) ppm EGBE, resulting 
in approximately a 7‐ to 10‐fold diﬀerence in predicted versus reported 
developmental toxicity dose levels. 
Prediction of in vivo dose‐response curves for developmental toxicity in human 
The predicted dose‐response curves for in vivo developmental toxicity of the 
glycol ethers EGME, EGEE and EGPE in human are shown in Figure 6 for a single‐
exposure (black lines) and for a repeated‐exposure regimen (grey lines). For 
repeated exposure, a 5‐day exposure regimen was chosen, representing daily 
exposure during a working week (8 h · day‐1 for inhalation exposure). No dose‐
response curves could be predicted for EGBE because the maximum BAA plasma 
concentration reached using the human PBK model was lower than the BAA 
concentrations that aﬀect ES‐D3 cell diﬀerentiation. The in vitro concentration‐
response curves (BMC1 to BMC99 values) for the alkoxyacetic acid metabolites in 
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Figure 5. Predicted dose‐response curves for developmental toxicity of glycol ethers EGME (A and E), 
EGEE (B and F), EGBE, (C and G) and EGPE (D and H) after repeated oral (A‐C), subcutaneous (D), or 
inhalation (E‐H) exposure in the rat. The individual data points represent measured developmental 
toxicity data taken from in vivo developmental toxicity studies as reported in the literature. The 
developmental toxicity endpoints represented by the symbols are shown in Table 5. For all endpoints, 
except for fetal bw decrease, the fraction of aﬀected embryos or fetuses was calculated. For the endpoint 
fetal bw decrease, the average decrease in fetal bw of fetuses in the exposed groups was calculated as 
fraction of the average bw of fetuses of the control group. The curves represent the predicted dose‐
response curves for developmental toxicity and are acquired by translating in vitro eﬀect concentrations 
ranging from BMC1 up to BMC99 from laboratory 1 (straight line) or laboratory 2 (dashed line) into in 
vivo dose levels using the PBK model. ‘‘*’’ indicates a dose at which maternal toxicity including 
hemolysis was observed. 
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Figure 6. Predicted dose‐response curves for developmental toxicity of glycol ethers EGME (A and D), 
EGEE (B and E) and EGPE, (C and F) after oral (A‐C) or inhalation (D‐F) exposure in human. The curves 
represent the predicted dose‐response curves for developmental toxicity for a 1‐day (black lines) or a 5‐
day (grey lines) exposure and are acquired by translating in vitro eﬀect concentrations ranging from 
BMC1 up to BMC99 from laboratory 1 (straight lines) or laboratory 2 (dashed lines) into in vivo dose levels 
using the PBK model. 
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Discussion 
The aim of the present study was to investigate the feasibility of using a 
combination of in vitro toxicity data and PBK modeling to predict in vivo dose‐
response curves for developmental toxicity, thereby providing a platform to use in 
vitro toxicity data not only qualitatively (presence or absence of eﬀect) but also 
quantitatively (prediction of dose‐response curves). This study shows that our 
predicted BMDL10 values for in vivo developmental toxicity of glycol ethers in rat 
diﬀered a factor of 0.2‐6 from the measured BMDL10 values determined from 
reported in vivo developmental toxicity studies. Predicted BMDL10 values might in 
the future replace measured BMDL10 values determined in in vivo developmental 
toxicity studies and could be used as points of departure in risk assessment to 
derive safe exposure levels for humans. This may be achieved by applying 
Chapter 5 
Table 6. Predicted BMDL10 values for developmental toxicity in human exposed for 1 or 5 days to glycol 
ethers via inhalation (8 h · day‐1) using the in vitro‐in silico approach (in vitro toxicity data were taken 
from two diﬀerent laboratories (De Jong et al., 2009) leading to diﬀerent predicted BMDL10 values per 
chemical). 
n.d.: BMDL10 could not be determined because BMCL10 concentration of BAA could not be reached 
using the human PBK model. 
the ES‐D3 cell diﬀerentiation assay (De Jong et al., 2009) translated into in vivo 
dose‐response curves for human are shown in Figures 6A‐C for oral exposure and 
in Figures 6D‐F for inhalation exposure. For inhalation exposure, which is a more 
relevant exposure route for glycol ethers than oral exposure, BMDL10 values for 
developmental toxicity were predicted for a 1‐ or 5‐day exposure (Table 6). These 
BMDL10 values were predicted by translating in vitro BMCL10 values into in vivo 
dose levels using the human PBK model. The results show that upon repeated 
exposure, predicted BMDL10 values decrease compared with a single exposure.  
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uncertainty factors for interspecies variation, as also currently used in risk 
assessment based on animal toxicity studies. In addition, one might even use the 
human PBK models to obtain dose‐response curves and BMDL10 values for human, 
thereby eliminating the need for an uncertainty factor for interspecies diﬀerences 
in kinetics. 
From the in vivo developmental toxicity studies, BMDL10 values were derived for 
diverse developmental toxicity endpoints (i.e., resorptions, fetal bw decrease, 
malformations and fetal deaths), whereas the predicted BMDL10 values were 
derived for one in vitro developmental toxicity readout parameter (i.e., inhibition 
of embryonic stem cell diﬀerentiation into contracting cardiomyocytes). Although 
the ES‐D3 cell diﬀerentiation assay determines the concentrations of a chemical 
that inhibit cardiomyocyte diﬀerentiation, the present study was not intended to 
specifically predict dose levels aﬀecting cardiac development during embryonic 
development. The inhibition of cardiac diﬀerentiation was rather used to represent 
a sensitive readout parameter for in vitro developmental toxicity (Genschow et al., 
2004), which in the ideal situation could represent the most sensitive in vivo 
developmental toxicity endpoint. However, one might argue that other 
developmental toxicity endpoints such as developmental neurotoxicity might be 
less well predicted with the use of the in vitro eﬀect concentrations that inhibit 
cardiomyocyte diﬀerentiation. Therefore, for predicting BMDL10 values for other 
developmental toxicity endpoints such as developmental neurotoxicity, an in vitro 
assay focusing on this specific endpoint (Breier et al., 2010) might improve the 
approach to an even further extent. The type of observed glycol ether‐induced 
malformations will probably depend on the developmental stage at which the 
embryo is exposed to the glycol ethers (and their alkoxyacetic acid metabolites). 
Horton et al. (1985) showed, for example, that exposure of mice to EGME on 
gestational day 7 (GD7) resulted in exencephaly, whereas paw anomalies 
dominated when mice were exposed later in pregnancy (GD11). Because the present 
study did not intend to predict the developmental toxicity for a specific 
developmental toxicity endpoint, no critical window of glycol ether exposure was 
defined for the predictions. 
The predicted dose‐response curves for developmental toxicity were acquired by 
using the peak plasma concentrations of the alkoxyacetic acid metabolites as input 
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in the PBK models. Sweeney et al. (2001) evaluated for diﬀerent EGME 
developmental toxicity studies in rat and mice the relation between the MAA peak 
plasma concentration and the percentage of malformed fetuses, and the relation 
between the average daily area under the blood concentration‐time curve (AUC) of 
MAA and the percentage of malformed fetuses. No preferred dose metric (MAA 
peak plasma concentration or average daily AUC of MAA) was obtained. For the 
translation of in vitro data into in vivo data in the present study, alkoxyacetic acid 
peak concentrations were selected as the preferred dose metric to be used as input 
values for the PBK models. 
In the in vivo developmental toxicity studies with EGBE and EGPE, developmental 
toxicity was only observed at dose levels that also caused maternal toxicity, 
including hemolysis (Sleet et al., 1989; Tyl et al., 1984; Unilever Research, 1984). In 
vitro studies showed that hemolytic eﬀects of BAA are already found at 1 mM 
(lowest concentration tested; Ghanayem et al., 1989), indicating that hemolysis 
occurs at lower BAA concentrations than the concentrations inhibiting embryonic 
stem cell diﬀerentiation (De Jong et al., 2009). Because maternal toxicity was not 
taken into account in the present study, in which we aimed to predict 
developmental toxicity, this may explain why our predicted developmental toxicity 
dose levels are higher than the developmental toxicity dose levels measured in in 
vivo studies, due to developmental toxicity as a secondary eﬀect of maternal 
toxicity. 
De Jong et al. (2009) showed that the ranking of the potencies of the glycol ether 
alkoxyacetic acid metabolites in the ES‐D3 cell diﬀerentiation assay of the EST is 
the same as that of the potencies of their parent glycol ethers in vivo. However, 
diﬀerences in in vitro potencies were small (at maximum threefold) compared with 
diﬀerences in in vivo potencies for developmental toxicity (at maximum 24‐fold) 
(De Jong et al., 2009). The present study shows that the predicted diﬀerences in 
potencies of the glycol ethers improve, when combining the in vitro toxicity data 
with PBK models simulating in vivo kinetics (Table 7). The physiological parameter 
values used in the rat and human PBK models are representative for the beginning 
of pregnancy (Gargas et al., 2000a). During pregnancy, some physiological 
parameter values will change, for example, the size of some tissue compartments. It 
is not expected that this would have a large influence on the model outcome of the 
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present models, because the sensitivity analysis of the model revealed that the 
influence of these parameters, including richly perfused tissue (fetus) (Gargas et al., 
2000a), is low (Figure 4). Although the approach used assumes that in vitro 
developmentally toxic concentrations have to reach the embryo to result in 
developmental toxicity, it was not necessary to include a specific fetal 
compartment in the model, because fetal MAA and EAA concentrations were 
found to be identical to maternal plasma concentrations in rats exposed to EGME 
(Gargas et al., 2000a) and EGEEA (Gargas et al., 2000b), respectively. It was 
assumed that this is also true for BAA and PAA. We aimed to build our PBK model 
based on parameter values derived from in silico (partition coeﬃcients) or in vitro 
(metabolism) methods. The parameter values for EGPE metabolism were assumed 
to be equal to those of EGBE based on comparable LogP values and VanderWaals 
volumes (Table 3), which are important descriptors in Quantitative Structure‐
Activity Relationships (QSARs) for metabolism (Chang et al., 2009; Soﬀers et al., 
2001). Given the outcomes of the sensitivity analysis, which revealed that metabolic 
parameters were of limited influence, and considering the model outcomes of the 
EGPE model (Figure 2F), it seems to be justified to use the kinetic parameter values 
for EGBE metabolism in the EGPE model. The parameter values for the oral uptake 
(ka) of the glycol ethers and the parameter values for urinary excretion of the 
Reverse dosimetry glycol ethers 
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alkoxyacetic acid metabolites (Kex) were acquired using in vivo kinetic data. The 
sensitivity analysis showed that the ka and the Kex were not sensitive parameters for 
the prediction of peak plasma levels of the alkoxyacetic acids (SC ka = 0, SC Kex = ‐
0.1). Although the Kex is not a sensitive parameter, diﬀerences in peak plasma 
concentrations of MAA, EAA, BAA and PAA reached are to a large extent the result 
of the large diﬀerences in Kex values (at maximum 18‐fold for rat and 11‐fold for 
human), which are directly related to the plasma half‐lives of the alkoxyacetic acid 
metabolites. The present study shows that PAA has a shorter plasma half‐life in 
rats (1.0‐2.6 h) than BAA (1.5‐3.2 h; Ghanayem et al., 1990), EAA (7.6‐10 h; Aasmoe 
and Aarbakke, 1997; Aasmoe et al., 1999) and MAA (14‐19 h; Aasmoe and Aarbakke, 
1997; Aasmoe et al., 1999). This indicates that the developmental toxicity potencies 
of the glycol ethers EGME, EGEE, EGBE and EGPE in rats are related to the plasma 
half‐lives of their alkoxyacetic acid metabolites, as we suggested before (De Jong et 
al., 2009). The plasma half‐life of PAA, as measured in rats in the present study, 
was comparable with that of 2,4‐D in rats (1.1‐2.1 h; Timchalk, 2004). Because no 
human data on the excretion kinetics of PAA are available in the literature, the 
excretion data of 2,4‐D in human were therefore assumed to be suitable to derive 
the parameter value for PAA excretion for the human PBK model. However, 
because the Kex seems to play an important role in determining diﬀerences in in 
vivo developmental toxicity potencies of the glycol ethers, an inaccurate estimation 
of this parameter value would result in incorrectly predicted developmental 
toxicity dose levels. 
No dose‐response curves for developmental toxicity of EGBE could be predicted 
for human. Due to the high excretion rate of BAA in the human model, a steady‐
state level of BAA is reached (Figure 7), which is lower than the BAA 
concentrations that decrease the ES‐D3 cell diﬀerentiation in vitro by 10%. The 
predicted dose‐response curve for developmental toxicity of EGPE for human, 
using the in vitro ES‐D3 cell diﬀerentiation assay data of laboratory 2, does not 
reach a 100% of aﬀected fetuses (Figures 6C and 6F). This is due to the steady‐state 
level that is reached for PAA (Figure 7), which equals the BMC50 value of PAA 
derived from the ES‐D3 cell diﬀerentiation assay data of laboratory 2. 
The extrapolation of in vitro toxicity data with human PBK models may predict 
safe dose levels for human, without the need for applying an uncertainty factor for 
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interspecies diﬀerences in kinetics. With the use of probabilistic PBK models, in 
which distributions rather than single points are used for parameter values, one 
might even take the variability of in vivo kinetics in the human population into 
account (chapter 7). This would enable a better prediction of dose‐response curves 
for in vivo developmental toxicity for humans and eliminate the need not only for 
an uncertainty factor for interspecies diﬀerences in kinetics, but also for an 
uncertainty factor for intraspecies diﬀerences in kinetics. However, predicted 
developmental toxicity dose levels for humans cannot be verified with in vivo 
human data. Consequently, possible interspecies diﬀerences in dynamics might be 
overlooked. Therefore, one might want to keep the uncertainty factor for these 
diﬀerences in dynamics. 
Altogether, the results of the present study show that our predicted dose‐response 
curves for glycol ether‐induced developmental toxicity in rats, based on ES‐D3 cell 
diﬀerentiation assay data in combination with PBK modeling, are in good 
concordance with glycol ether developmental toxicity dose levels reported in 
literature. The diﬀerences between our predicted BMDL10 values and the BMDL10 
values derived from in vivo studies for glycol ethers are small considering the 
experimental diﬀerences in BMDL10 values that might be derived from in vivo 
Reverse dosimetry glycol ethers 
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five subsequent daily exposures to EGBE and EGPE respectively, at doses ranging from 0 to 100 mmol · 
kg bw‐1. 
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(developmental) toxicity studies. The predicted BMDL10 values could be used as 
points of departure in risk assessment practices, thereby contributing to the 
reduction of animal use in the risk assessment of these chemicals. It is concluded 
that the combined in vitro‐in silico approach, after further development and 
evaluation, may contribute to a science‐based risk assessment of chemicals, using 
no or reduced numbers of laboratory animals. 
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Abstract 
The present study determines the relative developmental toxicity potencies of 
retinoids in the embryonic stem cell (ES‐D3 cell) diﬀerentiation assay of the 
embryonic stem cell test, and compares the outcomes with their relative potencies 
in in vivo and two other in vitro assays for developmental toxicity. The results 
reveal that the potency ranking obtained in the ES‐D3 cell diﬀerentiation assay is 
similar to the reported potency rankings in the two other in vitro assays for 
developmental toxicity. TTNPB ((E)‐4[2‐(5,6,7,8‐tetrahydro‐5,5,8,8‐tetramethyl‐2‐
naphthalenyl)‐1‐propenyl]benzoic acid) was the most potent retinoid, whereas 
etretinate and retinol had the lowest potency. All‐trans‐retinoic acid, 13‐cis‐retinoic 
acid, 9‐cis‐retinoic acid and acitretin showed an intermediate potency. In vivo 
potency rankings of the developmental toxicity of retinoids appear to be dependent 
on the species and/or exposure regimens used. The obtained in vitro potency 
ranking does not completely correspond with the in vivo potency rankings, 
although TTNPB is correctly predicted to be the most potent and retinol the least 
potent congener. The lack of in vivo kinetic processes in the ES‐D3 cell 
diﬀerentiation assay might explain the deviating potency predictions of some 
retinoids. Therefore, knowledge on the chemical‐specific species‐dependent in vivo 
kinetics is essential when using in vitro toxicity data for the estimation of in vivo 
developmental toxicity potencies within series of related chemicals. 
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Introduction 
For the registration of industrial chemicals under REACH (Registration, 
Evaluation, Authorization and restriction of CHemicals), information on safety is 
required. It is estimated that more than 25% of the 3.9 million laboratory animals 
needed for safety testing for REACH will be used for developmental toxicity studies 
(Van der Jagt et al., 2004). Also for pharmaceuticals, food additives and pesticides, 
regulatory agencies require safety studies performed in laboratory animals, 
including developmental toxicity studies. Because of the high number of laboratory 
animals used for developmental toxicity testing, the development, validation and 
application of in vitro and in silico assays that can contribute to the replacement, 
reduction and refinement (3Rs) of experimental animal studies, is urgently needed. 
Currently, in vitro assays are considered to be useful in the development and early 
safety testing of pharmaceuticals and food additives and for setting priorities for 
toxicity testing of chemicals within the REACH framework. 
For developmental toxicity, three in vitro assays have been scientifically validated 
so far, which are the rat limb bud micromass (MM) test, the postimplantation rat 
whole‐embryo culture (WEC) test and the embryonic stem cell test (EST) 
(Genschow et al., 2002). Of these three assays, the EST, using embryonic stem cells, 
is the only test in which no primary animal tissues are required. The EST measures 
the potency of the test chemical to inhibit cell proliferation of embryonic 
fibroblasts (BALB/c‐3T3 cells) and embryonic stem cells (ES‐D3 cells) (cell 
proliferation assays), and the potency of the test chemical to inhibit ES‐D3 cell 
diﬀerentiation into contracting cardiomyocytes (ES‐D3 cell diﬀerentiation assay). 
The acquired EC50 values in these assays are applied in a prediction model to 
predict the embryotoxic potency (non‐, weak or strong embryotoxic) of the 
chemical. The EST, including its prediction model, was validated under the 
supervision of the European Centre for the Validation of Alternative Methods 
(ECVAM) and was able to predict the developmental toxicity potencies of twenty 
diﬀerent chemicals with an overall accuracy of 78% (Genschow et al., 2004). The 
usefulness of the prediction model is questioned however, since only two of 
thirteen chemicals that were tested in the European Framework Program project 
ReProTect were correctly classified using the prediction model (Marx‐Stoelting et 
al., 2009). It is also not known whether the prediction model is able to classify the 
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developmental toxicity potencies of chemicals within a chemical class. The ES‐D3 
cell diﬀerentiation assay, used as standalone assay, has been shown to be able to 
predict the in vivo potency ranking of four glycol ethers based on the in vitro toxic 
eﬀect concentrations of their toxic alkoxyacetic acid metabolites (De Jong et al., 
2009). This makes the diﬀerentiation assay of the EST a useful tool to set priorities 
for developmental toxicity testing within a series of glycol ethers (De Jong et al., 
2009). However, it remains to be established whether the diﬀerentiation assay of 
the EST is also able to correctly predict the relative developmental toxicity 
potencies of chemicals belonging to other chemical classes. 
The aims of the present study were 1) to compare the potency ranking of retinoids 
obtained in the in vitro ES‐D3 cell diﬀerentiation assay of the EST with reported 
potency rankings of these retinoids in two other in vitro assays for developmental 
toxicity, the MM test and the WEC test and 2) to determine the applicability of the 
ES‐D3 cell diﬀerentiation assay to predict the relative in vivo developmental 
toxicity potencies of retinoids, in order to investigate the potential of the ES‐D3 cell 
diﬀerentiation assay as a tool to set priorities for developmental toxicity testing 
within a series of retinoids. 
To this end, the relative potencies of retinol, all‐trans‐retinoic acid (ATRA), 13‐cis‐
retinoic acid (13‐cis‐RA), 9‐cis‐retinoic acid (9‐cis‐RA), etretinate, acitretin and 
TTNPB ((E)‐4[2‐(5,6,7,8‐tetrahydro‐5,5,8,8‐tetramethyl‐2‐naphthalenyl)‐1‐
propenyl]benzoic acid) (Figure 1) were determined in the ES‐D3 cell diﬀerentiation 
assay and compared with their relative potencies in the two other in vitro test 
systems as reported in the literature. Furthermore, the relative potencies of these 
retinoids in the ES‐D3 cell diﬀerentiation assay were also compared with their 
relative potencies derived from reported in vivo studies. The in vitro and in vivo 
potencies of the retinoids were determined using the benchmark dose (BMD) 
approach, using the BMC50 values (benchmark concentration at which a 
benchmark response of 50% (BMR50) is reached) for the in vitro developmental 
toxicity potency ranking, and the BMD10 values (benchmark dose at which the 
BMR10 is reached) for the in vivo developmental toxicity potency ranking. Finally, 
the retinoids were also tested in the ES‐D3 cell diﬀerentiation assay in the presence 
of the retinoic acid receptor (RAR) antagonist Ro 41‐5253 (Figure 1), to investigate 
whether the retinoid‐induced inhibition of cardiomyocyte diﬀerentiation was RAR‐
mediated. 
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Materials and methods 
Chemicals 
9‐Cis‐RA, 13‐cis‐RA, acitretin, ATRA, retinol and TTNPB were purchased from 
Sigma‐Aldrich (Zwijndrecht, The Netherlands) and etretinate from Sequoia 
Research Products (Berkshire, UK). Ro 41‐5253 was purchased from Enzo Life 
Sciences (Raamsdonksveer, The Netherlands) and dimethyl sulfoxide (DMSO) 
from Acros Organics (Geel, Belgium). 
ES‐D3 cell culture 
The murine ES‐D3 cell line was a kind gift from Johnson & Johnson (Beerse, 
Belgium), and was cultured according to the method described by De Smedt et al. 
(2008). Briefly, cells were cultured in cell culture Petri dishes (35 mm × 10mm, 
Corning, Schiphol‐Rijk, The Netherlands) at 37 oC in a humidified atmosphere of 
5% CO2 in Dulbecco’s Modified Eagle Medium (Invitrogen, Breda, The 
Netherlands) supplemented with 20% (v/v) fetal calf serum (BioWhittaker, 
Verviers, Belgium), 2 mM glutamine (Invitrogen), 50 U/ml penicillin/50 µg/ml 
Retinoids in embryonic stem cell test 
Figure 1. Chemical structure of retinoids used in the present study. Straight arrow = metabolism; dashed 
arrow = isomerization. ATRA: all‐trans‐retinoic acid; 13‐cis‐RA: 13‐cis‐retinoic acid; 9‐cis‐RA: 9‐cis‐
retinoic acid; TTNPB: (E)‐4[2‐(5,6,7,8‐tetrahydro‐5,5,8,8‐tetramethyl‐2‐naphthalenyl)‐1‐propenyl]
benzoic acid. 
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streptomycin (Invitrogen), 1% (v/v) non‐essential amino acids (Invitrogen) and 0.1 
mM β‐mercaptoethanol (Sigma‐Aldrich). To keep cells undiﬀerentiated, 1000 U/ml 
murine leukemia inhibiting factor (ESGRO®, Chemicon International, Amsterdam, 
The Netherlands) was added to the culture medium. Cells were subcultured three 
times a week, using non‐enzymatic dissociation buﬀer (Sigma‐Aldrich) to detach 
cells. 
ES‐D3 cell diﬀerentiation assay 
To determine the concentrations aﬀecting ES‐D3 cell diﬀerentiation into 
contracting cardiomyocytes, the ES‐D3 cell diﬀerentiation assay as described by De 
Smedt et al. (2008) was used, with small modifications as described by Louisse et 
al. (2010a). Briefly, on day 0, droplets of 20 µl cell suspension (3.75 · 104 cells/ml) 
were seeded on the inside of the lid of a 96‐well plate. Caps of Eppendorf tubes 
were placed at the corners of the well plate to elevate the lid in order to prevent 
direct contact of the hanging drops with the well plate. Wells were filled with 250 
µl phosphate buﬀered saline (Invitrogen) to obtain the right humidity and to 
prevent evaporation of the hanging drops. On day 3, cell aggregates, called 
embryoid bodies (EBs), were formed and these were transferred to bacteriological 
petri dishes (Greiner Bio‐one, Alphen a/d Rijn, The Netherlands). On day 5, EBs 
were transferred to 24‐well plates (Corning, 1 EB/well) and were incubated for 
another 5 days. On day 10, the number of wells containing contracting 
cardiomyocytes was determined using light microscopy. Exposure to test 
chemicals, added from a 400 times concentrated stock solution in DMSO to culture 
medium, started at day 0 and lasted for 10 days. Exposure medium was refreshed at 
day 3 and day 5. Solvent controls (0.25% DMSO, v/v) were included in each 
experiment. A test was considered valid when at least 21 out of 24 wells of the blank 
(non‐exposed cells) and the solvent control plate contained contracting 
cardiomyocytes. For each plate, the number of EBs diﬀerentiated into contracting 
cardiomyocytes was determined. All experimental handlings, except for the 
determination of the number of wells containing contracting cardiomyocytes, were 
carried out under yellow light, in order to prevent photodegradation of the 
retinoids. Each retinoid was tested in triplicate, resulting in three in vitro datasets 
per retinoid. 
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Data analysis 
In vitro data. The in vitro datasets were used to derive BMC50 values on the basis 
of concentration‐response analysis using the United States Environmental 
Protection Agency (US EPA)’s benchmark dose software (BMDS) version 2.1. For 
data analysis, the number of non‐diﬀerentiated EBs and the total number of EBs, in 
both the solvent control plate and the exposure plates, were used. All models for 
dichotomous data were used to describe the data. Goodness‐of‐fit of the models 
was assessed based on the P‐values, the scaled residuals and the graphical displays 
acquired. Based on the goodness‐of‐fit of the models, for each individual dataset it 
was determined which model was used to derive a BMC50 value. Each dataset was 
analyzed separately, resulting in three BMC50 values per chemical. The average 
BMC50 values were used for the in vitro potency ranking. Figures of concentration‐
response eﬀects were made using SigmaPlot 9.01. Concentration‐response curves 
were included in these figures using a 3‐parameter logistic model. These curves 
were not used for determination of BMC50 values. In order to test for significant 
eﬀects of Ro 41‐5253 on the inhibition of cardiomyocyte diﬀerentiation by the 
retinoids, one‐tailed Student’s t‐tests were used (Graphpad Prism 5). 
In vivo data. Developmental toxicity studies using oral dosing of the retinoids in 
rat, mouse and rabbit reported in the literature, were used to determine the in vivo 
developmental toxicity potency ranking of the retinoids. The studies used are listed 
in Table 2. Data on malformations were used for dose‐response analysis using 
BMDS version 2.1. For data analysis, the number of malformed fetuses and the total 
number of fetuses in both the control groups and the exposure groups were used. 
All models for dichotomous data were used to describe the in vivo developmental 
toxicity data. Goodness‐of‐fit of the models was assessed based on the P‐values, the 
scaled residuals and the graphical displays acquired. Based on the goodness‐of‐fit 
of the models, for each individual dataset it was determined which model was used 
to derive a BMD10 value. The acquired BMD10 values were used for the in vivo 
developmental toxicity potency ranking. If present, data for total malformations 
were used for BMD analysis. If no data on total malformations were available, the 
obtained BMD10 value for cleft palate incidence was used for the potency ranking. 
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Results 
Retinoids cause a concentration‐dependent decrease in ES‐D3 cell diﬀerentiation 
which is counteracted by the RAR‐antagonist Ro 41‐5253 
All retinoids tested caused a concentration‐dependent inhibition of ES‐D3 cell 
diﬀerentiation into contracting cardiomyocytes (Figure 2). The BMC50 values 
derived from these data are presented in Table 1, including the resulting potency 
ranking of the retinoids in the ES‐D3 cell diﬀerentiation assay. The most potent 
retinoid in inhibiting ES‐D3 cell diﬀerentiation was TTNPB (Figure 2, Table 1). 
When comparing BMC50 values, TTNPB is two orders of magnitude more potent 
than ATRA, 13‐cis‐RA, 9‐cis‐RA and acitretin and four orders of magnitude more 
potent than retinol and etretinate (Table 1). In vitro potency diﬀerences between 
ATRA, 13‐cis‐RA, 9‐cis‐RA and acitretin are small (at most 3.6‐fold), as is the in 
vitro potency diﬀerence between retinol and etretinate (1.9‐fold) (Table 1). 
Figure 3 shows the eﬀects of ATRA and acitretin at their BMC50 concentrations, 
and retinol, 13‐cis‐RA, 9‐cis‐RA, etretinate and TTNPB at their BMC90 
concentrations in the absence or presence of 5 µM of the RAR‐antagonist Ro 41‐
5253. The results show that the retinoid‐induced inhibition of ES‐D3 cell 
diﬀerentiation is counteracted by the RAR‐antagonist Ro 41‐5253 (Figure 3). 
Relative developmental toxicity potencies of retinoids in the MM test and the WEC 
test 
The relative developmental toxicity potencies of the retinoids in the MM test and 
the WEC test as reported in the literature are shown in Table 1. In the MM test, a 
potency ranking of TTNPB > acitretin > ATRA > 13‐cis‐RA > etretinate was obtained 
by Kistler (1987). Similar results were obtained in the MM test by Reiners et al. 
(1988) and Kochhar et al. (1995) (Table 1). 
Steele et al. (1987) obtained a potency ranking of ATRA ≈ 13‐cis‐RA ≈ acitretin > 
etretinate in the WEC test, and Cicurel and Schmid (1988) found a ranking of 
TTNPB > ATRA > 13‐cis‐RA in this assay. A higher potency of ATRA compared with 
13‐cis‐RA was also found by others in the WEC test (Tesh, 1988; Klug et al., 1989). 
Acitretin was reported to be more potent than etretinate (Bechter and Hall, 1987) 
and ATRA to be more potent than retinol (Morriss and Steele, 1977) in the WEC 
test (Table 1). 
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Chapter 6 
Figure 3. Retinoid‐induced inhibition of ES‐D3 cell diﬀerentiation. All retinoids were tested in triplicate 
in the ES‐D3 cell diﬀerentiation assay, indicated by diﬀerent symbols. 
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Relative developmental toxicity potencies of retinoids in vivo 
Table 2 shows the results of the BMD analysis of the in vivo developmental 
toxicity data as reported in the literature and the resulting potency rankings of the 
retinoids in vivo. Potency rankings were made for diﬀerent species and/or exposure 
regimens for total malformations. In some of the studies, no data on total 
malformations were reported. In these cases the BMD10 values obtained for data on 
cleft palate incidence were used for the potency ranking. If data were available on 
both total malformations and cleft palate incidence, both a BMD10 value for total 
malformations and a BMD10 value for cleft palate incidence were obtained (Table 
2). Using the BMD10 values presented in Table 2, diﬀerent rankings were obtained, 
dependent on the species and/or exposure regimen used. For rats exposed on 
gestational day (GD) 9 or GD10 (Table 2, ranking A) the potency ranking was 
TTNPB > ATRA > retinol. In rats exposed on GD10‐11 (Table 2, ranking B) ATRA 
was found to have a higher potency than acitretin. The obtained potency ranking 
for mice exposed on GD11 (Table 2, ranking C) was ATRA ≈ etretinate > 9‐cis‐RA > 
13‐cis‐RA, whereas in mice exposed on GD7‐16 (Table 2, ranking D) the potency 
Retinoids in embryonic stem cell test 
Figure 3. Counteraction of Ro 41‐5253 on retinoid‐induced inhibition of ES‐D3 cell diﬀerentiation. ES‐
D3 cells were exposed to the retinoids in the absence (white bars) or presence (grey bars) of 5 µM Ro 41‐
5253 (n = 3‐5).  
* Significant diﬀerence (p < 0.05) between absence and presence of 5 µM Ro 41‐5253. 
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ranking was TTNPB > acitretin > 13‐cis‐RA. Finally, the potency ranking in rabbits 
exposed on GD7‐19 or GD6‐18 (Table 2, ranking E) was TTNPB > acitretin > ATRA ≈ 
13‐cis‐RA. 
TTNPB was the most potent retinoid in vivo in all species, indicated by BMD10 
values that are three or more orders of magnitude lower than the BMD10 values for 
the other retinoids. For etretinate and 9‐cis‐RA, BMD10 values could only be 
derived for mice exposed on GD11. The potency of etretinate was found to be in the 
same range of that of ATRA (between 1.4‐fold lower and 1.7‐fold higher), whereas 
the potency of 9‐cis‐RA was between 1.8‐ and 4.4‐fold lower than that of ATRA 
(Table 2). For retinol, a BMD10 value could only be derived for rats exposed on 
GD10. The potency of retinol was 5.3‐fold lower than that of ATRA and 5600‐fold 
lower than that of TTNPB. The in vivo potency ranking of ATRA, acitretin and 13‐
cis‐RA was dependent on the species and/or exposure regimen used. Acitretin was 
found to be 12‐fold less potent than ATRA in rats exposed on GD10‐11, whereas 
acitretin (exposed on GD7‐19) was found to be 8.4‐fold more potent than ATRA 
(exposed on GD6‐18) in rabbits. When comparing in vivo potencies of ATRA and 13‐
cis‐RA, large diﬀerences were found between the derived BMD10 values in mice 
exposed on GD11 (between 3.1‐ and 7.8‐fold), whereas in rabbits exposed on GD6‐
18, ATRA and 13‐cis‐RA had almost the same potency (1.2‐fold diﬀerence). 
 
Discussion 
The aims of the present study were 1) to compare the potency ranking of retinoids 
in the ES‐D3 cell diﬀerentiation assay of the EST with reported potency rankings of 
these retinoids in the MM test and the WEC test and 2) to determine the 
applicability of the ES‐D3 cell diﬀerentiation assay to predict the relative in vivo 
developmental toxicity potencies of retinoids, in order to investigate the potential 
of the ES‐D3 cell diﬀerentiation assay as a tool to set priorities for developmental 
toxicity testing within a series of retinoids. 
All retinoids tested showed a concentration‐dependent inhibition of ES‐D3 cell 
diﬀerentiation. The obtained in vitro potency ranking, based on the derived BMC50 
values, is in general in concordance with the potency rankings of the retinoids in 
the MM test and the WEC test, as reported in the literature (Table 1), that is 
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TTNPB being the most potent, etretinate and retinol being the least potent, and 
ATRA, 9‐cis‐RA, 13‐cis‐RA and acitretin having an intermediate potency. However, 
the relative potencies of the retinoids with intermediate potency (ATRA, 9‐cis‐RA, 
13‐cis‐RA and acitretin) is slightly diﬀerent in the test systems (Table 1). Acitretin 
was 1.4‐1.6‐fold more potent than ATRA in the MM test, whereas in the present 
study ATRA was 3.6‐fold more potent than acitretin (Table 1). In the WEC test, no 
clear diﬀerence in potency between ATRA and acitretin was observed. When 
comparing the EC50 values of ATRA and 13‐cis‐RA in the MM test, Kistler (1987) 
and Kochhar et al. (1995) obtained large diﬀerences of respectively 5‐ and 33‐fold, 
whereas Reiners et al. (1988) obtained a diﬀerence of only 1.2‐fold (Table 2). In the 
present study, the diﬀerence between the BMC50 values of ATRA and 13‐cis‐RA was 
1.5‐fold (Table 1). When interpreting the results of the ATRA isomers, it must be 
noted that during exposure, isomerization to other isomers can take place. This has 
been shown to happen for ATRA and 13‐cis‐RA in the WEC test (Klug et al., 1989), 
resulting in a combined exposure to the diﬀerent retinoic acid isomers. Therefore, 
a specific exposure to one of the retinoic acid isomers is not possible, to some 
extent hampering the interpretation of the results for the individual retinoic acid 
isomers. 
To determine the applicability of the ES‐D3 cell diﬀerentiation assay to predict 
the developmental toxicity potency ranking of retinoids in vivo, the in vitro 
developmental toxicity potency ranking was compared with the in vivo 
developmental toxicity potency rankings, based on BMD10 values derived from 
reported in vivo developmental toxicity studies. If possible, BMD10 values were 
obtained for total malformations. If these data were not presented in the studies 
used, data on cleft palate incidence were used, in order to include as many retinoid 
congeners as possible in the in vivo potency rankings. It must be noted that 
diﬀerent BMD10 values for total malformations compared with BMD10 values for 
cleft palate incidence might be expected using an identical exposure regimen. This 
is reflected for example in the 2.5‐fold higher BMD10 value for cleft palate incidence 
than the BMD10 value for total malformations, obtained from the data of Campbell 
et al. (2004) for mice exposed on GD11 to ATRA (Table 2). On the other hand, the 
BMD10 value for cleft palate incidence obtained from the data of Kochhar et al. 
(1995) is only 1.1‐fold higher than the BMD10 value for total malformations obtained 
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from the data of Campbell et al. (2004) (Table 2), suggesting that valid in vivo 
potency rankings could be obtained, based on BMD10 values derived for total 
malformations and/or cleft palate incidence. 
The results show that diﬀerent in vivo developmental toxicity potency rankings 
were obtained among diﬀerent species and exposure regimens (Table 2). 
Diﬀerences in dynamics and kinetics among species might play a role in the 
diﬀerences in in vivo developmental toxicity potency rankings. In all species, 
TTNPB was the most potent congener in vivo, which was correctly predicted by the 
ES‐D3 cell diﬀerentiation assay. The retinoids ATRA, 9‐cis‐RA and acitretin showed 
intermediate potencies in vivo, which was also found in the ES‐D3 cell 
diﬀerentiation assay (Table 1). The lowest potency, based on the derived BMD10 
values, was obtained for retinol (Table 2), as was also correctly predicted by the ES‐
D3 cell diﬀerentiation assay. However, although no BMD10 value could be 
determined for total malformations or cleft palate incidence for 13‐cis‐RA in rats, it 
must be noted that a lower potency of 13‐cis‐RA compared to that of retinol was 
reported for rats being exposed on GD10 (Tembe et al., 1996). 
Etretinate was one of the least potent retinoids in the ES‐D3 cell diﬀerentiation 
assay (Table 1), whereas it was found to be relatively potent in vivo (Table 2). 
Reiners et al. (1988) compared the in vitro (MM test) and in vivo (mouse) potencies 
of ATRA, etretinate and etretinate’s metabolite acitretin. A relatively low potency 
of etretinate was obtained in vitro, whereas it was relatively potent in vivo. The high 
in vivo potency is due to the metabolism of etretinate to acitretin, leading to high 
concentrations of acitretin in the fetuses (Reiners et al., 1988). The lack or low 
expression level of this bioactivation system in the cells used in the ES‐D3 cell 
diﬀerentiation assay, in the limb bud cells used in the MM test, and in the embryos 
used in the WEC test, might explain the misclassification of etretinate as a retinoid 
with a relatively low teratogenic potency. Etretinate’s potency was increased in the 
WEC test and the MM test when carboxylic ester hydrolase was added to the test 
system (Bechter and Hall, 1987; Kochhar et al., 1989), resulting in the formation of 
etretinate’s metabolite acitretin (Kochhar et al., 1989), corroborating the need of 
acitretin formation in etretinate‐induced developmental toxicity. 
The relatively low potency of 13‐cis‐RA in rats and mice was not found in rabbits, 
having only a 1.2‐fold lower potency than ATRA (Table 2). This corresponds with 
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the results of the ES‐D3 cell diﬀerentiation assay, in which 13‐cis‐RA was 1.5‐fold 
less potent than ATRA (Table 1). The low potency of 13‐cis‐RA compared with 
ATRA in rats and mice in vivo is ascribed to a lower placental transfer of 13‐cis‐RA 
than that of ATRA (Collins et al., 1994; Tzimas et al., 1995). Although the placental 
transfer of 13‐cis‐RA is also lower than that of ATRA in rabbits (Tzimas et al., 1994), 
both retinoids have almost the same developmental toxicity potencies in rabbits. 
This might be due to a slower excretion of 13‐cis‐RA than of ATRA in this species 
(Tzimas et al., 1994). The role of in vivo kinetics in the interspecies diﬀerences in in 
vivo developmental toxicity potencies of ATRA and 13‐cis‐RA is summarized by Nau 
(2001). 
These examples show that the knowledge of in vivo kinetic processes (absorption, 
distribution, metabolism and excretion) is indispensable when interpreting results 
of in vitro toxicity experiments for estimating in vivo potency rankings. When 
combining in vitro toxicity data with information on in vivo kinetics, better 
estimations of in vivo toxicity potencies or in vivo toxic dose levels can be made. 
Previously, we have shown that with the use of physiologically based kinetic (PBK) 
models, which describe the in vivo kinetics of chemicals, in vitro toxic eﬀect 
concentrations obtained in the ES‐D3 cell diﬀerentiation assay can be extrapolated 
to in vivo dose levels (Verwei et al., 2006; Louisse et al., 2010b). Chapter 7 presents 
such a combined in vitro‐in silico model for the prediction of developmental 
toxicity dose levels of ATRA in rat and human. 
Retinoid‐induced developmental toxicity eﬀects are suggested to be RAR‐
mediated. Disruption of ATRA‐induced pathways might result in disruption of the 
embryonic development resulting in malformations (Collins and Mao, 1999). Ali‐
Khan and Hales (2006) showed that retinol‐induced limb defects in mouse limbs 
(ex vivo) are prevented by the RAR‐antagonist BMS 453. Furthermore, Eckhardt 
and Schmitt (1994) showed that Ro 40‐6055‐induced developmental toxicity in the 
MM test was counteracted by the RAR‐antagonist Ro 41‐5253. The present study 
shows that Ro 41‐5253 also counteracts the retinoid‐induced inhibition of ES‐D3 
cell diﬀerentiation, suggesting that the RAR is involved in the in vitro 
developmental toxicity eﬀects induced by the retinoids in the ES‐D3 cell 
diﬀerentiation assay. This indicates that the ES‐D3 cell diﬀerentiation assay 
contains a relevant pathway for retinoid‐induced developmental toxicity, making it 
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a useful tool for assessing developmental toxicity potencies of retinoids and 
possible other RAR‐agonists. 
Altogether, it is concluded that the ES‐D3 cell diﬀerentiation assay results in a 
similar potency ranking of retinoids as obtained in the MM test and the WEC test, 
that is TTNPB being the most potent retinoid, ATRA, 13‐cis‐RA, 9‐cis‐RA and 
acitretin showing an intermediate potency, and etretinate and retinol being the 
least potent. Therefore, it can be seen as an equally adequate in vitro method for 
predicting in vivo developmental toxicity potencies as the other in vitro assays for 
developmental toxicity. Moreover, because the ES‐D3 cell diﬀerentiation assay does 
not use primary animal tissues, it can even be seen as a better in vitro method, 
leading to a larger reduction of animal use in developmental toxicity testing. 
However, although TTNPB was correctly classified as the most potent retinoid by 
the ES‐D3 cell diﬀerentiation assay and retinol as the least potent, not all retinoids 
were correctly ranked on their in vivo potencies. This shows that the ES‐D3 cell 
diﬀerentiation assay is not suﬃcient as standalone for predicting in vivo 
developmental toxicity potencies of retinoids. The deviating ranking could be 
explained by the lack of in vivo kinetic processes in the in vitro assay, which play a 
role in the developmental toxicity potencies of these retinoids in vivo. Therefore, 
knowledge on chemical‐specific species‐dependent in vivo kinetics is essential 
when using in vitro toxicity data for estimation of in vivo developmental toxicity 
potencies within series of related chemicals. 
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Abstract 
The use of high numbers of laboratory animals for toxicity testing in chemical 
safety assessment meets increasing ethical and economic constraints. The 
development, validation and application of reliable alternatives for in vivo toxicity 
testing is therefore urgently needed. In order to use toxicity data obtained from in 
vitro assays for risk assessment, in vitro concentration‐response curves need to be 
translated into in vivo dose response‐curves. This can be achieved by reverse 
dosimetry using physiologically based kinetic (PBK) modeling. The present study 
provides a proof‐of‐principle of this combined in vitro‐in silico approach by 
translating in vitro concentration‐response curves of the retinoid all‐trans‐retinoic 
acid (ATRA) obtained in the embryonic stem cell (ES‐D3 cell) diﬀerentiation assay 
of the embryonic stem cell test (EST), into in vivo dose‐response curves for 
developmental toxicity using a PBK model that is solely based on kinetic model 
parameter values derived using in vitro techniques. The results reveal that dose 
levels of ATRA causing in vivo developmental toxicity were predicted within one 
order of magnitude compared with reported in vivo developmental toxicity data 
from the literature. This indicates for the first time the feasibility of using only in 
vitro toxicity and kinetic data for defining an in vivo dose‐response curve suitable 
for risk assessment practice. 
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Introduction  
For the registration of chemicals, such as pharmaceuticals, industrial chemicals, 
food additives and pesticides, regulatory agencies require safety studies performed 
in laboratory animals. Increased use of laboratory animals is foreseen for safety 
evaluations because of the European Commission’s REACH (Registration, 
Evaluation, Authorization and restriction of CHemicals) legislation. It is expected 
that more than half of the laboratory animals needed for REACH will be used for 
reproductive and developmental toxicity testing (Van der Jagt et al., 2004). The use 
of these high numbers of laboratory animals for toxicity testing meets increasing 
ethical and economic constraints, indicating that the development, validation and 
application of reliable alternatives for in vivo studies is urgently needed. Currently, 
in vitro assays are considered to be useful in the development and early safety 
testing of pharmaceuticals, new food additives and pesticides, and for setting 
priorities for toxicity testing of industrial chemicals within the REACH framework. 
However, at present in vitro toxicity data are hardly used in chemical risk 
assessment. One of the reasons is that concentration‐response curves are obtained 
in in vitro assays, whereas in vivo dose‐response curves are required in the hazard 
characterization process. Therefore, in vitro toxic eﬀect concentrations need to be 
translated into in vivo toxic dose levels, in order to increase the acceptance and 
implementation of in vitro assays in toxicological risk assessment strategies.  
The translation of in vitro toxicity data into in vivo eﬀect doses (DeJongh et al., 
1999; Verwei et al., 2006a; Forsby and Blaauboer, 2007; Rotroﬀ et al., 2010; 
Wetmore et al., 2012) or in vivo dose‐response curves (Paini et al., 2010; Louisse et 
al., 2010) can be achieved using physiologically based kinetic (PBK) modeling with 
a reverse dosimetry approach. With reverse dosimetry, in vitro concentration‐
response data are set as internal concentrations in a PBK model, after which the 
PBK model calculates the doses that are needed to reach these internal 
concentrations (in the blood or target tissue) in the in vivo situation. This 
translation results in predicted in vivo dose‐response data (Figure 1).  
We have recently shown that with this reverse dosimetry approach, in vivo dose‐
response curves for the developmental toxicity of a group of glycol ethers can be 
reliably predicted based on in vitro concentration‐response curves obtained in the 
embryonic stem cell (ES‐D3 cell) diﬀerentiation assay of the embryonic stem cell 
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test (EST) (Louisse et al., 2010). To further extend the potential of the approach to 
predict in vivo developmental toxicity dose levels, examples with chemicals from 
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Figure 1. Graphic representation of the PBK model developed for ATRA to extrapolate the in vitro 
concentration‐response curve of ATRA determined in the ES‐D3 cell diﬀerentiation assay to predicted 
dose‐response curves for ATRA‐induced in vivo developmental toxicity in rat and human.  
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other chemical categories are needed. In addition, PBK models, which are currently 
often built using in vivo kinetic data (Rietjens et al., 2011), should instead be 
preferentially based on parameter values obtained using only in vitro and/or in 
silico techniques to increase the contribution to the replacement, reduction and 
refinement (3Rs) of animal use in toxicological research. 
The aim of the present study was to assess the feasibility of predicting in vivo 
developmental toxicity dose levels of the retinoid all‐trans‐retinoic acid (ATRA) 
with reverse dosimetry, using a PBK model that is based on kinetic parameter 
values derived using in vitro techniques only. ATRA is the major metabolite of 
retinol (vitamin A) and is required for various processes in the body (Collins and 
Mao, 1999). Proper levels of vitamin A must be maintained for normal 
embryogenesis, whereas vitamin A deficiency and high retinoid intake induce 
adverse eﬀects to the developing conceptus (Collins and Mao, 1999). To predict 
dose‐response curves for in vivo ATRA‐induced developmental toxicity, the reverse 
dosimetry approach using PBK modeling was applied. In the present study, the 
following steps were followed: I) the determination of an in vitro concentration‐
response curve for ATRA‐induced developmental toxicity, II) the development of a 
PBK model for ATRA kinetics in rat and human, III) the evaluation of the PBK 
model predictions for in vivo ATRA kinetics, IV) the translation of the in vitro 
concentration‐response curve into predicted in vivo dose‐response curves for rat 
and human using the PBK model for reverse dosimetry and V) the comparison of 
the predicted dose‐response curves for ATRA‐induced developmental toxicity with 
data on in vivo ATRA‐induced developmental toxicity in rats, in order to evaluate 
the predictive value of the approach. 
The results obtained show that the reverse dosimetry approach, combining in 
vitro toxicity data and in silico PBK modeling, is a promising tool to predict in vivo 
dose‐response curves for ATRA‐induced developmental toxicity. To the best of our 
knowledge, this is the first proof‐of‐principle that in vivo dose‐response curves for a 
systemic endpoint can be predicted without the need of in vivo studies. The 
predicted dose‐response curves obtained can be used to set points of departure to 
derive safe exposure levels for humans, pointing at the potential of the approach to 
increase the acceptance and implementation of in vitro assays in toxicological risk 
assessment strategies.  
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Materials and methods  
Chemicals 
ATRA and taurocholate were purchased from Sigma‐Aldrich (Zwijndrecht, the 
Netherlands) and [11,12‐3H(N)]‐ATRA, [1‐methyl‐14C]‐caﬀeine and D‐[1‐3H(N)]‐
mannitol from Perkin‐Elmer (Groningen, the Netherlands). Polydimethylsiloxane 
(PDMS) was obtained from General Electrics Plastics BV (Bergen op Zoom, the 
Netherlands) and hexane from Biosolve (Valkenswaard, the Netherlands). Ethanol, 
KOH and HEPES were purchased from Merck Chemicals (Darmstadt, Germany). 
Reverse dosimetry approach to translate in vitro concentration‐response curves into 
in vivo dose‐response curves for developmental toxicity 
I) Determination of in vitro developmental toxicity in the ES‐D3 cell diﬀerentiation 
assay 
The in vitro developmental toxicity data of ATRA in the ES‐D3 cell 
diﬀerentiation assay were taken from our previous study (Louisse et al., 2011). The 
data of three independent experiments were combined to one data set, by 
calculating per concentration the total number of non‐diﬀerentiated embryoid 
bodies (EBs) as a fraction of the total number of EBs (sample size) used for that 
concentration. The data were used for BMD analysis using the models for quantal 
data of the PROAST software, developed by the Dutch National Institute for Public 
Health and the Environment (RIVM, Bilthoven, the Netherlands), to determine 
Benchmark concentrations for the inhibition of ES‐D3 cell diﬀerentiation.  
II) Development of a PBK model for ATRA kinetics in rat and human 
The following steps were followed to develop a PBK model for ATRA: 1) 
definition of a conceptual model, 2) translation of the conceptual model into a 
mathematical model by defining mathematical equations, 3) defining the model 
parameter values and 4) solving the mathematical equations using appropriate 
software. Subsequently, the model predictions were evaluated to determine 
whether the model can be used for reverse dosimetry. 
The conceptual model defined for ATRA is shown in Figure 1 (step 1). The kinetic 
processes for this model were translated into a mathematical model for Berkeley 
Madonna software (UC Berkeley, CA, USA) (step 2). The processes of stomach 
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emptying (rat, liquid: 15 min (Reilly et al., 1990), human, liquid: 15 min (Sun et al., 
1988)) and the small intestinal transition (rat: 1.5h, human: 4h (Davies and Morris, 
1993)) are included in the model. Values for anatomical and physiological 
parameters were taken from literature (Brown et al., 1997, Table 1), whereas values 
for chemical‐specific kinetic model parameters were determined in the present 
study (step 3). These kinetic parameter values were obtained using data derived 
using only in vitro techniques and include parameter values for 1) intestinal 
absorption, 2) partitioning into tissues (i.e. distribution) and 3) metabolic clearance 
(i.e. metabolism and subsequent excretion). The mathematical equations were 
subsequently solved (step 4) using Berkeley Madonna software.  
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Intestinal absorption. Intestinal ATRA uptake values were determined by using 
apparent permeability (Papp) coeﬃcients ((amount transported (µmol) · time‐1 (s))/
(surface area (cm2) · concentration applied (mM)) for transport across human 
intestinal colorectal adenocarcinoma (CaCo‐2) monolayers. To this end, CaCo‐2 
cells (P7‐P9, obtained from ATCC) were grown on Costar 12‐well transwell plate 
inserts (Corning; membrane pore size: 0.4 µm,  surface area: 1.12 cm2) by adding 0.5 
mL of a 2.24 · 105 cell suspension in culture medium (DMEM (Invitrogen, Breda, the 
Netherlands, cat. no. 61965), supplemented with 10% FCS (BioWhittaker, Verviers, 
Belgium), 100 µM NEAA (Invitrogen) and 50 µg/ml gentamycin (Invitrogen)) to 
each transwell plate insert (apical compartment) and 1.5 mL of culture medium to 
the basolateral compartment. Cells were grown in a humidified atmosphere (5% 
CO2) at 37oC. Culture medium was refreshed every two to three days. Transport 
studies were performed 20 days post‐seeding. For transport studies, the apical 
compartment was filled at t=0 with 0.65 mL 10 mM HEPES in HBSS (Invitrogen) 
(pH 6.5) containing the test chemicals ([11,12‐3H(N)]‐ATRA (1 nM – 10 µM), [1‐
methyl‐14C]‐caﬀeine (10 µM, control for transcellular transport) or D‐[1‐3H(N)]‐
mannitol (10 µM, control for paracellular transport)), in the absence or presence of 
10 mM taurocholate. The basolateral compartment was filled with 1.5 mL HBSS (pH 
7.4) in the absence or presence of 0.6 mM BSA (Sigma‐Aldrich). Samples from the 
apical compartment (0.15 mL) were taken at t=0 min and t=20 min.  Samples from 
the basolateral compartment (0.5 mL) were taken at t=10 min (followed by the 
addition of 0.5 mL HBSS to retain a volume of 1.5 mL) and t=20 min. Initial 
experiments using varying incubation times showed that transport velocity was 
linear until 30 minutes (data not shown). At t=20 min, the transwell filters with 
cells were washed with HBSS and incubated in 0.5 mL 80% 1.5 M KOH/20% 
ethanol. Radioactivity was measured after adding 10 mL of OptiPhase HiSafe 
(Perkin Elmer) to the samples and the filters with cells, using a Tri‐Carb Liquid 
Scintillation Counter (Perkin Elmer). The calculated amount in the three 
compartments (apical compartment, basolateral compartment and filter plus cells) 
were used for mass balance calculations. 
The rate of ATRA transfer can be calculated using these Papp coeﬃcients, as was 
done before for folic acid by Verwei et al. (2006b). Because Papp coeﬃcients 
((amount transported/time)/(surface area × concentration applied) are values 
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describing the transport velocity (amount per time), depending on the surface area 
and the concentration applied, the transfer rate across the intestinal wall can be 
obtained by multiplying the Papp coeﬃcient by the surface area of the intestine and 
the luminal concentration in the intestine. In the present PBK model this resulted 
in: intestinal transfer rate ATRA (µmol · h‐1) = Papp coeﬃcient (cm · h‐1) × absorptive 
surface area (cm2) × luminal concentration of ATRA (mM). The absorptive surface 
area of the rat intestines (94 cm2) was calculated assuming a radius of 0.18 cm 
(Zimmerman et al., 2001) and a small intestine length of 83 cm (McConnell et al., 
2008). The absorptive surface area of the human intestines (25800 cm2) was taken 
from Verwei et al. (2006b). The luminal concentration of ATRA is calculated by the 
model by dividing the amount of ATRA (µmol) by the small intestinal volume 
(mL). The small intestinal volume was calculated to be 8.4 mL for rat (radius: 0.18 
cm, length: 83 cm) and 9 L for human (radius: 2.5 cm (Kararli, 1995), length: 460 
cm (Hossenpour and Behdad, 2008)).  
Tissue:blood partition coeﬃcients. Tissue:blood partition coeﬃcients were 
calculated by dividing obtained tissue:buﬀer (PBS, Invitrogen) partition coeﬃcients 
by obtained blood:buﬀer partition coeﬃcients. The tissue:buﬀer and blood:buﬀer 
partition coeﬃcients were determined using a recently developed SPME‐based 
approach developed by the Netherlands Organization for Applied Scientific 
Research (TNO, Zeist, the Netherlands) (Vaes, 2010). In this method, the chemical 
of interest is able to distribute over three diﬀerent phases (compartments), which 
are i) a buﬀer phase, ii) a serum (or tissue homogenate) phase and iii) a coating 
phase. It is assumed that the chemical will distribute over these phases according 
to the following equation: 
1) Mt = Cb * Vb +  Cs * Vs + Cc * Vc 
in which Mt = total mass, Cb = concentration in buﬀer, Vb = volume buﬀer, Cs = 
concentration in serum (or tissue homogenate), Vs = volume serum (or tissue 
homogenate), Cc = concentration in coating and Vc = volume coating. The 
concentration of the chemical in the coating can be described as: 
2) Cc = Cb * Kc 
in which Cc = concentration in coating, Cb = concentration in buﬀer and Kc = 
coating:buﬀer partition coeﬃcient. The concentration of the chemical in the serum 
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can be described as: 
3) Cs = Cb * Ks 
in which Cs = concentration in serum (or tissue homogenate), Cb = concentration 
in buﬀer and Ks = serum (or tissue homegenate):buﬀer partition coeﬃcient. 
These equations can be rewritten as: 
4) Ac = Mt / (1 +  ((Vb + Ks * Vs) / (Vc * Kc)))  
in which Ac = amount in coating, Mt = total mass, Vb = volume buﬀer, Ks = serum 
(or tissue homogenate):buﬀer partition coeﬃcient, Vs = volume serum (or tissue 
homogenate), Vc = volume coating and Kc = coating:buﬀer partition coeﬃcient.  
In the experimental set‐up, 96‐well plates (Flexible 96, Clear 96‐well Flexible 
PET microplates, round bottom (Perkin Elmer)) were coated with increasing 
volumes of polydimethylsiloxane (PDMS) (Vc). This was achieved by adding 200 µL 
of varying PDMS concentrations dissolved in hexane to the wells, after which the 
hexane was allowed to evaporate. Increasing concentrations of serum (Sigma‐
Aldrich) (or tissue homogenates (tissues obtained from a supernumerary 2‐months
‐old male Wistar rat of the animal facility)), obtained by dilution in buﬀer, were 
spiked with [11,12‐3H(N)]‐ATRA, after which 200 µL of these solutions were added 
per (coated) well. The serum (or tissue homogenate) concentration can be 
described as a volume of serum and a volume of buﬀer (together amounting to 200 
µL) resulting in varying serum (or tissue homogenates) volumes (Vs) and buﬀer 
volumes (Vb). It was assumed that ATRA in blood binds only to serum 
components, assuming that blood consists of two third of plasma (Lee and Blaufox, 
1985), implicating that pure blood was considered as 1.5 times diluted plasma. Per 
96‐well plate, a maximum of 96 situations can be created with diﬀerent 
combinations of Vc, Vb and Vs. Plates are put overnight at an orbital shaker to allow 
equilibration of the chemical over the diﬀerent phases. Subsequently, per well, 50 
µL of the medium was removed from the wells and transferred to a non‐coated 96‐
well plate, and the remaining medium from the coated 96‐well plate was removed 
and the plate was washed. To both plates, 200 µL of OptiPhase HiSafe was added 
per well, after which the plates were covered with TopSeal®‐A‐96‐well microplate 
press‐on adhesive sealing film (Perkin Elmer). Radioactivity measurements were 
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performed using a 1450‐023 MicroBeta TriLux Microplate Scintillation and 
Luminescence Counter (Perkin Elmer) to obtain Ac (radioactivity in coating) and 
Mt (radioactivity in coating + radioactivity of transferred medium (times four, 
because one fourth of medium is used for radioactivity counting of medium)). 
From equation 4, Vb, Vs and Vc are varying (chosen) values and Ac and Mt are 
determined by radioactivity measurements. The remaining values for Ks and Kc are 
unknown. These are estimated using the solver function of Microsoft Excel by 
solving equation 4 for the maximal 96 diﬀerent combinations of Vb, Vs and Vc, 
resulting in an estimated Ks and Kc. The free fraction in pure serum (or tissue 
homegenate) can be obtained by using the Ks (free fraction = 1 / (Ks + 1)). 
Metabolic clearance. Data on the in vitro kinetic conversion of ATRA by 
microsomes as reported in the literature (Table 2) were used to determine the 
model parameter values for metabolic clearance. The reported apparent Km values 
were applied to the model, whereas the apparent Vmax values were scaled to a 
complete organ assuming a microsomal protein yield of 35 mg/g rat liver 
(Medinsky et al., 1994), 7 mg/g rat kidney (Beierschmitt and Weiner, 1986), 20 mg/
g rat lung (Medinsky et al., 1994), 4 mg/g rat brain (Ravindranath and 
Anandatheerthavarada, 1990) and 32 mg/g human liver (Barter et al., 2007). For the 
rat model, kinetic constants obtained using liver, kidney, lung and brain fractions 
were used. For the human model, kinetic constants on the formation of 4‐OH‐
ATRA were obtained using cytochrome P450 (CYP) enzyme kinetics (CYP2C8, 
CYP3A4, CYP3A5, CYP3A7, CYP26A1) and kinetic constants on the formation of all‐
trans‐retinoyl β‐glucuronide were obtained using uridine 5'‐diphospho‐
glucuronosyltransferase (UGT) enzyme kinetics (UGT2B7). 4‐OH‐ATRA levels in 
vivo are low, probably due to a rapid oxidation of the C4‐hydroxylated ATRA 
(Marchetti et al., 1997), resulting in ATRA’s main oxidized metabolite 4‐oxo‐ATRA. 
The expression levels of CYP and UGT enzymes in the human population is 
variable. Expression levels of these enzymes in human livers were incorporated in 
the model using data reported in the literature (Naraharisetti et al., 2010; Lin et al., 
2002; Sim et al., 2005; Tay et al., 2010, Zaya et al., 2006). A Monte Carlo simulation 
for a virtual population of 1000 individuals was performed, in which in each 
simulation, the expression levels of the CYP and UGT enzymes were randomly 
taken from a log‐normal distribution. The expression levels of the enzymes were 
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assumed to vary independently. For this simulation, the mean µw and SD σw 
describing the log‐normal distribution of each enzyme expression level value were 
derived from the data reported in the literature using the following equations: 
µw = ln(µx/√(1+CVx2)) 
and 
σw = ln(1+CVx2) 
where µx is the mean and CVx is the coeﬃcient of variation of the non‐log‐
transformed enzyme expression level values as reported in the literature (Zhang et 
al., 2007; Punt et al., 2010). 
III) PBK model evaluation 
Model predictions were evaluated by comparing model predicted ATRA blood 
concentrations with ATRA blood concentrations from in vivo kinetic studies 
reported in the literature (Table 3). A sensitivity analysis was performed to identify 
the key parameters highly influencing the model output (peak blood 
concentrations and blood AUC). The eﬀect of a 5% increase in parameter value was 
evaluated by calculating normalized sensitivity coeﬃcients (SC = (C’ ‐ C) / (P’ ‐ P) × 
(P / C)) as described by Evans and Andersen (2000) (C = initial value of model 
output, C’ = value of model output resulting from 5% increase in parameter value, P 
= initial parameter value, P’ = 5% increased parameter value). For the sensitivity 
analysis of the human model, the expression levels of the biotransformation 
enzymes were set at their median expression level. 
IV) Translation of the in vitro concentration‐response curve into predicted in vivo 
dose‐response curves  
To predict the dose‐response curves for in vivo developmental toxicity of ATRA, 
in vitro data for the ATRA‐induced inhibition of ES‐D3 cell diﬀerentiation were 
used as input in the blood compartment of the PBK model and translated into in 
vivo oral dose levels. Because it is assumed that the free fraction of the chemical 
will cause ATRA’s toxicity, corrections were made to take the diﬀerences in the free 
fraction in the in vitro compared to the in vivo situation into account. To this end, 
the free fractions for the diﬀerent situations (culture medium, rat blood and 
human blood) were determined using the approach described in the section on 
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tissue:blood partition coeﬃcients, after which corrections factors were calculated. 
Predictions of dose‐response curves for in vivo developmental toxicity were made 
by relating the toxic eﬀect to 1) the Cmax in blood, as was done before for the glycol 
ethers (Louisse et al., 2010) and 2) the AUC in blood. To relate the toxic eﬀect to 
the AUC in blood, the concentration‐response data were translated into AUC‐
response data, by multiplying the applied concentration with the assay time 
(Daston et al., 2010), assuming an unchanged concentration of the test chemicals in 
the exposure medium over time. The model was then used to calculate the 
corresponding dose levels of ATRA leading to these ATRA AUC values in the blood 
compartment, resulting in the predicted dose‐response data for in vivo 
developmental toxicity. Subsequently, BMD modeling was applied using PROAST 
software to obtain the predicted in vivo dose‐response curves for developmental 
toxicity. 
V) Evaluation of the predictive value of the approach 
To evaluate the potential of the in vitro‐in silico approach to predict in vivo 
developmental toxicity of ATRA, the predicted dose‐response curves for the rat 
were compared with data obtained in in vivo developmental toxicity studies 
reported in the literature as listed in Table 4. Developmental toxicity endpoints 
reported in these studies include several types of malformations. Furthermore, the 
in vivo data were used to derive BMD10 values on the basis of dose‐response 
analyses using PROAST software. These BMD10 values derived from in vivo data 
were compared with predicted BMD10 values, which were acquired by performing 
dose‐response modeling on the predicted dose‐response data using PROAST 
software. 
 
Results  
I) In vitro concentration‐response curve for ATRA‐induced developmental toxicity 
In vitro concentration‐response data on ATRA‐induced inhibition of ES‐D3 cell 
diﬀerentiation were used as input data for the reverse dosimetry approach. The 
data reported for three independent ES‐D3 cell diﬀerentiation studies (Louisse et 
al., 2011) were combined to one dataset to which concentration‐response modeling 
Reverse dosimetry all-trans-retinoic acid 
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Table 4. In vivo developmental toxicity studies used to evaluate predicted dose‐response curves for 
ATRA‐induced developmental toxicity in rats. In all studies, rats were exposed using gastric intubation 
at GD10. Symbols shown correspond with symbols used in Figure 7. BMD10 values calculated from these 
data are shown in Figure 9. 
was applied using benchmark dose (BMD) analysis. Figure 2 shows the in vitro data 
and the 95% lower and upper confidence limits of the concentration‐response 
curve fitted to these data, which were subsequently used as input (as internal 
concentrations) in the PBK model to predict in vivo dose‐response curves (step IV). 
Figure 2. Concentration‐response data of ATRA‐induced inhibition of ES‐D3 cell diﬀerentiation based 
on data from Louisse et al. (2011). The circles represent the combined data obtained in three 
independent ES‐D3 cell diﬀerentiation assays. The dashed lines represent the 95% lower (left curve) 
and the 95% upper (right curve) confidence limit of the curve fitted to the data. 
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II) Development of a PBK model for ATRA kinetics in rat and human  
To translate the in vitro concentration‐response curve into in vivo dose‐response 
curves, a PBK model describing the in vivo kinetics of ATRA is required. The 
conceptual basis for this model is shown in Figure 1, which was converted into 
mathematical equations. Subsequently, the parameter values determining the 
ADME processes, such as values for physiological and anatomical parameters, 
tissue:blood partition coeﬃcients and other kinetic parameters were defined. The 
physiological and anatomical parameter values used for the model were obtained 
from the literature (Table 1). The kinetic parameter values were obtained using 
only in vitro techniques and include parameter values for 1) intestinal absorption, 
2) partitioning into tissues (i.e. distribution) and 3) metabolic clearance (i.e. 
metabolism and subsequent excretion). 
Parameter value for intestinal absorption. PBK model parameter values for 
intestinal absorption were estimated by studying the transfer rate of ATRA across 
CaCo‐2 cells cultured in a transwell system. From these studies, apparent 
permeability (Papp) coeﬃcients are obtained, representing the transport rate as a 
function of the intestinal surface area and the concentration applied (expressed in 
cm · s‐1). To assess the eﬀect of typical in vivo conditions, ATRA’s transport 
characteristics were studied in the in vitro system using diﬀerent medium 
conditions in the apical compartment (representing the intestinal cavity) and the 
basolateral compartment (representing portal blood). The presence of the bile acid 
taurocholate in the apical compartment decreases the Papp coeﬃcient, whereas the 
presence of albumin in the basolateral compartment increases the Papp coeﬃcient 
(Figure 3). The Papp coeﬃcient for ATRA is not dependent on the concentration 
applied in the apical compartment (Figure 3), indicating that this value can be used 
to calculate the intestinal absorption (amount · time‐1) for all concentrations 
applied. The average Papp coeﬃcient (20·10‐6 cm · s‐1 equivalent to 5.6 ·10‐9 cm · h‐1) 
obtained using physiological conditions (taurocholate in the apical compartment 
and albumin in the basolateral compartment) was converted to obtain the PBK 
model parameter value for intestinal absorption (in ml · h‐1). This parameter value 
was obtained by multiplying the converted Papp coeﬃcient by the surface area of 
the intestinal lumen (see materials and methods for calculations).  
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Figure 3. Apparent permeability (Papp) coeﬃcients for mannitol, caﬀeine and ATRA transport across 
monolayers of CaCo‐2 cells cultured in a transwell system. Mannitol and caﬀeine were used as controls 
for paracellular and transcellular transport, respectively. White bars: apical: HBSS, basolateral: 0.6 mM 
BSA in HBSS; light grey bars: apical: 10 mM taurocholate in HBSS, basolateral: 0.6 mM BSA in HBSS; 
dark grey bars: apical: HBSS, basolateral: HBSS; black bars: apical: 10 mM taurocholate in HBSS, 
basolateral: HBSS. 
Parameter values for tissue:blood partition coeﬃcients. To predict the 
distribution of ATRA over diﬀerent tissues in the body, tissue:blood partition 
coeﬃcients needed to be determined. These were obtained by determining 
tissue:buﬀer partition coeﬃcients and blood:buﬀer partition coeﬃcients using a 
recently developed SPME‐based method (Vaes, 2010). Tissue:blood partition 
coeﬃcients were obtained by dividing the tissue:buﬀer partition coeﬃcients (Table 
5) by the blood:buﬀer partition coeﬃcient (measured to be 325). Table 5 shows the 
obtained tissue:buﬀer partition coeﬃcients (with olive oil representing fat tissue) 
and the calculated tissue:blood partition coeﬃcients. The rest‐of‐body:blood 
partition coeﬃcient in the model was set at 1. The tissue:blood partition 
coeﬃcients determined for rat were also used for the human PBK model. 
Parameter values for metabolic clearance. The excretion of ATRA was assumed to 
result from metabolic clearance only. This was based on previous observations that 
the amount of reported unchanged ATRA excreted in urine, bile and faeces is 
negligible (Swanson et al., 1981; Hänni et al., 1976; Li et al., 1996). To obtain model 
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Table 5. Measured rat tissue:buﬀer partition coeﬃcients and calculated rat tissue:blood partition 
coeﬃcients. 
a determined by dividing the tissue:buﬀer partition coeﬃcient by the blood:buﬀer partition coeﬃcient 
(i.e. 325). 
parameter values for hepatic clearance, data on kinetics for the in vitro conversion 
of ATRA by liver microsomes reported in the literature were used (Table 2). For 
rats, kinetic constants (apparent Vmax and Km values) obtained in vitro using liver 
microsomes were available from the literature (Table 2). The apparent Vmax values 
of the reactions were scaled to a rat liver assuming a microsomal protein yield of 35 
mg/g rat liver (Medinsky et al., 1994), yielding model parameter values for hepatic 
clearance. For rats also kinetic constants obtained using kidney, lung and brain 
microsomes were available from the literature (Table 2). These data were 
incorporated in the model assuming a microsomal protein yield of 7 mg/g rat 
kidney (Beierschmitt and Weiner, 1986), 20 mg/g rat lung (Medinsky et al., 1994) 
and 4 mg/g rat brain (Ravindranath and Anandatheerthavarada, 1990), 
respectively. 
For humans, kinetic constants obtained in vitro using specific biotransformation 
enzymes were available from the literature (Table 2). The data on apparent Vmax 
values of the reactions were scaled to a human liver assuming a liver microsomal 
protein yield of 32 mg/g human liver (Barter et al., 2007). The expression levels of 
the biotransformation enzymes in human liver microsomes have been reported in 
the literature for diﬀerent individuals (Naraharisetti et al., 2010; Lin et al., 2002; 
Sim et al., 2005; Tay et al., 2010; Zaya et al., 2006). These data were used to 
determine the distribution of the expression levels of these enzymes in human 
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livers. When assuming that these data would be representative for the human 
population, predictions for a virtual human population can be made, using Monte 
Carlo simulations. These simulations were used in step III to assess interindividual 
diﬀerences in ATRA kinetics in the human population. 
III) PBK model evaluation 
To evaluate the PBK model predictions of ATRA kinetics, PBK model predictions 
for ATRA blood concentrations in time were compared with ATRA blood 
concentrations from reported in vivo kinetic studies (Figures 4 and 5). Table 3 gives 
an overview of the in vivo kinetic studies available for evaluation of the predictions 
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Figure 4. ATRA blood concentrations in rats after intravenous (A, B, C) or oral (D, E, F) dosing. Symbols 
represent average blood levels (SDs are depicted by error bars) from in vivo studies reported in the 
literature (for references for the respective curves A‐F see Table 3). Lines represent model predicted 
blood concentrations. ATRA dose levels for the diﬀerent curves were as follows: A) 0.015 (triangles, 
······), 0.25 (squares, – – –) or 5 (circles, ―) mg · kg bw‐1. B) 2.8 (triangles, ······), 6.9 (squares, – – –) or 14 
(circles, ―) mg · kg bw‐1. C) 8 mg · kg bw‐1, D) 6 mg · kg bw‐1, E) 14 mg · kg bw‐1 F) 20 mg · kg bw‐1. 
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made by the in this study developed PBK models for rat and human including their 
exposure regimens. Comparison of the reported in vivo data for rat with predictions 
made by the rat PBK model reveals that the PBK model reliably predicts ATRA 
blood concentration‐time curves in rat (Figure 4) after intravenous (Figures 4A‐C) 
and oral (Figures 4D‐F) exposure to diverse doses of ATRA.  
For the evaluation of the human PBK model, a kinetic study was used in which 
data on blood concentrations for six individuals were presented (Adamson et al., 
1993). The data from these six individuals reflect the large interindividual variation 
in ATRA blood levels in humans, amounting to more than two orders of magnitude 
at certain time points (Figure 5). This figure also shows the blood concentrations 
predicted by the PBK model for the 1st, the 5th, the 50th, the 95th and the 99th 
percentile of a virtual population of 1000 people, using a Monte Carlo simulation. 
Most data points on the blood concentrations of the 6 individuals that were dosed 
with 2 mg · kg bw‐1 fall within the 5th and the 95th percentile of the blood 
concentrations predicted for the virtual population (Figure 5A). When the human 
individuals were dosed with 4 mg · kg bw‐1, most data points on the blood 
concentrations fall within the 1st and the 95th percentile of the blood concentrations 
modeled for the virtual population (Figure 5B). 
Reverse dosimetry all-trans-retinoic acid 
Figure 5. ATRA blood concentrations in human after oral dosing. Symbols represent blood 
concentrations from individuals taken from an in vivo kinetic study reported in the literature (Adamson 
et al., 1993). Straight lines represent the median of the model predicted blood concentrations, whereas 
dashed lines represent the 5th and the 95th percentiles and dotted lines the 1st and 99th percentiles of the 
blood concentrations predicted for a virtual population, using a Monte Carlo simulation. ATRA dose 
levels for the diﬀerent curves were as follows: A)  2 mg · kg bw‐1, B) 4 mg · kg bw‐1. 
186 
 
To further evaluate the PBK models a sensitivity analysis was performed to 
identify the key parameters that influence the model output to the largest extent. 
This analysis was carried out for the rat and human model, using doses of 0.1, 1, 10 
and 100 mg ATRA · kg bw‐1. This analysis reveals that predicted ATRA blood 
concentrations (Cmax and AUC) are most dependent on the parameter value for 
intestinal absorption, the muscle:blood partition coeﬃcient, and the parameters 
for hepatic clearance in both rat and human (Figure 6). The analysis also revealed 
Chapter 7 
Figure 6. Normalized sensitivity coeﬃcients (NSCs) for kinetic model parameters for rat (A, B) and 
human (C, D) PBK models for ATRA blood Cmax values (A, C) and AUC values (B, D) at diﬀerent oral 
doses. White bars: 0.1 mg · kg bw‐1; light grey bars: 1 mg · kg bw‐1; dark grey bars: 10 mg · kg bw‐1; black 
bars: 100 mg · kg bw‐1. NSCs are shown for model parameters for which at least at one of the dose 
metrics (Cmax, AUC) at one of the doses the NSC > |0.1|. Absorption: intestinal absorption, PC f:b: 
partition coeﬃcient fat:blood, PC m:b: partition coeﬃcient muscle:blood, PC r:b: partition coeﬃcient 
rest of body:blood, Km_ox: Km oxidation, Vmax_ox: Vmax oxidation, Km_gluc: Km glucuronidation, 
Vmax_gluc: Vmax glucuronidation, Km_X: Km enzyme X, Vmax_X: Vmax enzyme X.  
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that the output of the rat PBK model is not sensitive to the parameters for 
metabolism in kidney, lung and brain, indicating a negligible role of extrahepatic 
clearance in total ATRA clearance. 
IV) Translation of the in vitro concentration‐response curve into predicted in vivo 
dose‐response curves, and V) the evaluation of the predictive value of the approach  
After obtaining the in vitro concentration‐response curve and developing the 
PBK model needed for reverse dosimetry, the concentrations of the in vitro 
concentration‐response curve are used as input in the blood compartment of the 
PBK model and translated into in vivo dose levels, defining predicted in vivo dose‐
response data for ATRA‐induced developmental toxicity. Applying dose‐response 
modeling on the obtained predicted dose‐response data results in the predicted in 
vivo dose‐response curve. In order to make these translations, the following aspects 
need prior consideration: 1) the possible correction needed for the diﬀerence in the 
free fraction of ATRA in the in vitro compared with the in vivo situation and 2) the 
choice of the dose metric used (maximal chemical concentration achieved (i.e. the 
Cmax) or the area under the chemical concentration time curve (i.e. the AUC)) to 
correlate exposure to toxicity. 
ATRA has a high binding aﬃnity for proteins and lipids (Smith et al., 1973), 
which leads to diﬀerences in the free fraction of ATRA in the in vitro (culture 
medium) compared to the in vivo (blood) situation (Gülden et al., 2006; Blaauboer, 
2010). Because it is assumed that the toxic eﬀect is caused by the free fraction of 
ATRA, corrections need to be made for diﬀerences in the free fraction in the in 
vitro situation (culture medium) compared to the in vivo situation (rat or human 
blood). This was achieved by multiplying the in vitro concentration‐response curve 
(Figure 2) with a correction factor, which was obtained by dividing the free fraction 
in culture medium by the free fraction in blood, which were determined using the 
SPME‐based method. The correction factors amounted to 3.5 for rat blood and 6.0 
for human blood, reflecting that the protein‐bound fraction in vivo is higher than 
that in culture medium. 
Generally, it is assumed that the (toxic) eﬀect of a chemical can be best related 
to either the Cmax or the AUC. For the prediction of dose‐response curves for ATRA
‐induced developmental toxicity, the predictions for rat were based on the Cmax or 
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on the AUC reached in the blood compartment of the PBK model. To calculate in 
vitro AUC values needed for the extrapolations based on relating the toxicity to the 
AUC, the concentration‐response curve (Figure 2) was multiplied by the exposure 
duration (i.e. 10 days). In vitro concentrations were translated into in vivo doses 
using the rat PBK model, after which BMD modeling was applied to obtain the 
predicted in vivo dose‐response curves for developmental toxicity. Figure 7 presents 
the 95% lower and upper confidence limits of these dose‐response curves predicted 
based on either the Cmax or the AUC. This figure also includes data points reported 
for in vivo developmental toxicity of ATRA in rats. Comparison of the reported 
experimental data with the two sets of predicted dose‐response curves reveals that 
predictions based on relating the toxic eﬀect to the AUC show a better 
concordance with data from reported in vivo developmental toxicity studies in rat 
than predictions based on relating the toxic eﬀect to the Cmax (Figure 7).  
Based on the evaluation of the predictions for rats, predictions for ATRA‐
induced developmental toxicity in humans were made by relating the 
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Figure 7. In vivo developmental toxicity of ATRA in rats. Symbols represent data from in vivo studies 
reported in the literature (A: Wise et al., 2010, B: Tembe et al., 1995, C: Bürgin and Schmitt, 2003). 
Endpoints represented by the symbols used are listed in Table 4. Lines represent the predicted dose‐
response curve by extrapolating the in vitro data (Figure 2) to in vivo dose levels using the rat PBK 
model. Subsequently, BMD modeling was applied to obtain the predicted in vivo dose‐response curves 
for developmental toxicity. Both the 95% lower and upper confidence limits of the predicted dose‐
response curves are presented. Dotted lines represent the predictions made by relating the 
developmental toxicity eﬀect to the Cmax, whereas dashed lines represent the predictions made by 
relating the developmental toxicity eﬀect to the AUC. 
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developmental toxicity eﬀect to the AUC. Dose‐response curves for ATRA‐induced 
developmental toxicity in humans were predicted for a virtual population of 1000 
individuals, using a Monte Carlo simulation. The predicted dose‐response curve for 
the 5th, the 50th and the 95th percentile of this virtual population is shown in Figure 
8, indicating a large predicted interindividual variation in sensitivity to this 
chemical in the human population. 
Reverse dosimetry all-trans-retinoic acid 
Figure 8. Predicted in vivo developmental toxicity of ATRA in human. Dose‐response curves for ATRA‐
induced developmental toxicity in humans were predicted by extrapolating the in vitro data (Figure 2) 
to in vivo dose levels using the human PBK model. Subsequently, BMD modeling was applied to obtain 
the predicted in vivo dose‐response curves for developmental toxicity. Both the 95% lower and upper 
confidence limits of the predicted dose‐response curves are presented. Predictions were made for a 
virtual population of 1000 individuals, using a Monte Carlo simulation. The predicted dose‐response 
curves for the 5th (A), the 50th (B) and the 95th (C) percentile of this virtual population are shown. 
Predictions are made by relating the developmental toxicity eﬀect to the AUC. 
Finally, the reverse dosimetry approach was used to predict BMD10 values
(benchmark doses at which a benchmark response equivalent to a 10% eﬀect size 
(BMR10) is reached). The lower limit of the 95% confidence interval on the BMD10 
(BMDL10) can be used as point of departure in human risk assessment practices 
(Barlow et al., 2009). BMD10 values were predicted by extrapolating the 
concentrations of the in vitro concentration‐response curve (Figure 2) to in vivo 
dose levels (obtained by relating the toxic eﬀects to the AUC) after which the 
resulting dose‐response data were used for BMD analysis. The predicted BMD10 
value for ATRA‐induced developmental toxicity in rat thus obtained was compared 
with BMD10 values determined from data from reported in vivo developmental 
toxicity studies (Table 4), which were shown to be within the same order of 
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magnitude (Figure 9). The predicted BMDL10 value for ATRA‐induced 
developmental toxicity in rats amounted to 6 mg · kg bw‐1. For humans, BMDL10 
values were predicted in the same way as for rat, for a virtual population of 1000 
individuals, using a Monte Carlo simulation. The BMDL10 values for ATRA‐induced 
developmental toxicity for the 5th, 50th and 95th percentile of this virtual population 
amounted to 0.02, 0.05 and 0.1 mg · kg bw‐1, indicating a higher sensitivity of 
humans than of rats to ATRA‐induced developmental toxicity. 
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Figure 9. BMD10 values in rats for ATRA‐induced developmental toxicity. BMD10 values were 
determined for data from in vivo studies reported in the literature as shown in Table 4 and Figure 7. The 
lines cover the BMD10 values for diﬀerent ATRA‐induced malformations ranging from the BMDL10 
(lower limit of the 95% confidence interval on the BMD10) to the BMDU10 (upper limit of the 95% 
confidence interval on the BMD10). The grey area represents the predicted BMD10 (ranging from the 
BMDL10 to the BMDU10). 
* BMD10 value could not be determined for this endpoint. 
Discussion 
The aim of the present study was to assess the feasibility of predicting in vivo 
developmental toxicity dose levels of the retinoid all‐trans‐retinoic acid (ATRA) 
with reverse dosimetry, using a PBK model that is based on kinetic parameter 
values derived using in vitro techniques only. To this end, in vitro concentration‐
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response curves of ATRA‐induced inhibition of ES‐D3 cell diﬀerentiation were 
translated into in vivo dose‐response curves using PBK modeling with a reverse 
dosimetry approach. The results obtained reveal that the predicted BMD10 value for 
ATRA‐induced developmental toxicity in rats is within one order of magnitude 
compared with BMD10 values for ATRA‐induced developmental toxicity derived 
from reported in vivo developmental toxicity studies from the literature. To the 
best of our knowledge, this provides the first proof‐of‐principle indicating that 
toxic dose levels for this complex systemic endpoint can be accurately predicted 
based on in vitro kinetic and toxicity data only. Therefore, it indicates the feasibility 
of the use of this combined in vitro‐in silico approach in toxicological risk 
assessment strategies. 
For the extrapolation of the in vitro concentration‐response curve of ATRA in the 
ES‐D3 cell diﬀerentiation assay to in vivo dose‐response curves, a PBK model 
describing the in vivo kinetics of ATRA needed to be developed. The PBK model 
parameter values for kinetic processes (intestinal uptake, tissue partitioning and 
metabolic clearance) are often obtained using in vivo kinetic data, but were in the 
present study solely derived using in vitro techniques. ATRA clearance was 
described by metabolism in the liver compartment and not via urinary and biliary 
excretion. This was based on previous observations that the amount of reported 
unchanged ATRA excreted in urine, bile and faeces is negligible (Swanson et al., 
1981; Hänni et al., 1976; Li et al., 1996). Predictions for ATRA concentrations in rat 
blood were in general in good concordance with the ATRA blood concentrations 
reported in the literature upon intravenous and oral intake (Figures 3 and 4). 
Deviations are in all cases less than one order of magnitude and no consistency in 
under‐ or overestimation is noticed, which may reflect variation between the in 
vivo kinetic studies. This indicates that the PBK model developed using solely in 
vitro‐derived kinetic parameter values can be reliably used for reverse dosimetry.  
Moreover, the human PBK model reliably predicts ATRA blood concentrations 
in time upon oral intake. Reported blood concentrations in humans are highly 
variable between individuals (Adamson et al., 1993; Figure 6). These interindividual 
diﬀerences were also predicted by the PBK model, using a Monte Carlo simulation 
for a virtual population of 1000 individuals with varying expression levels of 
biotransformation enzymes in the liver as reported in the literature (Naraharisetti 
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et al., 2010; Lin et al., 2002; Sim et al., 2005; Tay et al., 2010, Zaya et al., 2006). Most 
reported blood concentrations in humans fall within the 1st and the 99th percentile 
of the PBK‐model based predicted blood concentrations for the simulated 
population (Figure 6). The fact that certain in vivo data points fall outside the 99th 
percentile of the PBK‐model based predicted blood concentrations for the 
simulated population indicates that the human PBK model may slightly 
underestimate blood concentrations. Considering the results of the sensitivity 
analysis, this may be due to the overestimation of partitioning into muscle tissue, 
an overestimation of hepatic clearance, or an underestimation of intestinal 
absorption, because of the high normalized sensitivity coeﬃcients obtained for 
these model parameters (Figures 5C and 5D). 
Since it was concluded that both the rat and human PBK model reliably predict 
ATRA blood concentrations in time, the PBK models were used for reverse 
dosimetry, translating the in vitro concentration‐response curve into in vivo dose‐
response curves for ATRA‐induced developmental toxicity. The obtained predicted 
dose‐response curve for ATRA‐induced developmental toxicity in rats showed that 
predicted developmental toxicity dose levels of ATRA were closer to the in vivo rat 
data when predictions were based on relating the toxic eﬀect to the AUC, than 
when predictions were based on relating the toxic eﬀect to the Cmax. This is in line 
with the study reported by Tzimas et al. (1997), who found a better correlation 
when correlating various developmental toxicity endpoints to the AUC (correlation 
coeﬃcients of 0.90‐0.98) than when correlating the developmental toxicity 
endpoints to the Cmax (correlation coeﬃcients of 0.22‐0.43). To predict in vivo 
developmental toxicity by relating the developmental toxicity eﬀects to the AUC, in 
vitro AUC values were obtained by multiplying the applied concentration in the ES
‐D3 cell diﬀerentiation assay with the assay time, as suggested by Daston et al. 
(2010). By doing so, it is assumed that the concentration of the test chemical in the 
exposure medium remains constant over time and that the sensitivity of the 
diﬀerentiating stem cells during the diﬀerentiation period is constant as well. The 
influence of possible diﬀerences in sensitive periods on the extrapolation of in vitro 
developmental toxicity data to the in vivo situation needs further research, but is 
beyond the scope of the present study. The fact, however, that deviations between 
predicted and observed dose‐response curves were limited, suggests that the 
approach taken provides a reasonable way of estimating the AUC. 
Chapter 7 
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Since predicted dose‐response curves for rats were best related to the dose 
metric AUC, dose‐response curves for ATRA‐induced developmental toxicity in 
humans were based on relating the toxic eﬀect to the AUC as well. Because the 
human PBK model developed allowed the prediction of the in vivo kinetics for a 
virtual population using Monte Carlo simulations, dose‐response curves for ATRA‐
induced developmental toxicity could be predicted for this virtual population as 
well. This resulted in dose‐response curves for diﬀerent individuals, ranging from 
relative sensitive to relative insensitive individuals. Presenting diﬀerent percentiles 
(e.g. the 5th, the 50th and the 95th) of the dose‐response curves for this virtual 
population reveals the distribution of sensitivity to ATRA‐induced developmental 
toxicity, based on interindividual diﬀerence in kinetics (Figure 8).  
To evaluate whether the presented reverse dosimetry approach can be used to 
determine points of departure for risk assessment, BMD10 values were predicted by 
extrapolating the concentrations of the in vitro concentration‐response curve to in 
vivo dose levels after which the resulting dose‐response data were used for BMD 
analysis.  The predicted BMD10 value for rat thus obtained was shown to be in 
concordance with BMD10 values determined from reported in vivo developmental 
toxicity studies described in the literature, indicated by the less than one order of 
magnitude diﬀerence between the predicted and the in vivo BMD10 values (Figure 
9). Considering the experimental diﬀerences in BMD10 values derived from the 
diﬀerent in vivo studies, the diﬀerences between our predicted BMD10 value and the 
BMD10 values derived from in vivo studies are small (Figure 9). This indicates that 
the reverse dosimetry approach could be used in the risk assessment process to set 
safe exposure limits by applying uncertainty factors for interspecies and 
intraspecies diﬀerences in kinetics and dynamics. No such factors need to be 
applied when predictions are made using the developed human PBK model, 
because these result in BMD10 values for humans. The predicted BMDL10 for the 
median of the virtual human population amounted to 0.05 mg · kg bw‐1, which is 
120‐fold lower than the BMDL10 predicted for rats (i.e. 6 mg · kg bw‐1). This 
indicates that the default uncertainty factor for interspecies diﬀerences in kinetics 
(amounting to √10) for the extrapolation of rats to humans would be too low for 
ATRA. To protect also the relative sensitive individuals in the human population, 
the BMDL10 for the 5th percentile of the population (i.e. 0.02 mg · kg bw‐1) might be 
used to set safe exposure limits. The BMDL10 for the 5th percentile of the population 
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is 2.5‐fold lower than the BMDL10 for the 50th percentile of the population. This 
indicates that the default uncertainty factor for intraspecies diﬀerences in kinetics 
(amounting to √10) for the extrapolation of the ‘average’ human to relatively 
sensitive individuals would be suﬃcient. The obtained results indicate that using a 
reverse dosimetry approach with the human ATRA PBK model, might provide a 
better prediction of in vivo ATRA‐induced developmental toxicity in humans, than 
the classical approach translating toxicity data obtained in rats to humans using 
default uncertainty factors for inter‐ and intraspecies diﬀerences.  
Although the approach presented is promising to be used in the toxicological 
risk assessment of chemicals, there are some limitations. Predictions were made for 
single exposures in the present study. Making predictions for repeated exposures to 
ATRA is complex, because ATRA plasma levels decrease upon repeated dosing (up 
to 9‐fold in rats) (Collins et al., 1995). This is probably due to increased expression 
levels of biotransformation enzymes (Collins et al., 1995; Tay et al., 2010). In order 
to make predictions for ATRA‐induced developmental toxicity after repeated 
dosing, the change in expression levels of biotransformation enzymes should be 
incorporated in the PBK model, to account for these changes in clearance. This 
phenomenon needs further consideration in future reverse dosimetry work. 
Another aspect to consider in future reverse dosimetry approaches for 
developmental toxicity is the placental transfer of chemicals. In the present study, 
predictions of dose‐response curves were based on the in vitro concentration‐
response data as input in the blood compartment of the PBK model, as was done 
before for the glycol ethers (Louisse et al. 2010). No specific compartment for the 
embryo was incorporated in the PBK model, because it has been reported that the 
embryo AUC of ATRA only slightly diﬀers from the maternal plasma AUC of ATRA 
upon single dosing (Collins et al., 1995). For the natural retinoid 13‐cis‐retinoic acid 
and the synthetic retinoid CD394 however, the embryonic concentrations are 
reported to be 10‐fold (Nau, 2001) and 6‐fold (Sass et al., 1995), respectively, lower 
than the maternal plasma concentrations. Therefore, the assumption of equal 
maternal and embryo levels cannot be made for all chemicals, indicating that in 
vitro placental transport models are needed in order to predict the placental 
transfer of these chemicals to the fetus.  
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To the best of our knowledge, the present study is the first proof‐of‐principle 
showing that in vivo dose‐response curves for developmental toxicity can be 
accurately predicted without the need of in vivo studies.  It shows the feasibility of 
the reverse dosimetry approach, integrating in vitro and in silico techniques, to 
predict in vivo developmental toxicity dose levels. This is indicated by the less than 
one order of magnitude diﬀerence between the predicted BMD10 value for ATRA‐
induced developmental toxicity and the BMD10 values determined from reported in 
vivo developmental toxicity studies described in the literature. This diﬀerence is 
small considering the experimental diﬀerences in BMD10 values derived from the in 
vivo developmental toxicity studies (Figure 9). Furthermore, the present study 
uncovered the species diﬀerences in ATRA kinetics, resulting in the prediction of a 
120‐fold higher sensitivity of humans to ATRA‐induced developmental toxicity 
than of rats. This indicates that the default uncertainty factor for interspecies 
diﬀerences in kinetics to determine safe exposure levels for humans (amounting to 
√10) would be too low for ATRA. Therefore, reverse dosimetry using human PBK 
models may be the best tool to predict human toxicity dose levels to be used to set 
safe exposure levels for humans. However, since the assay used to define the in 
vitro concentration‐response curves in the present study is based on mouse 
embryonic stem cells, possible interspecies diﬀerences in dynamics might be 
overlooked. Therefore, an uncertainty factor for these diﬀerences in dynamics 
would still be needed. If the in vitro model used to determine the in vitro 
concentration‐response curves would be based on human cells instead of mouse 
cells, no uncertainty factor for interspecies diﬀerences in dynamics would be 
needed, leaving only the need for uncertainty factors accounting for human 
interindividual diﬀerences in dynamics. Altogether, it is concluded that the 
combined in vitro‐in silico approach has the potential to be used in toxicological 
risk assessment strategies, thereby contributing to the 3Rs of animal use. 
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Summary 
The aim of the present thesis is to provide the proof‐of‐principle that in vitro 
concentration‐response curves can be converted into in vivo dose‐response curves, 
using physiologically based kinetic (PBK) modeling with a reverse dosimetry 
approach, in order to provide alternative methods for in vivo studies in 
toxicological risk assessment. Developmental toxicity was chosen as toxicological 
endpoint for this proof‐of‐principle study, since these type of toxicity studies are 
estimated to require more than one fourth of the animals expected to be needed 
under the European REACH (Registration, Evaluation, Authorization and 
restriction of CHemicals) legislation (Van der Jagt et al., 2004). Also for 
pharmaceuticals, food additives and pesticides, regulatory agencies require safety 
studies performed in laboratory animals, including developmental toxicity studies. 
Therefore, the application of reliable alternatives for in vivo developmental toxicity 
studies would contribute significantly to the replacement, reduction and 
refinement (3Rs) of animal use in toxicological risk assessment. 
Chapter 1 of the present thesis provides background information introducing 
the topic, and defines the aim of the thesis. It describes important factors that are 
needed to develop the concept of translating in vitro concentration‐response 
curves into predicted in vivo dose‐response curves for developmental toxicity, using 
PBK modeling with a reverse dosimetry approach. Briefly, these factors include 1) 
an in vitro model to obtain in vitro concentration‐response curves for 
developmental toxicity, 2) the selection of chemicals to be studied and 3) the 
development of the PBK models needed for reverse dosimetry.  
The in vitro model used was the embryonic stem cell (ES‐D3 cell) diﬀerentiation 
assay of the validated embryonic stem cell test (EST) (Genschow et al., 2004). In 
this assay, the eﬀect of the chemical of interest on ES‐D3 cell diﬀerentiation into 
functional (contracting) cardiomyocytes is assessed. The chemical‐induced 
inhibition of ES‐D3 cell diﬀerentiation is the in vitro developmental toxicity 
endpoint assessed. The ES‐D3 cell diﬀerentiation assay is the only validated in vitro 
developmental toxicity assay for which no primary animal tissues are required 
(Genschow et al., 2002; Genschow et al., 2004). Therefore, alternatives for in vivo 
developmental toxicity studies using this in vitro assay would result in the largest 
contribution to the 3Rs of animal use for developmental toxicity testing.  
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To provide the proof‐of‐principle that the obtained in vitro concentration‐
response curves in the ES‐D3 cell diﬀerentiation assay can be converted into in vivo 
dose‐response curves using PBK modeling with a reverse dosimetry approach, 
appropriate model compounds needed to be selected fulfilling certain criteria. 
First, a list of chemicals was put together containing chemicals meeting two 
criteria, being 1) the presence of in vivo kinetic data on the chemical in the 
literature, in order to be able to build and/or evaluate the PBK models developed 
and used for reverse dosimetry and 2) the presence of in vivo developmental 
toxicity data of the chemical in the literature, in order to evaluate whether the 
ultimately predicted dose‐response curves for developmental toxicity are in 
concordance with data obtained in in vivo developmental toxicity studies. From 
this list of appropriate chemicals that could be used for the research, only series of 
structurally related chemicals were selected. This third criterion enabled the 
assessment of relative diﬀerences within a series of chemicals, thereby providing an 
additional possibility for qualitative evaluation of the predictions made. Two series 
of model chemicals were selected, being 1) a group of glycol ethers, which need to 
be bioactivated in order to cause developmental toxicity, which are hydrophilic, 
show low protein binding and have an unspecific mode of action and 2) a group of 
retinoids, containing several members that directly act as teratogens without 
bioactivation, which are hydrophobic, show high protein binding and have a 
specific mode of action.  
In order to translate the in vitro concentration‐response curves obtained in the 
ES‐D3 cell diﬀerentiation assay into in vivo dose‐response curves with reverse 
dosimetry, PBK models describing the ADME (Absorption, Distribution, 
Metabolism and Excretion) processes of the chemicals of interest needed to be 
developed. The process of PBK model development is described in chapter 1 and 
can be divided in the following steps: 1) definition of a conceptual model, 2) 
translation of the conceptual model into a mathematical model by defining 
mathematical equations, 3) determination of the model parameter values, 4) 
solving the mathematical equations using appropriate software and 5) evaluation of 
the model performance. Subsequently, the model can be used to make predictions 
(step 6), e.g. to predict dose‐dependent inter‐ or intraspecies diﬀerences in 
kinetics, or, as was done in the present thesis, to translate internal concentrations 
set as input in the model into predicted external dose levels (i.e. reverse 
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dosimetry). 
In chapter 2, in vitro assays are presented that have been described in the 
literature for the endpoint developmental toxicity. These assays can be divided in 1) 
cellular assays, using either primary cells or cells from continuous cell lines and 2) 
whole embryo culture (WEC) assays. An overview is given of the varying readout 
parameters, ranging from gene or protein expression changes to cell death or in 
vitro malformations, that have been assessed in these in vitro assays. Chapter 2 also 
describes how in vitro developmental toxicity data may be used, according to the 
literature, to make predictions for the in vivo situation. This can be done in several 
ways: the in vitro data may be used to 1) predict the developmental toxicity class to 
which a chemical belongs (e.g., non‐, weak or strong embryotoxic) using a 
prediction model, 2) predict the relative developmental toxicity potency of a 
chemical based on the in vitro eﬀect concentrations (usually within a group of 
structurally related chemicals) and 3) predict in vivo developmental toxicity dose 
levels by translating in vitro eﬀect concentrations into in vivo eﬀect doses, using 
PBK modeling. However, the prediction of in vivo developmental toxicity based on 
in vitro data can be over‐ or underestimated due to various reasons. These include: 
1) the lack or the low expression levels of biotransformation enzymes in in vitro test 
systems compared with the in vivo situation, 2) the possible lack of relevant cells or 
tissues in the in vitro test system for the eﬀects observed in vivo, 3) the lack of 
secondary adverse eﬀects resulting from maternal or placental toxicity in the in 
vitro test system and 4) the lack of relevant kinetic data needed to construct a PBK 
model that reliably describes the in vivo kinetics, for the quantitative extrapolation 
of in vitro eﬀect concentrations to in vivo eﬀect doses.  
The first group of chemicals selected to develop the proof‐of‐principle for 
translating in vitro concentration‐response curves into in vivo dose‐response curves 
using PBK modeling with reverse dosimetry, was a group of glycol ethers. The 
glycol ethers used were ethylene glycol monomethyl ether (EGME), ethylene glycol 
monoethyl ether (EGEE), ethylene glycol monobutyl ether (EGBE) and ethylene 
glycol monophenyl ether (EGPE). These glycol ethers are in vivo mainly 
metabolized to their alkoxyacetic acid metabolites, being methoxyacetic acid 
(MAA), ethoxyacetic acid (EAA), butoxyacetic acid (BAA) and phenoxyacetic acid 
(PAA), respectively, which are considered to be responsible for the developmental 
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toxicity of the glycol ethers (ECETOC, 2005). It was shown in the validation studies 
of the EST and the rat postimplantation WEC test, that MAA’s toxic eﬀect 
concentrations are in the milimolar range (Genschow et al., 2004; Piersma et al., 
2004). In vivo studies show that MAA’s peak plasma concentrations at doses 
causing developmental toxicity in rats and mice in vivo, are in the millimolar range 
as well (Sweeney et al., 2001). Considering MAA’s high in vitro and in vivo eﬀect 
concentrations and its acidic nature, it was hypothesized that the alkoxyacetic acid 
metabolite‐induced developmental toxicity may be caused by the induction of an 
intracellular pH (pHi) decrease of embryonic cells, resulting in an inhibition of cell 
growth and diﬀerentiation, thereby disturbing embryonic development. To further 
investigate this mode of action of the alkoxyacetic acid metabolites of the glycol 
ethers, the eﬀects of MAA on the pHi of ES‐D3 cells and embryonic fibroblasts 
(Balb/c‐3T3 cells) were assessed in chapter 3 of the present thesis. In this study, 
the chemicals acetazolamide (ACZ) and valproic acid (VPA) were used as positive 
controls because for these chemicals a relation between a chemical‐induced pHi 
decrease in the conceptus and the developmental toxicity outcome has been 
established previously in in vivo studies (Scott et al., 1990; Scott et al., 1997). The 
results obtained showed that MAA, ACZ and VPA cause a pHi decrease at 
concentrations that induce inhibition of ES‐D3 cell diﬀerentiation, indicating that 
the pHi decrease caused by these chemicals is related to the inhibition of cell 
diﬀerentiation. Two other developmental toxicants, all‐trans‐retinoic acid and 5‐
fluorouracil, did not decrease the pHi of embryonic cells at concentrations that 
aﬀect ES‐D3 cell diﬀerentiation, pointing at a diﬀerent mode of action of these 
chemicals, as also described in the literature (Collins and Mao, 1999; Shuey et al., 
1994). MAA and ACZ induced a concentration‐dependent inhibition of ES‐D3 cell 
diﬀerentiation, which was potentiated by amiloride, an inhibitor of the Na+/H+‐
antiporter, corroborating an important role of the pHi on the mechanism of 
developmental toxicity of both chemicals. The results presented in chapter 3 
indicate that a decrease of the pHi is likely to be the mode of developmental 
toxicity of the alkoxyacetic acid metabolites of the glycol ethers and corroborate 
the role of the alkoxyacetic acid metabolites in the mode of action for the 
developmental toxicity of the parent glycol ethers. Confirmed by this mode of 
action, the in vitro concentration‐response curves (chapter 4) to be converted into 
in vivo dose‐response curves (chapter 5) were made with the toxic alkoxyacetic acid 
Summary, general discussion, future perspectives and conclusions 
206 
 
metabolites instead of with the parent glycol ethers, considering that subsequent 
PBK modeling (chapter 5) would take into account the bioactivation of the glycol 
ethers to their alkoxyacetic acid metabolites. 
Chapter 4 presents the concentration‐response curves of MAA, EAA, BAA, PAA, 
EGME and EGEE in the ES‐D3 cell diﬀerentiation assay and compares the 
outcomes with literature data on the in vivo developmental toxicity eﬀects of 
EGME, EGEE, EGBE and EGPE in mice. All glycol ether alkoxyacetic acid 
metabolites tested showed a concentration‐dependent inhibition of cardiomyocyte 
diﬀerentiation, with MAA as the most potent chemical followed by EAA, BAA and 
PAA, respectively. Both parent glycol ethers tested (EGME and EGEE, up to 10 mM) 
did not inhibit ES‐D3 cell diﬀerentiation, corroborating that the metabolites are 
the proximate developmental toxicants in vivo. The potencies of the glycol ether 
alkoxyacetic acid metabolites in the ES‐D3 cell diﬀerentiation assay were compared 
with in vivo toxicity data of the glycol ethers in mice. The potency ranking of the 
chemicals in the ES‐D3 cell diﬀerentiation assay corresponded with the available in 
vivo data on their parent glycol ether’s potencies (EGME > EGEE > EGBE > EGPE). 
The relative diﬀerences between the potencies of the chemicals appeared more 
pronounced in the in vivo studies than in the ES‐D3 cell diﬀerentiation assay. A 
possible explanation for this discrepancy can be the absence of in vivo kinetic 
processes in the in vitro test system, which are known to diﬀer between these 
chemicals in the in vivo situation. 
These diﬀerences in in vivo kinetics can be described in PBK models to be used 
for the translation of the in vitro eﬀect concentrations into in vivo eﬀect doses. 
Chapter 5 describes the results of applying this reverse dosimetry approach for the 
glycol ethers EGME, EGEE, EGBE and EGPE in rat and human. A PBK model was 
developed, describing the kinetics of the four glycol ethers and their 
developmentally toxic alkoxyacetic acid metabolites in rat and human.  The in vitro 
concentration‐response curves of these metabolites in the ES‐D3 cell 
diﬀerentiation assay (chapter 4) were used as input in the PBK model to translate 
in vitro concentration‐response curves into predicted in vivo dose‐response curves 
for developmental toxicity of the parent glycol ethers in rat and human. The 
predicted dose‐response curves for rat were found to be in concordance (within 
one order of magnitude) with the developmental toxicity dose levels measured in 
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diﬀerent in vivo rat developmental toxicity studies. The results thus obtained in 
chapter 5 provide the first proof‐of‐principle that in vitro concentration‐response 
curves can be converted into in vivo dose‐response curves suitable for risk 
assessment practice, using PBK modeling with a reverse dosimetry approach. 
Therefore, it was concluded that this approach, after further evaluation, may 
contribute to a science‐based risk assessment of chemicals, using no or reduced 
numbers of laboratory animals. 
The second group of chemicals used to assess the reliability of predicting in vivo 
dose‐response curves for in vivo developmental toxicity by using the reverse 
dosimetry approach, was a group of retinoids. Retinoids are chemicals that possess 
a chemical structure or functional properties similar to retinol (vitamin A). The 
retinoids investigated were retinol, all‐trans‐retinoic acid (ATRA), 13‐cis‐retinoic 
acid (13‐cis‐RA), 9‐cis‐retinoic acid (9‐cis‐RA), etretinate, acitretin and TTNPB ((E)
‐4[2‐(5,6,7,8‐tetrahydro‐5,5,8,8‐tetramethyl‐2‐naphthalenyl)‐1‐propenyl] benzoic 
acid). Proper levels of vitamin A must be maintained for normal embryogenesis, 
whereas vitamin A deficiency and high retinoid intake may induce adverse eﬀects 
to the developing conceptus (Collins and Mao, 1999). Several retinoids have been 
shown to be teratogenic in a number of experimental animals, including mice, rats, 
guinea pigs, hamsters, rabbits, dogs, pigs, chickens and monkeys (Collins and Mao, 
1999). Retinoids have previously been shown to be active in the limb bud 
micromass test in the nanomolar to micromolar range (Kistler, 1987), indicating 
the higher in vitro potency of these chemicals compared with the glycol ether 
alkoxyacetic acid metabolites. Furthermore, whereas the mechanism of 
developmental toxicity of the glycol ethers is likely to be unspecific (induction of 
pHi decrease), the mechanism of retinoid‐induced developmental toxicity is more 
complex (disturbance of intracellular retinoid signal transduction pathways 
(Collins and Mao, 1999)). 
Chapter 6 presents the concentration‐response curves of retinol, ATRA, 13‐cis‐
RA, 9‐cis‐RA, etretinate, acitretin and TTNPB in the ES‐D3 cell diﬀerentiation assay 
and compares the outcomes of their relative potencies with the relative potencies 
detected in two other in vitro assays for developmental toxicity (the limb bud 
micromass test and the rat postimplantation WEC test) and with the relative 
potencies in in vivo (mouse, rat and rabbit) developmental toxicity studies. The 
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results reveal that the potency ranking obtained in the ES‐D3 cell diﬀerentiation 
assay is similar to the reported potency rankings in the two other in vitro assays for 
developmental toxicity. TTNPB was the most potent retinoid, whereas etretinate 
and retinol had the lowest potency. ATRA, 13‐cis‐RA, 9‐cis‐RA and acitretin showed 
an intermediate potency. In vivo potency rankings of the developmental toxicity of 
retinoids appear to be dependent on the species and/or exposure regimens used. 
The obtained in vitro potency ranking did not completely correspond with the in 
vivo potency rankings, although TTNPB was correctly predicted to be the most 
potent and retinol the least potent congener. The diﬀerences between the kinetics 
in the ES‐D3 cell diﬀerentiation assay and the kinetic processes in vivo may explain 
the deviating potency predictions of some retinoids. Therefore, it was concluded 
that knowledge on species‐dependent chemical‐specific in vivo kinetics is essential 
when using in vitro toxicity data for the estimation of in vivo developmental 
toxicity potencies within series of related chemicals. 
In chapter 7, the reverse dosimetry approach was applied for the retinoid ATRA, 
translating the in vitro concentration‐response curve for the inhibition of ES‐D3 
cell diﬀerentiation into in vivo dose‐response curves, using a PBK model describing 
ATRA’s kinetics in rat and human. Whereas for the PBK models developed for the 
glycol ethers (chapter 5) kinetic data from in vivo studies were required to derive 
certain model parameter values (i.e. for clearance of the alkoxyacetic acid 
metabolites), the PBK model for ATRA was solely based on parameter values 
derived using in vitro techniques. Predictions of dose‐response curves for in vivo 
developmental toxicity were made by relating the toxic eﬀect to 1) the maximal 
concentration (Cmax) in blood, as was done before for the glycol ethers (chapter 5) 
and 2) the area under the concentration‐time curve (AUC) in blood. The predicted 
developmental toxicity dose levels of ATRA were closer to the in vivo rat data when 
predictions were based on relating the toxic eﬀect to the AUC, than when 
predictions were based on relating the toxic eﬀect to the Cmax. This is in line with 
results reported in the literature, showing that the developmental toxicity outcome 
of ATRA in vivo is best correlated with the dose metric AUC (Tzimas et al., 1997). 
The predicted dose‐response curves for rat were found to be in concordance 
(within one order of magnitude) with the developmental toxicity dose levels 
measured in diﬀerent in vivo rat developmental toxicity studies. It is important to 
stress that an essential addition of this study to the previous reverse dosimetry 
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work on glycol ethers (chapter 5) is, that no kinetic data from in vivo studies were 
needed to derive the model parameter values for the ATRA PBK model. This study 
thus provides the first proof‐of‐principle that in vivo dose‐response relationships 
for this systemic endpoint can be predicted using reverse dosimetry with a PBK 
model that was parameterized without in vivo data. The predicted dose‐response 
curves can be used to set points of departure for deriving safe exposure levels for 
humans, pointing at the potential of the approach as a tool in toxicological risk 
assessment strategies. 
 
General discussion 
The present thesis shows the proof‐of‐principle that in vitro concentration‐
response curves can be translated into predicted in vivo dose‐response curves using 
PBK modeling with a reverse dosimetry approach, which may increase the 
acceptance of the use of in vitro toxicity data in risk assessment practice. Using this 
approach, the important bottleneck that in vitro toxicity data for systemic 
endpoints can only be used qualitatively can be overcome, since the predicted  
dose‐response curves can be used quantitatively by determining points of 
departure for the risk assessment. Reverse dosimetry approaches have previously 
been used to translate a single in vitro eﬀect concentration (e.g. an EC50 value) into 
a single in vivo eﬀect dose (e.g. a lowest observed adverse eﬀect level (LOAEL)) 
(DeJongh et al., 1999; Verwei et al., 2006; Forsby and Blaauboer, 2007). However, 
the in vitro eﬀect concentrations and the in vivo eﬀect doses were arbitrarily chosen 
in these studies. By translating all data obtained in the in vitro experiment to the in 
vivo situation enables dose‐response modeling on the predicted in vivo dose‐
response data, defining a predicted in vivo dose‐response curve, which can be used 
in the risk assessment process. The present thesis has shown the feasibility of this 
approach for chemicals belonging to two groups of chemicals with diverse 
chemical properties and mechanisms of developmental toxicity, indicating that the 
approach may be feasible for chemicals of diverse nature.  
In the following sections, the possibilities and limitations of the use of in vitro‐in 
vivo extrapolations using PBK modeling with a reverse dosimetry approach for risk 
assessment are discussed. Recommendations for future research to further develop 
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and validate and ultimately implement the combined in vitro‐in silico approach are 
put forward. The topics to be specifically considered when discussing the results of 
the present thesis are 1) the choice of the in vitro assay for developmental toxicity, 
2) developments in the field of PBK modeling, 3) additional factors to be taken into 
account when translating in vitro concentrations into in vivo doses and 4) future 
perspectives and conclusions for the use of in vitro‐in vivo extrapolations using PBK 
modeling with a reverse dosimetry approach for risk assessment.  
The choice of an in vitro toxicity assay for developmental toxicity 
In the present thesis, the ES‐D3 cell diﬀerentiation assay of the EST was used as 
in vitro assay to determine in vitro toxic eﬀect concentrations for the endpoint 
developmental toxicity (Genschow et al., 2002; Genschow et al., 2004). The EST is 
the only validated in vitro assay for which no primary animal tissues are required. 
The validation study carried out by the European Centre for the Validation of 
Alternative Methods (ECVAM) showed consistency in the obtained toxic eﬀect 
concentrations for 20 chemicals in four diﬀerent laboratories (Genschow et al., 
2004), pointing at the reproducibility of the test system. The readout parameter in 
the ES‐D3 cell diﬀerentiation assay is the chemical‐induced inhibition of ES‐D3 cell 
diﬀerentiation into functional (contracting) cardiomyocytes. This readout 
parameter may be subjective and not representative for chemicals that induce 
malformations in the in vivo situation diﬀerent than those on the heart. Therefore, 
several studies have investigated the eﬀect of chemicals on other readouts in 
diﬀerentiating embryonic stem cells, such as on the expression of specific genes for 
neuronal diﬀerentiation (Stumann et al., 2007; Kuegler et al., 2010; Theunissen et 
al., 2010; Theunissen et al., 2011; Zimmer et al., 2011a; Zimmer et al., 2011b), 
osteoblast diﬀerentiation (Zur Nieden et al., 2010a; Zur Nieden et al., 2010b) or 
endothelial diﬀerentiation (Fesstag et al., 2007). These readouts may be useful to 
predict adverse eﬀects on specific developmental pathways, such as 
neurodevelopment, bone formation, or vasculogenesis and/or angiogenesis, 
respectively. Furthermore, it has been proposed that with transcriptome 
approaches the sensitivity of the embryonic stem cell‐based test system may 
possibly increase (Van Dartel et al., 2011). However, with the interpretation of 
toxicogenomic data, one must be aware that gene expression changes per se are not 
necessarily adverse. A change in gene expression may reflect an adaptation of the 
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cell or tissue to a situation, not resulting in an adverse eﬀect. Van Dartel et al. 
(2011) compared the eﬀect of the chemical flusilazole in the ‘classical’ ES‐D3 cell 
diﬀerentiation assay with the eﬀects of a 24‐hour exposure of diﬀerentiating ES‐D3 
cells to this chemical on gene expression changes. Although the sensitivity using 
the transcriptomic approach had slightly increased (Van Dartel et al., 2011), it is not 
straightforward to use the obtained concentration‐response curves for deriving 
adverse eﬀect concentrations, because, especially at low concentrations, the gene 
expression changes may reflect an adaptation of the cell, not resulting in adverse 
eﬀects. Since the chemical‐induced inhibition of ES‐D3 cell diﬀerentiation into 
functional cardiomyocytes is considered as adverse, the ‘classical’ ES‐D3 cell 
diﬀerentiation assay may provide relevant in vitro adverse eﬀect concentrations for 
reverse‐dosimetry, in order to predict in vivo toxic dose levels. Although the ES‐D3 
cell diﬀerentiation assay determines the concentrations of a chemical that inhibit 
cardiomyocyte diﬀerentiation, it was not intended in the present thesis to 
specifically predict dose levels aﬀecting cardiac development during embryonic 
development. The inhibition of cardiac diﬀerentiation was rather used to represent 
a sensitive in vitro readout parameters for developmental toxicity (Genschow et al., 
2004), which in the ideal situation could represent the most sensitive in vivo 
readout parameter for the endpoint developmental toxicity. One might argue that 
other developmental toxicity endpoints such as developmental neurotoxicity or 
developmental immunotoxicity might be less well predicted with the use of the in 
vitro eﬀect concentrations that inhibit cardiomyocyte diﬀerentiation. Therefore, for 
other developmental toxicity endpoints such as developmental neurotoxicity or 
developmental immunotoxicity, it should be assessed whether in vivo 
developmental toxicity dose levels are better predicted based on in vitro 
concentration‐response curves obtained in assays focusing on these specific 
endpoints (e.g. Breier et al., 2010; Mainali and Tew, 2004) than when dose levels are 
predicted based on in vitro concentration‐response curves obtained in the classical 
ES‐D3 cell diﬀerentiation assay. 
The in vitro assays for developmental toxicity described in the literature have 
varying levels of biological complexity, ranging from cellular assays (e.g. the ES‐D3 
cell diﬀerentiation assay or the limb bud micromass test) to WEC assays (e.g. the 
rat postimplantation WEC assay). If the developmental toxicant has an adverse 
eﬀect on specific cell types, the toxicity may not be detected in an in vitro test 
Summary, general discussion, future perspectives and conclusions 
212 
 
system in which these cells are absent. This would suggest that WEC assays, which 
are closer to the in vivo situation than cellular assays, would be better test systems 
to detect adverse eﬀects of a range of chemicals aﬀecting diﬀerent cell types and 
with diﬀerent modes of action (Piersma, 2004; Piersma, 2006). In addition, a 
battery of cellular assays covering the relevant cell types that can be aﬀected during 
development could be used to detect a developmental toxicant that might not be 
detected by a single cellular assay (Piersma, 2006). Instead of using cellular assays 
in which specific cell types are present, embryonic stem cells, which can be 
diﬀerentiated into a mix of relevant cell types, are useful to assess chemical‐
induced eﬀects on diﬀerent cell types, and on the diﬀerentiation into these 
diﬀerent cell types, using multiple readouts in one test system. Diﬀerentiating ES‐
D3 cells may be a useful tool to accomplish this, because although the readout in 
the classical ES‐D3 cell diﬀerentiation assay is the inhibition of ES‐D3 cell 
diﬀerentiation into contracting cardiomyocytes, cell types of all the three germ 
layers are present in these cultures (Doetschman et al., 1985; Toumadje et al., 
2003). 
To assess whether the three ECVAM‐validated in vitro developmental toxicity 
assays (the ES‐D3 cell diﬀerentiation assay, the limb bud micromass (MM) test, and 
the rat postimplantation WEC test), which have diﬀerent levels of biological 
complexity, diﬀer in their sensitivity to two of the developmental toxicants studied 
in the present thesis, MAA and ATRA, the reported eﬀect concentrations for these 
chemicals in these assays were compared. To this end, the averages of the reported 
EC50 values in the ECVAM validation studies (Genschow et al., 2004; Piersma et al., 
2004; Spielmann et al., 2004) were calculated (Table 1). Table 1 shows that these 
average EC50 values for MAA diﬀer at most 4‐fold between the assays. The average 
EC50 values for ATRA diﬀer almost up to 80‐fold between the assays (Table 1). At 
first sight, this may indicate large diﬀerences in the sensitivity of the test systems 
to ATRA and much smaller, if any, diﬀerences in the sensitivity of the test systems 
to MAA. However, a chemical can be more freely available in one test system 
compared with another, depending on the composition of the culture medium and 
the physico‐chemical properties of the chemical. This phenomenon may play a role 
in the large diﬀerences in the obtained nominal eﬀect concentrations for the 
hydrophobic ATRA.  
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The main factor that may influence the free fraction of a hydrophobic chemical 
in vitro is the percentage of serum that is present in the assay medium. The 
percentages serum applied in the three in vitro developmental toxicity assays are 
shown in Table 1. The solid phase microextraction (SPME) method as described in 
chapter 7 was used to determine the free fraction of a chemical in culture medium 
with increasing serum concentrations. This measurements show that with 
increasing serum percentages (v/v) in the medium, the free fraction of ATRA 
decreases (Figure 1). Diﬀerences in free fractions have to be taken into account in 
in vitro‐in vivo extrapolations, as discussed in chapter 7, but should also be 
considered when assessing diﬀerences in the sensitivity of in vitro test systems. The 
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Figure 1. Free fraction of ATRA in cell culture medium with increasing concentrations of serum. Data 
are obtained using SPME method described in chapter 7. 
graph presented in Figure 1 was used to determine the free EC50 values in the three 
assays (Table 1). These free EC50 values for ATRA in the three in vitro 
developmental toxicity assays now only diﬀer at maximum 19‐fold (Table 1), 
resulting in a 4‐fold decrease in relative diﬀerence, than when comparing nominal 
EC50 values. Still, the almost 20‐fold diﬀerence in the sensitivity of the test systems 
to ATRA remains large. Since the AUC is the dose metric that best correlates to the 
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developmental toxicity outcome of ATRA in vivo, in vitro AUC values can best be 
used in the comparison of assay sensitivity to ATRA. To this end, the free EC50 
values were multiplied with the assay times, in order to calculate in vitro EAUC50 
values (Daston et al., 2010). Comparison of these in vitro AUC values indicates that 
the diﬀerences in the sensitivity of the test systems are at maximum only 5‐fold 
(Table 1). Table 1 also presents the same analysis for MAA. Since it is reported that 
MAA does not bind to proteins (O’Flaherty et al., 1995), the free EC50 values are 
expected to be the same as the nominal EC50 values. Diﬀerences in the assay 
sensitivity to MAA increase 2‐fold to an overall diﬀerence of 8‐fold when the in 
vitro developmental toxicity outcomes are based on in vitro AUC values (Table 1). 
Altogether, these findings indicate that the three in vitro developmental toxicity 
assays generally have the same sensitivity to MAA and ATRA, when the 
developmental toxicity outcome is related to the in vitro Cmax for MAA and to the in 
vitro AUC for ATRA. Given that the ES‐D3 cell diﬀerentiation assay is the only 
validated in vitro developmental toxicity assay for which no primary animal tissues 
are required, it may be considered as the best available in vitro model for the 
largest contribution to the 3Rs of animal use in toxicological studies. 
To contribute even more to the 3Rs of animal use, serum‐free culture methods 
should be developed and implemented, as the use of serum requires high numbers 
of (fetal) calves (Jochems et al., 2002; Van der Valk et al., 2004). Recently, a serum‐
free culture method for ES‐D3 cells and ES‐D3 cell diﬀerentiation has been 
developed (Riebeling et al., 2011). Another advantage of serum‐free test systems is a 
better standardization, because batch‐to‐batch variation of serum can highly 
influence the outcome of the assay. Diﬀerentiation processes (e.g. of embryonic 
stem cells) are very sensitive to medium conditions, reflected by the fact that with 
certain batches of serum, ES‐D3 cells do not diﬀerentiate into functional 
cardiomyocytes (data not shown). Therefore, the development of serum‐free 
culture protocols for in vitro (developmental) toxicity assays is important for test 
system standardization to increase the reproducibility of test outcomes. However, 
FCS is an important source of proteins in culture medium, and one must be aware 
that the absence of proteins in test systems may also have limitations. For example, 
it was shown for ATRA that the presence of proteins is required for its 
solubilization and stabilization in culture medium, indicated by irreproducible 
results in in vitro studies if proteins were absent (Klaassen et al., 1999). Therefore, 
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serum free culture media should contain a certain amount of proteins to enable 
testing of hydrophobic and relatively unstable chemicals. 
Another aspect to consider in the choice of an in vitro assay is the origin of the 
biological material. Many of the cellular in vitro developmental toxicity assays are 
based on mouse embryonic stem cells (Chapter 2, Table 1). In theory, human 
embryonic stem cell‐based test systems may provide better predicted 
concentration‐response eﬀects for humans than the often used mouse embryonic 
stem cell‐based test systems. There may be possible interspecies diﬀerences in 
dynamics in these cell systems, although the impact of these interspecies 
diﬀerences in dynamics on the obtained eﬀect concentrations needs to be 
established. The ethical constraints and the relatively diﬃcult culture methods met 
with the use of human embryonic stem cells may hamper their application in 
testing strategies. Comparison of eﬀect concentrations of model compounds in 
human and mouse embryonic stem cell‐based test systems is needed in order to 
determine which test system would be the most appropriate to apply in a testing 
strategy to estimate toxic dose levels for humans using the reverse dosimetry 
approach. Furthermore, the comparison of these data may also be useful to get 
insight in interspecies diﬀerences, which may be useful for the extrapolation of 
toxicity data obtained in laboratory animals to humans in present risk assessment 
strategies. 
PBK model development 
The development of PBK models accurately describing in vivo kinetics is 
indispensable in the reverse dosimetry approach to translate in vitro concentration‐
response curves into in vivo dose‐response curves. PBK models are needed that 
reliably describe the in vivo kinetics. Development of these PBK models requires 
robust data for parameterization. Current PBK models often use chemical‐specific 
parameter values describing the ADME processes, determined using in vivo kinetic 
data (Rietjens et al., 2011). To limit the use of animals, in vitro and in silico 
approaches are preferred to determine these parameter values whenever possible. 
The parameter values for blood clearance of the toxic alkoxyacetic acid metabolites 
in the glycol ether PBK model needed to be determined using in vivo kinetic data 
(chapter 5). For the ATRA PBK model, all the kinetic model parameter values were 
determined using in vitro input data only. This was possible assuming that only 
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ATRA contributes to the developmental toxicity outcome, and that ATRA itself is 
only cleared by the liver. For a chemical for which information on the kinetics is 
lacking, the role of urinary (or biliary) clearance on the total clearance of the toxic 
moieties (parent compound and/or metabolite) is not known, indicating that these 
processes cannot beforehand be ignored.  
If PBK models should be built using parameter values obtained using in vitro/in 
silico methods, additional eﬀort in the development and evaluation of these 
methods is needed. Recently, an overview was made for the non‐animal based 
methods that are available for obtaining kinetic parameter values (Adler et al., 
2011). It was concluded that for most kinetic data, non‐animal based methods are 
available or present at an advanced development stage. However, no appropriate 
non‐animal based methods are available for predicting renal and biliary excretion 
(Adler et al., 2011). Therefore, the development of in vitro methods to estimate 
parameter values for renal and biliary clearance is of utmost importance. 
Furthermore, for the endpoint developmental toxicity, experimental models to 
estimate parameter values for placental transport of chemicals are of particular 
importance. Although the embryo levels of the chemicals used in the present thesis 
were reported to be close to the maternal blood levels, this is not necessarily the 
case for all chemicals. For certain chemicals, the placenta may acts as a barrier and 
aﬀect the concentrations that will be reached in the conceptus, and with that the 
developmental toxicity outcome of the chemical. The use of ex vivo perfused 
placenta studies may be useful for the estimation of these parameter values for 
placental transport. However, to carry out these studies, one is dependent on the 
availability of (fresh) human placentas, which is a limitation of the approach. Cell 
culture models studying transport of chemicals across human placental cell layers 
mimicking the placental barrier may provide an easier system to obtain PBK model 
parameter values for placental transport (Van der Aa et al., 1998). To enter the fetal 
circulation, chemicals need to cross a layer of trophoblast cells and the endothelial 
cells of the fetal blood vessels (Van der Aa et al., 1998).  Human choriocarcinoma 
(BeWo) cells representing the human trophoblast and human umbilical vein 
endothelial cells (HUVECs) representing the fetal endothelial barrier, can be 
cultured on transwell inserts, mimicking the placental barrier (Bode et al., 2006; 
Kazakoﬀ et al., 1995). These in vitro cell systems may be useful to provide PBK 
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model parameter values for placental transfer of chemicals, in order to predict fetal 
exposure levels. Furthermore, in silico models predicting placental transfer may be 
used to estimate parameter values for placental transfer of chemicals and resulting 
fetal exposure (Hewitt et al., 2007). 
Another aspect that needs further consideration in PBK model development is 
the eﬀect of repeated dosing on the in vivo kinetic characteristics. These eﬀects 
need to be incorporated in PBK models, when predictions are to be made for 
repeated chemical exposure, if chemical exposure aﬀects the expression levels of 
metabolizing enzymes. For glycol ethers, repeated dosing does not aﬀect their in 
vivo kinetics. Therefore, prediction of in vivo kinetics of glycol ethers upon 
repeated dosing was feasible with the developed PBK model, as shown in chapter 5. 
For ATRA however, biotransformation enzymes are induced upon exposure 
(Collins et al., 1995; Tay et al., 2010). It is therefore not possible to make predicted 
dose‐response curves for ATRA‐induced developmental toxicity after repeated 
dosing if the eﬀects of ATRA exposure on biotransformation enzyme expression 
levels are neglected. Therefore, only studies using single exposures were used for 
the evaluation of the predicted dose‐response curves for ATRA‐induced 
developmental toxicity in the present thesis (chapter 7). In order to make 
predictions for ATRA‐induced developmental toxicity after repeated dosing, the 
change in expression levels of metabolizing enzymes should be incorporated in the 
model, to account for resulting changes in hepatic clearance. These required input 
data for the model should preferably be obtained using in vitro techniques. 
However, at present, data obtained from induction studies of biotransformation 
enzymes (in for example hepatocytes) is only usable for qualitative considerations, 
whereas these studies are not suitable to make quantitative predictions for the in 
vivo situation (Coecke et al., 2006). This indicates that adequate in vitro models 
have to be further optimized and validated in order to make them suitable for 
making quantitative predictions on enzyme induction in the in vivo situation. 
A major limitation of the use of PBK models in risk assessment is that the 
development of PBK models is a labor‐ and time‐consuming process, and only 
applicable for data‐rich chemicals for specific PBK models. In order to accelerate 
the process of PBK model development, generic PBK models are being developed 
(e.g. in the European Framework Program ChemScreen project and the United 
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States Environmental Protection Agency (US EPA)’s ToxCast program) for which 
step 1 (definition of the conceptual model) and step 2 (translation of the conceptual 
model into a mathematical model by defining mathematical equations) are made 
generic for chemicals belonging to a specific chemical category, or even for 
chemicals of diverse nature that do not belong to a specific chemical category. In 
that case no conceptual and no mathematical model need to be developed, 
implicating that ‘only’ the appropriate chemical‐specific values for the model 
parameters defined in the generic PBK model need to be determined. Still, the 
determination of some model parameter values may be a labor‐ and time‐
consuming step. Therefore, the use of in silico modeling, such as quantitative 
structure activity relationship (QSAR) modeling should be considered for the 
prediction of model parameter values. At present in silico models are often used for 
the prediction of tissue:blood partition coeﬃcients for PBK models. For these 
predictions the LogP value of the chemical and sometimes information on the free 
fraction of the chemical in blood is needed (DeJongh et al., 1997; Poulin and Theil, 
2002; Berezhkovskiy, 2004). For very hydrophobic chemicals these in silico models 
may result in large overestimations in predicted tissue:blood partition coeﬃcients, 
as is the case for ATRA (data not shown). Therefore, the applicability domains of 
these in silico models should be taken into account and the potential of in silico 
modeling for estimating values for kinetic model parameters remains to be proven. 
Translation of in vitro concentrations into in vivo doses 
The translation of in vitro concentration‐response curves obtained in in vitro 
assays into in vivo dose‐response curves is not a straightforward process. Initially 
two important questions should be answered to be able to reliably predict in vivo 
dose‐response curves:  
Is the toxic outcome of chemical exposure related to the dose metric maximum 
concentration (Cmax), or to the dose metric area under the concentration‐time 
curve (AUC)? 
Is the toxic eﬀect resulting from chemical exposure caused by the parent 
compound itself and/or by (one of) its metabolite(s)? 
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Is the toxic outcome of chemical exposure related to the dose metric Cmax, or to the 
dose metric AUC?  
The extrapolation of the in vitro concentration‐response curves for the 
alkoxyacetic acid metabolites in the ES‐D3 cell diﬀerentiation assay to predicted 
dose‐response curves for in vivo developmental toxicity of the parent glycol ethers 
was based on relating the developmental toxicity outcome of these chemicals to 
the Cmax of the alkoxyacetic acid metabolites reached upon parent glycol ether 
exposure. This resulted in accurate predictions of in vivo dose‐response curves for 
the rat. For ATRA however, predicted dose‐response curves for in vivo 
developmental toxicity better corresponded to in vivo toxicity data when the toxic 
eﬀect was related to the dose metric AUC, than when the toxic eﬀect was related to 
the dose metric Cmax (Chapter 7). These findings for ATRA are in line with the 
study reported by Tzimas et al. (1997), who found a better correlation when 
correlating various in vivo developmental toxicity endpoints to the AUC 
(correlation coeﬃcients of 0.90‐0.98) than when correlating the in vivo 
developmental toxicity endpoints to the Cmax (correlation coeﬃcients of 0.22‐0.43).  
To predict in vivo developmental toxicity by relating the toxic eﬀects to the AUC, 
in vitro AUC values can be obtained by multiplying the applied in vitro eﬀect 
concentration with the assay time (Daston et al., 2010). It should be taken into 
account that the concentration of the test chemical in the exposure medium may 
not remain constant over time, resulting in overestimations of in vitro (calculated) 
AUC values (Figure 2). Therefore, the in vitro toxic potency may be underestimated 
and thus also the in vivo toxic potency, with the translation of the in vitro data to 
the in vivo situation. Furthermore, the sensitivity of the test system may not be 
constant during assay time either. This may especially be an issue in ‘dynamic 
assays’, such as the ES‐D3 cell diﬀerentiation assay, for which during the whole 
culture period (10 days) diﬀerent cell types with possible diﬀerences in sensitivity 
to chemicals are present. Theoretically, it may therefore be possible that for a 
certain chemical, the assay is sensitive from the start of the assay until day 10, 
whereas for a second or a third chemical the assay may be sensitive from the start 
of the assay until day 3 or day 5.  
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In the in vivo situation, the conceptus may also diﬀer in sensitivity to chemicals 
during diﬀerent developmental stages. Diﬀerences in sensitive periods in the in 
vitro ES‐D3 cell diﬀerentiation might reflect the sensitive periods in the in vivo 
developing conceptus. If so, the ES‐D3 cell diﬀerentiation assay might be used to 
predict sensitive periods of the conceptus to a chemical in the in vivo situation. Van 
Dartel et al. (2009) exposed diﬀerentiating ES‐D3 cells to varying test chemicals 
during diﬀerent time frames of the diﬀerentiation assay, to assess the eﬀect of the 
exposure period and exposure duration on cardiac diﬀerentiation. In general, it was 
shown that a longer exposure period resulted in lower observed eﬀect 
concentrations. For diﬀerent chemicals, diﬀerences in sensitive periods were 
observed, which may be related to diﬀerences in their modes of action (Van Dartel 
et al., 2009). 
In order to assess whether the toxic eﬀect of a chemical is best related to the Cmax 
or the AUC, or even another dose metric such as an AUC above a certain threshold, 
the eﬀect of exposure duration on the test outcome could be investigated. In a first 
attempt, this was done for MAA and ATRA in the ES‐D3 cell diﬀerentiation assay 
(Figure 3). To this end, EBs were exposed from day 3 for 4, 8, 24 or 48 hours to 1, 10 
or 100 mM MAA (Figure 3A) or to 1, 10 or 100 nM ATRA (Figure 3B). Figure 3 shows 
that MAA‐induced inhibition of ES‐D3 cell diﬀerentiation is hardly dependent on 
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Figure 2. Hypothetical concentration of test chemicals in the ES‐D3 cell diﬀerentiation assay for a 
chemical that is stable for the whole test duration (straight line) and for a chemical that is unstable 
(dashed line). Medium, including test chemical, is replaced at day 3 and day 5 of the assay. 
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the exposure duration, whereas the potency of ATRA clearly increases with longer 
exposure durations. This may indicate that MAA‐induced toxicity can be best 
related to the Cmax, whereas ATRA‐induced toxicity can be best related to the AUC. 
Performing the ES‐D3 cell diﬀerentiation assay by using varying exposure durations 
may therefore be useful to predict whether toxic eﬀects are related to the Cmax or to 
the AUC.  
Is the toxic eﬀect resulting from chemical exposure caused by the parent compound 
itself and/or by (one of) its metabolite(s)? 
The (toxic) eﬀect of a chemical may be caused by the parent chemical itself and/
or by (one of) its metabolite(s). Chemicals that cause developmental toxicity by 
(one of) their metabolite(s) are called proteratogens, which need to be bioactivated 
in order to induce toxicity. In in vitro test systems, the expression levels of 
biotransformation enzymes may be too low to convert the parent compound to a 
significant extent (Coecke et al., 2006). If this is the case, the parent compound will 
be less potent in the in vitro test system than its toxic metabolite(s). If for 
proteratogens the concentration‐response curve obtained for the parent chemical 
Chapter  8 
Figure 3. Eﬀect of exposure duration of MAA (A) and ATRA (B) on ES‐D3 cell diﬀerentiation into 
contracting cardiomyocytes. Cells were exposed to 1 mM MAA (A, white bars), 10 mM MAA (A, grey 
bars), 100 mM MAA (A, black bars), 1 nM ATRA (B, white bars), 10 nM ATRA (B, grey bars) or 100 nM 
ATRA (B, black bars). Exposure started when embryoid bodies (EBs) were cultured in petri dishes (day 
3) and lasted 4, 8, 24 or 48 h. 
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in the in vitro assay is translated into in vivo dose levels using reverse dosimetry, it 
can be expected that the predicted toxic doses are underestimating the in vivo 
potency of the chemical. An example of the implications of this underestimation of 
predicted developmental toxicity dose levels is shown in Figure 4 for the glycol 
ether EGME. It shows that the translation of the concentration‐response curve for 
MAA‐induced inhibition of ES‐D3 cell diﬀerentiation to the in vivo situation 
accurately predicts measured in vivo EGME‐induced developmental toxicity as 
reported in the literature. On the other hand, when the concentration‐response 
curve for EGME‐induced inhibition of ES‐D3 cell diﬀerentiation is translated to the 
in vivo situation, EGME’s developmental toxicity would be largely underestimated 
(Figure 4). This indicates that the in vivo developmental toxicity is caused by 
EGME’s metabolite MAA and not by EGME itself, as reported in the literature.  
Summary, general discussion, future perspectives and conclusions 
Figure 4. Predicted dose‐response curves for EGME‐induced developmental toxicity based on the 
translation of the concentration‐response curve for MAA‐induced (straight line) and EGME‐induced 
(dashed line) inhibition of ES‐D3 cell diﬀerentiation using PBK modeling with reverse dosimetry. The 
toxic outcome was related the dose metric Cmax of MAA and EGME, respectively. Data on MAA‐induced 
inhibition of ES‐D3 cell diﬀerentiation were taken from De Jong et al. (2009), whereas data on EGME‐
induced inhibition of ES‐D3 cell diﬀerentiation were taken from Verwei et al. (2006). The circles 
represent measured in vivo data on EGME‐induced developmental toxicity reported in the literature 
(Toraason et al., 1985). 
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The addition of a metabolic system may increase the in vitro potency, but may 
also decrease the potency of the proteratogen. Whether an increase or a decrease 
in the potency will be observed with the addition of a metabolic system is 
dependent on the overall outcome of bioactivation and detoxification reactions and 
the concentration of the toxic metabolite(s) achieved. Furthermore, the addition of 
cellular fractions as a bioactivation system can itself cause toxicity in cellular 
systems (Tan et al., 1982) and WECs (Luijten et al., 2008). To investigate whether a 
new chemical is expected to be a proteratogen, the metabolites formed may be 
identified (e.g., using hepatocytes in culture, or liver fractions (microsomes, S9) 
and co‐factors) and tested (e.g., the main metabolites) in the in vitro test system. 
The in vivo formation of the metabolites can be described in the PBK model, after 
which parent compound exposure levels resulting in in vivo developmental toxicity 
can be predicted using reverse dosimetry, as was done in the present thesis for the 
glycol ethers. Although metabolite identification (whether or not in combination 
with metabolite production and testing) is a standard procedure in the drug 
development process, this may be a too expensive and time‐consuming process to 
apply in testing strategies for REACH chemicals. 
 
Future perspectives and conclusions for the use of the combined in vitro‐in 
silico approach in risk assessment 
The present thesis provides the proof‐of‐principle that in vitro concentration‐
response curves can be converted into in vivo dose‐response curves for 
developmental toxicity, using PBK modeling with a reverse dosimetry approach. In 
order to increase the confidence of using the approach for risk assessment, more 
proof‐of‐principle studies with other chemicals for developmental toxicity and 
more studies for other endpoints are needed. At present, a few examples using 
reverse dosimetry for predicting in vivo toxicity are reported in the literature (Punt 
et al., 2011). Reverse dosimetry‐based predictions have been made for a limited 
number of chemicals for the toxicological endpoints acute and repeated dose 
toxicity, neurotoxicity, genotoxicity and developmental toxicity (Punt et al., 2011). 
Reverse dosimetry approaches using PBK modeling are also being used in the US 
EPA’s ToxCast program and the European Framework Program projects ESNATS 
and ChemScreen to predict in vivo eﬀect levels based on in vitro eﬀect 
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concentrations. As more examples of the proof‐of‐principle for other chemicals and 
other endpoints will be provided, it can be considered to apply the approach in 
testing strategies for toxicological risk assessment. All the more, because the 
approach fits well within the toxicity testing strategies as envisioned in the in 2007 
released report ‘Toxicity Testing in the 21st century: A Vision and a Strategy’ by the 
United States National Academy of Sciences (NAS) (NRC, 2007). This report 
envisions a future in which all routine toxicity testing will be conducted using in 
vitro assays by evaluating cellular responses on chemical exposure. In the newly 
proposed risk assessment strategy, it will be estimated based on in vitro models and 
PBK modeling at which exposure levels adverse cellular perturbations will occur in 
the in vivo situation (Andersen and Krewski, 2009). PBK modeling using a reverse 
dosimetry approach can highly contribute to these estimations. 
The present thesis used reverse dosimetry by translating a complete in vitro 
concentration‐response curve into a complete in vivo dose‐response curve using 
PBK models accurately describing the in vivo kinetics of the chemical of interest. 
The predicted dose‐response curves may be used to set points of departure for the 
risk assessment to determine acceptable daily intake values (ADIs). However, this 
approach using complex PBK models may be too time‐consuming to apply for all 
the chemicals that have not been evaluated yet, and may therefore not be suitable 
to use for all chemicals. Therefore, a pre‐selection of chemicals using simple 
generic PBK models as used in the ToxCast program may be used to identify the 
chemicals of highest concern to prioritize for further testing. The ToxCast program, 
initiated within the EPA, aims at the development of methods for prioritizing 
(environmental) chemicals for further screening and testing. In the approach used, 
the test chemical is tested in a battery of more than 500 in vitro test assays, after 
which the potency of the chemical in each positive assay is summarized using AC50 
(concentration at 50% of maximum activity) or lowest eﬀective concentration 
(LEC) values, depending on the type of concentration‐response data that have been 
collected for the assay. In vitro assays are performed to estimate hepatic metabolic 
clearance and plasma protein binding in humans. These in vitro kinetic data are 
incorporated in the generic PBK model used for the in vitro‐in vivo extrapolations 
to calculate a daily human oral dose, called the oral equivalent dose, that would be 
required to produce an in vivo blood concentration of the chemical equivalent to 
the in vitro AC50 or LEC value (Rotroﬀ et al., 2010; Wetmore et al., 2012). If data on 
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exposure levels are available, the estimated oral equivalent dose is compared with 
human oral exposure estimates to assess whether an in vivo eﬀect would be 
expected (Rotroﬀ et al., 2010; Wetmore et al., 2012). If so, these chemicals may 
become of priority for further risk assessment.  
The chemicals that would be prioritized for further risk assessment, could be 
assessed in more detail using reverse dosimetry with more refined in vitro toxicity 
assays and PBK models, as was done in the present thesis. These PBK models could 
be used to accurately predict in vivo toxic dose levels for sensitive individuals 
within the human population, by describing interindividual diﬀerences in kinetics 
in the model using Monte Carlo simulations (chapter 7). The predicted dose‐
response curves could be used to set points of departure to determine safe 
exposure levels. If PBK modeling with a reverse dosimetry approach, translating in 
vitro concentration‐response curves into in vivo dose‐response curves, would be 
used for human risk assessment, only human PBK models need to be developed, 
implicating that no uncertainty factor for interspecies diﬀerences in kinetics would 
be needed. If human interindividual diﬀerences in kinetics are incorporated in the 
PBK model (chapter 7), no uncertainty factor for these interindividual diﬀerences 
in kinetics need to be applied either. Furthermore, if the in vitro model used to 
determine the in vitro concentration‐response curves would be based on human 
cells instead of mouse cells, no uncertainty factor for interspecies diﬀerences in 
dynamics would be needed, leaving only the need for uncertainty factors 
accounting for human interindividual diﬀerences in dynamics. On the other hand, 
an uncertainty factor may be introduced for uncertainties in the accuracy of 
predicted dose‐response eﬀects using the reverse dosimetry approach. For the 
chemicals used in the present thesis, diﬀerences in predicted dose‐response eﬀects 
and dose‐response eﬀects measured in reported in vivo rat studies were within one 
order of magnitude, indicating that an uncertainty factor of 10 may be used for 
uncertainties in the predictions. However, more data are needed to determine an 
appropriate value for this uncertainty factor. 
In conclusion, the present thesis shows the feasibility of translating 
concentration‐response curves obtained in in vitro toxicity assays into predicted in 
vivo dose‐response curves, which can be used for risk assessment practice. The 
work presented in this thesis provides the first proof that in vivo developmental 
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toxicity dose levels can be accurately predicted by combining only in vitro toxicity 
data and in silico PBK modeling, using a reverse dosimetry approach. This work 
may therefore contribute to an increased acceptance and future implementation of 
in vitro toxicity data in risk assessment practice and may even be considered as the 
most important approach to achieve the objectives of the 3Rs of animal use in 
toxicological risk assessment. 
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Samenvatting 
Het doel van dit proefschrift is om het ‘proof‐of‐principle’ te verschaffen dat in 
vitro concentratie‐respons curves kunnen worden omgezet naar in vivo dosis‐
respons curves door gebruik te maken van fysiologisch gebaseerd kinetisch (PBK)‐
modelleren met een omgekeerde‐dosimetrie‐aanpak, om alternatieve methoden te 
verschaffen voor in vivo studies in de toxicologische risicobeoordeling. Als 
toxicologisch eindpunt voor deze proof‐of‐principle‐studie is ontwikkelings‐
toxicologie gekozen, omdat er geschat wordt dat meer dan een kwart van de 
verwachte aantallen dieren die nodig zijn voor de Europese REACH (Registratie, 
Evaluatie, Autorisatie en restrictie van CHemicaliën)‐wetgeving gebruikt zal 
worden voor dit type studies (Van der Jagt et al., 2004). Ook voor farmaceutica, 
voedseladditieven en pesticiden vereisen regelgevende instanties 
veiligheidsstudies, inclusief ontwikkelingstoxiciteitsstudies, in dieren. De 
toepassing van betrouwbare alternatieven voor in vivo ontwikkelings‐
toxiciteitsstudies zou daarom een significante bijdrage leveren aan de vervanging, 
vermindering en verfijning (3V’s) van diergebruik in de toxicologische 
risicobeoordeling. 
Hoofdstuk 1 van dit proefschrift geeft achtergrondinformatie waarmee het 
onderwerp wordt geïntroduceerd en definieert het doel van het proefschrift. Het 
beschrijft belangrijke factoren die nodig zijn om het concept te ontwikkelen 
waarbij in vitro concentratie‐respons curves worden vertaald naar voorspelde in 
vivo dosis‐respons curves voor ontwikkelingstoxiciteit, door gebruik te maken van 
PBK‐modellering met een omgekeerde‐dosimetrie‐aanpak. In het kort omvatten 
deze factoren 1) een in vitro model om in vitro concentratie‐respons curves voor 
ontwikkelingstoxiciteit te verkrijgen, 2) de selectie van de te bestuderen 
chemicaliën en 3) de ontwikkeling van PBK‐modellen die nodig zijn voor 
omgekeerde dosimetrie. 
Het in vitro model dat is gebruikt is de embryonale stamcel (ES‐D3 cel) 
differentiatietest van de gevalideerde embryonale stamceltest (EST) (Genschow et 
al., 2004). In deze assay wordt het effect van de stof van interesse op de 
differentiatie van ES‐D3 cellen naar functionele (contracterende) hartspiercellen 
vastgesteld. De door de chemicalie geïnduceerde remming van ES‐D3‐
celdifferentiatie is het in vitro eindpunt voor ontwikkelingstoxicitieit. De ES‐D3‐
celdifferentiatietest is de enige gevalideerde in vitro ontwikkelingstoxiciteitsassay 
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waarvoor geen primair dierweefsel nodig is (Genschow et al., 2002; Genschow et al., 
2004). Alternatieven voor in vivo ontwikkelingstoxiciteit die gebruik maken van 
deze in vitro assay zouden daarom resulteren in de grootste bijdrage aan de 3V’s 
van diergebruik voor het testen voor ontwikkelingstoxiciteit. 
Om het ‘proof‐of‐principle’ te verschaﬀen dat de verkregen in vitro concentratie‐
respons curves in de ES‐D3‐celdiﬀerentiatietest kunnen worden omgezet naar in 
vivo dosis‐respons curves, door gebruik te maken van PBK‐modellering met een 
omgekeerde‐dosimetrie‐aanpak, moesten geschikte modelstoffen worden 
geselecteerd die aan bepaalde criteria voldoen. Eerst werd een lijst chemicaliën 
samengesteld die aan twee criteria voldoen, welke zijn 1) de aanwezigheid van in 
vivo kinetische data van de stof in de literatuur, om het bouwen en/of evalueren 
van de PBK‐modellen mogelijk te maken, die ontwikkeld en gebruikt worden voor 
omgekeerde dosimetrie, en 2) de aanwezigheid van in vivo ontwikkelings‐
toxiciteitsdata van de stof in de literatuur, om te evalueren of de uiteindelijk 
voorspelde dosis‐respons curves voor ontwikkelingstoxiciteit in overeenstemming 
zijn met data verkregen in in vivo ontwikkelingstoxiciteitsstudies. Van deze lijst 
van geschikte chemicaliën werden alleen structureel verwante chemicaliën 
geselecteerd. Dit derde criterium maakte de beoordeling van de relatieve 
verschillen binnen een groep chemicaliën mogelijk, wat daarbij een extra 
mogelijkheid voor een kwalitatieve evaluatie van de voorspellingen verschaft. Twee 
series modelstoffen werden gelecteerd, welke zijn 1) een groep glycol ethers, die 
gebioactiveerd moeten worden om ontwikkelingstoxiciteit te veroorzaken, die 
hydrofiel zijn, een lage mate van eiwitbinding vertonen en een niet‐specifiek 
werkingsmechanisme hebben, en 2) een groep retinoïden, waarvan verscheidene 
stoffen direct werken als teratogenen zonder bioactivatie, die hydrofoob zijn, een 
hoge mate van eiwitbinding vertonen en die een specifiek werkingsmechanisme 
hebben. 
Om de in vitro concentratie‐respons curves verkregen in de ES‐D3‐
celdifferentiatietest te vertalen naar in vivo dosis‐respons curves met omgekeerde 
dosimetrie moesten PBK‐modellen worden ontwikkeld die de ADME (Absorptie, 
Distributie, Metabolisme en Excretie)‐processen van de stoffen van interesse 
beschrijven. Het proces van PBK‐modelontwikkeling is beschreven in hoofdstuk 1 
en kan worden opgedeeld in de volgende stappen: 1) het definiëren van een 
conceptueel model, 2) het vertalen van het conceptuele model naar een wiskundig 
model door het definiëren van wiskundige vergelijkingen, 3) het bepalen van de 
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waardes voor de modelparameters, 4) het oplossen van de wiskundige 
vergelijkingen met geschikte software en 5) het evalueren van de modelprestaties. 
Vervolgens kan het model worden gebruikt om voorspellingen te maken (stap 6), 
bijvoorbeeld om dosis‐afhankelijke verschillen in kinetiek tussen of binnen soorten 
te voorspellen, of, zoals gedaan is in dit proefschrift, om interne concentraties, 
ingesteld als input in het model, te vertalen naar voorspelde externe doses (dat wil 
zeggen omgekeerde dosimetrie). 
In hoofdstuk 2 worden in vitro testen gepresenteerd die zijn beschreven in de 
literatuur voor het eindpunt ontwikkelingstoxiciteit. Deze testen kunnen worden 
opgedeeld in 1) cellulaire testen die gebruik maken van primaire cellen of cellen 
van continue cellijnen, en 2) hele‐embryo‐kweek (WEC)‐testen. Er wordt een 
overzicht gegeven van de verscheidene uitleesparameters, variërend van 
veranderingen in gen‐ of eiwitexpressie tot celdood of in vitro malformaties, die 
zijn onderzocht in deze in vitro testen. Hoofdstuk 2 beschrijft ook hoe in vitro 
ontwikkelingstoxiciteitsdata zouden kunnen worden gebruikt volgens de literatuur 
om voorspellingen te maken voor de in vivo situatie. Dit kan op verschillende 
manieren worden gedaan: de in vitro data zou kunnen worden gebruikt om 1) de 
ontwikkelingstoxiciteitsklasse waartoe een stof behoort (bijvoorbeeld niet, zwak of 
sterk embryotoxisch) te voorspellen met behulp van een predictiemodel, 2) de 
relatieve ontwikkelingstoxiciteitspotentie te voorspellen van een stof gebaseerd op 
de in vitro effectconcentraties (meestal binnen een groep van structureel verwante 
chemicaliën), en 3) in vivo ontwikkelingstoxiciteitsdoses te voorspellen door in 
vitro effectconcentraties te vertalen naar in vivo effectdoses met gebruik van PBK‐
modellering. De voorspelling van in vivo ontwikkelingstoxiciteit gebaseerd op in 
vitro data kan om verschillende redenen worden over‐ of onderschat. Deze 
omvatten: 1) het gebrek aan, of de lage expressie van biotransformatie‐enzymen in 
in vitro testsystemen vergeleken met de in vivo situatie, 2) het mogelijke gebrek aan 
relevante cellen of weefsels in het in vitro testsysteem voor de in vivo waargenomen 
effecten, 3) het gebrek aan secundaire schadelijke effecten als gevolg van toxische 
effecten in de moeder of in de placenta, in het in vitro testsysteem en 4) het gebrek 
aan relevante kinetiekdata die nodig zijn om een PBK model te bouwen dat 
betrouwbaar de in vivo kinetiek beschrijft, voor de kwantitatieve extrapolatie van 
de in vitro effectconcentraties naar in vivo effectdoses. 
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De eerste groep chemicaliën die is geselecteerd om het ‘proof‐of‐principle’ te 
ontwikkelen om in vitro concentratie‐respons curves te vertalen naar in vivo dosis‐
respons curves door gebruik te maken van PBK‐modellering met omgekeerde 
dosimetrie, was een groep glycolethers. De gebruikte glycolethers waren ethyleen 
glycol monomethyl ether (EGME), ethyleen glycol monoethyl ether (EGEE), 
ethyleen glycol monobutyl ether (EGBE) en ethyleen glycol monophenyl ether 
(EGPE). De glycolethers worden in vivo vooral gemetaboliseerd naar hun 
alkoxyazijnzuurmetabolieten, welke respectievelijk methoxyazijnzuur (MAA), 
ethoxyazijnzuur (EAA), butoxyazijnzuur (BAA) en phenoxyazijnzuur (PAA) zijn, 
die verantwoordelijk worden geacht voor de ontwikkelingstoxiciteit van de 
glycolethers (ECETOC, 2005). In de validatiestudies van de EST en de rat 
postimplantatie WEC‐test werd aangetoond dat de toxische eﬀectconcentraties van 
MAA zich in de millimolair‐range bevinden. In vivo studies laten zien dat de piek‐
plasmaconcentraties van MAA bij doses die bij ratten en muizen in vivo 
ontwikkelingstoxiciteit geven, zich ook in de millimolair‐range bevinden (Sweeney 
et al., 2001). Gezien de hoge in vitro en in vivo eﬀectconcentraties van MAA en zijn 
zure aard, werd er gehypothetiseerd dat de door de alkoxyazijnzuurmetaboliet‐
geïnduceerde ontwikkelingstoxiciteit kan worden veroorzaakt door het induceren 
van een intracellulaire pH (pHi)‐afname van embryonale cellen, wat resulteert in een 
remming van de celgroei en celdifferentiatie, waardoor de embryonale ontwikkeling 
wordt verstoord. Om dit werkingsmechanisme van de alkoxyazijnzuurmetabolieten 
van de glycolethers verder te onderzoeken, werden de effecten van MAA op de pHi 
van ES‐D3 cellen en embryonale fibroblasten (Balb/c‐3T3 cellen) onderzocht in 
hoofdstuk 3 van dit proefschrift. In deze studie werden de chemicaliën 
acetazolamide (ACZ) en valproïnezuur (VPA) gebruikt als positieve controle, omdat 
voor deze stoffen een relatie tussen een chemisch‐geïnduceerde daling van de pHi 
van de conceptus en de veroorzaakte ontwikkelingstoxiciteit al eerder is vastgesteld 
in in vivo studies (Scott et al., 1990; Scott et al., 1997). De verkregen resultaten 
toonden aan dat MAA, ACZ en VPA een pHi‐afname veroorzaken bij concentraties 
die remming van ES‐D3 celdifferentiatie induceren, wat aangeeft dat de door deze 
stoffen veroorzaakte pHi‐afname is gerelateerd aan de remming van celdifferentiatie. 
Twee andere ontwikkelingstoxische stoffen, all‐trans‐retinoïnezuur en 5‐
fluorouracil, hebben geen invloed op de pHi van embryonale cellen bij concentraties 
die invloed hebben op de ES‐D3 celdifferentiatie, wat wijst op een ander 
werkingsmechanisme van deze stoffen, zoals ook beschreven staat in de literatuur 
(Collins and Mao, 1999; Shuey et al., 1994). MAA en ACZ induceerden een 
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concentratie‐afhankelijke remming van de ES‐D3 celdifferentiatie, die werd 
versterkt door amiloride, een remmer van de Na+/H+‐antiporter, wat een belangrijke 
rol voor de pHi in het ontwikkelingstoxiciteitsmechanisme van beide chemicaliën 
bevestigt. De resultaten die gepresenteerd zijn in hoofdstuk 3 geven aan dat een 
afname van de pHi waarschijnlijk de wijze is waarop de alkoxyazijnzuurmetabolieten 
van de glycolethers ontwikkelingstoxiciteit veroorzaken, en bevestigen de rol van de 
alkoxyazijnzuurmetabolieten in het ontwikkelingstoxiciteitsmechanisme van de 
moeder‐glycolethers. Bevestigd door dit werkingsmechanisme zijn de in vitro 
concentratie‐respons curves (hoofdstuk 4), die moeten worden omgezet naar in vivo 
dosis‐respons curves, gemaakt met de toxische azijnzuurmetabolieten in plaats van 
met de moeder‐gycolethers, in ogenschouw nemende dat latere PBK‐modellering 
(hoofdstuk 5) rekening zou houden met de bioactivatie van de gycolethers tot hun 
alkoxyazijnzuurmetabolieten. 
Hoofdstuk 4 presenteert de concentratie‐respons curves van MAA, EAA, BAA, 
PAA, EGME en EGEE in de ES‐D3 celdifferentiatietest en vergelijkt de uitkomsten 
met literatuurgegevens over de in vivo ontwikkelingstoxiciteitseffecten van EGME, 
EGEE, EGBE en EGPE in muizen. Alle geteste alkoxyazijnzuurmetabolieten van de 
glycolethers lieten een concentratie‐afhankelijke remming van 
hartspierceldifferentiatie zien waarbij MAA het meest potent was, gevolgd door 
respectievelijk EAA, BAA en PAA. Beide moeder‐glycolethers die werden getest 
(EGME en EGEE, tot 10 mM) remden de ES‐D3 celdifferentiatie niet, wat daarmee 
bevestigt dat de metabolieten de ontwikkelingstoxische stoffen in vivo zijn. De 
potenties van de alkoxyazijnzuurmetabolieten van de glycol ethers in de ES‐D3 
celdifferentiatietest werden vergeleken met de in vivo toxiciteit van de glycolethers 
in muizen. De potentierangschikking van de stoffen in de ES‐D3 celdifferentiatietest 
kwam overeen met de beschikbare in vivo gegevens over de potenties van de  
moeder‐glycolethers (EGME > EGEE > EGBE > EGPE). De relatieve verschillen 
tussen de potenties van de stoffen bleken geprononceerder in de in vivo studies dan 
in de ES‐D3 celdifferentiatietest. Een mogelijke verklaring voor dit verschil kan de 
afwezigheid van in vivo kinetische processen in het in vitro testsysteem zijn, 
waarvan bekend is dat deze verschillen in de in vivo situatie voor deze stoffen. 
Deze verschillen in in vivo kinetiek kunnen worden beschreven in PBK‐modellen 
die worden gebruikt voor de vertaling van de in vitro effectconcentraties naar in vivo 
effectdoses. Hoofdstuk 5 beschrijft de resultaten van de toepassing van deze 
omgekeerde‐dosimetrie‐aanpak voor de glycolethers EGME, EGEE, EGBE en EGPE 
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in de rat en de mens.  Een PBK model dat de kinetiek van de vier glycolethers en hun 
ontwikkelingstoxische alkoxyazijnzuurmetabolieten beschrijft in de rat en de mens 
werd ontwikkeld. De in vitro concentratie‐respons curves van deze metabolieten in 
de ES‐D3 celdifferentiatietest (Hoofdstuk 4) werden gebruikt als input in het PBK‐
model om in vitro concentratie‐respons curves te vertalen naar voorspelde in vivo 
dosis‐respons curves voor de toxiciteit van de moeder‐glycolethers in de rat en de 
mens. De voorspelde dosis‐respons curves voor ratten bleken in overeenstemming 
(binnen een orde van grootte) met de ontwikkelingstoxiciteitsdosisniveaus gemeten 
in verscheidene in vivo ontwikkelingstoxiciteitsstudies in de rat. De aldus verkregen 
resultaten in hoofdstuk 5 vormen het eerste ‘proof‐of‐principle’ dat in vitro 
concentratie‐respons curves kunnen worden omgezet naar in vivo dosis‐respons 
curves met behulp van PBK modellering met een omgekeerde‐dosimetrie‐aanpak, 
die geschikt zijn voor gebruik in de risico‐evaluatie. Daarom werd geconcludeerd dat 
deze aanpak, na verdere evaluatie, kan bijdragen aan een op wetenschap gebaseerde 
risicobeoordeling van chemische stoffen, door geen gebruik te maken van 
proefdieren, of slechts van kleine aantallen. 
De tweede groep chemicaliën die werd gebruikt om de betrouwbaarheid te 
beoordelen van het voorspellen van in vivo dosis‐respons curves voor 
ontwikkelingstoxiciteit met behulp van de omgekeerde‐dosimetrie‐aanpak, was een 
groep retinoïden. Retinoïden zijn chemicaliën die een chemische structuur of 
functionele eigenschappen hebben die vergelijkbaar zijn met die van retinol 
(vitamine A). De onderzochte retinoïden zijn retinol, all‐trans‐retinoïnezuur 
(ATRA), 13‐cis‐retinoïnezuur (13‐cis‐RA), 9‐cis‐retinoïnezuur (9‐cis‐RA), etretinaat, 
acitretine en TTNPB ((E) ‐4 [2 ‐ (5,6,7,8‐tetrahydro‐5,5,8,8‐tetramethyl‐2‐
naftalenyl)‐1‐propenyl] benzoëzuur). Voor een normale embryogenese moeten de 
juiste niveaus van vitamine A worden gehandhaafd, terwijl een vitamine A‐tekort en 
een hoge retinoïdeninname schadelijke effecten kan veroorzaken aan de 
ontwikkelende conceptus (Collins en Mao, 1999). Van verscheidene retinoïden is 
aangetoond dat ze teratogeen zijn in een aantal proefdieren, waaronder muizen, 
ratten, cavia's, hamsters, konijnen, honden, varkens, kippen en apen (Collins en 
Mao, 1999). Van retinoïden is eerder laten zien dat ze actief zijn in de nanomolaire 
tot micromolaire range in de ‘limb bud micromass’‐kweektest (Kistler, 1987), wat de 
grotere in vitro potentie van deze stoffen in vergelijking met de 
alkoxyazijnzuurmetabolieten van de glycolethers laat zien. Verder is het 
mechanisme van retinoïden‐geïnduceerde ontwikkelingstoxiciteitseffecten 
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complexer (verstoring van de intracellulaire retinoïde‐signaaltransductie‐pathways 
(Collins en Mao, 1999) dan het waarschijnlijk niet‐specifieke ontwikkelings‐
toxiciteitsmechanisme van de glycolethers (inductie van pHi‐afname).  
Hoofdstuk 6 presenteert de concentratie‐respons curves van retinol, ATRA,  
13‐cis‐RA, 9‐cis‐RA, etretinaat, acitretine en TTNPB in de ES‐D3 celdifferentiatietest 
en vergelijkt de uitkomsten van hun relatieve potenties met de relatieve potenties 
die zijn gevonden in twee andere in vitro testen voor ontwikkelingstoxiciteit (de 
limb bud micromass‐kweektest en de rat postimplantatie WEC‐test) en met de 
relatieve potentie in in vivo (muis, rat en konijn) ontwikkelingstoxiciteitsstudies. De 
resultaten laten zien dat de potentieranking verkregen in de ES‐D3 
celdifferentiatietest vergelijkbaar is met de potentierankings zoals gerapporteerd 
voor de twee andere in vitro testen voor ontwikkelingstoxiciteit. TTNPB was de 
meest potente retinoïde, terwijl etretinaat en retinol de laagste potentie hadden. 
ATRA, 13‐cis‐RA, 9‐cis‐RA en acitretine toonden een gemiddelde potentie. In vivo 
potentierankings van de ontwikkelingstoxiciteit van retinoïden lijken afhankelijk te 
zijn van de diersoort en / of de gebruikte blootstellingsregimes. De verkregen in 
vitro potentieranking komt niet volledig overeen met de in vivo potentieranking, 
maar TTNPB werd correct als de meest potente en retinol als de minst potente 
congeneer voorspeld. De verschillen tussen de kinetiek van de ES‐D3 
celdifferentiatietest en de kinetische processen in vivo zouden de afwijkende 
potentievoorspellingen voor sommige retinoïden kunnen verklaren. Daarom werd 
geconcludeerd dat kennis van soort‐afhankelijke stof‐specifieke in vivo kinetiek van 
essentieel belang is bij het gebruik van in vitro toxiciteitsgegevens voor de schatting 
van in vivo ontwikkelingstoxiciteitspotenties binnen reeksen van verwante 
chemicaliën. 
In hoofdstuk 7 werd de omgekeerde‐dosimetrie‐aanpak toegepast voor de 
retinoïde ATRA, door de in vitro concentratie‐respons curve voor de remming van 
ES‐D3 celdifferentiatie te vertalen naar in vivo dosis‐respons curves, met behulp van 
een PBK model dat de kinetiek van ATRA beschrijft voor de rat en de mens. Terwijl 
voor de PBK‐modellen ontwikkeld voor de glycolethers (hoofdstuk 5) kinetische 
gegevens van in vivo studies nodig waren voor het afleiden van bepaalde 
modelparameterwaarden (d.w.z. voor de klaring van de alkoxyazijnzuur‐
metabolieten), was het PBK‐model voor ATRA uitsluitend gebaseerd op 
parameterwaarden afgeleid met behulp van in vitro technieken. Voorspellingen van 
de dosis‐respons curves voor in vivo ontwikkelingstoxiciteit werden gemaakt door 
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het toxische effect te relateren aan 1) de maximale concentratie (Cmax) in het bloed, 
zoals eerder gedaan voor de glycolethers (hoofdstuk 5) en 2) de oppervlakte onder de 
concentratie‐tijd curve (AUC) in het bloed. De voorspelde 
ontwikkelingstoxiciteitsdoses voor ATRA waren dichter bij de in vivo rat data 
wanneer voorspellingen waren gebaseerd door het toxische effect te relateren aan de 
AUC, dan wanneer voorspellingen waren gebaseerd door het toxische effect te 
relateren aan de Cmax. Dit is in overeenstemming met resultaten uit de literatuur, 
waaruit blijkt dat de effecten op de ontwikkelingstoxiciteitsuitkomst van ATRA in 
vivo het best is gecorreleerd met de dosismetriek AUC (Tzimas et al., 1997). De 
voorspelde dosis‐respons curves voor ratten bleken in overeenstemming (binnen 
een orde van grootte) met ontwikkelingstoxiciteitsdosisniveaus gemeten in 
verscheidene in vivo ontwikkelingstoxiciteitsstudies in de rat. Het is belangrijk om 
te benadrukken dat een essentiële aanvulling van deze studie op het eerdere 
omgekeerde‐dosimetrie‐werk aan de glycolethers (hoofdstuk 5) is, dat er geen 
kinetische gegevens van in vivo studies nodig waren voor het afleiden van de 
modelparameterwaarden voor het PBK‐model van ATRA. Deze studie verschaft dus 
het eerste  ‘proof‐of‐principle’ dat in vivo dosis‐respons‐relaties voor dit systemische 
eindpunt kunnen worden voorspeld met behulp van omgekeerde dosimetrie met 
een PBK model dat is geparameterizeerd zonder in vivo gegevens. De voorspelde 
dosis‐respons curves kunnen worden gebruikt om startpunten vast te stellen voor 
het afleiden van veilige blootstellingsniveaus voor de mens, wat wijst op de 
mogelijkheden van de aanpak als een instrument in toxicologische 
risicobeoordelingsstrategieën. 
 
Toekomstperspectieven en conclusies voor het gebruik van de 
gecombineerde in vitro‐in silico aanpak in de risicobeoordeling 
Dit proefschrift verschaft het ‘proof‐of‐principle’ dat in vitro concentratie‐respons 
curves kunnen worden omgezet naar in vivo dosis‐respons curves voor 
ontwikkelingstoxiciteit, met behulp van fysiologisch gebaseerd kinetisch (PBK)‐
modelleren met een omgekeerde‐dosimetrie‐aanpak. Om het vertrouwen van het 
gebruik van de aanpak voor de risico‐evaluatie te verhogen, zijn meer ‘proof‐of‐
principle’‐studies met andere ontwikkelingstoxische stoffen en meer onderzoeken 
naar andere eindpunten nodig. Op dit moment zijn een aantal voorbeelden van het 
voorspellen van in vivo toxiciteit met behulp van omgekeerde dosimetrie 
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gerapporteerd in de literatuur (Punt et al., 2011). Voor een beperkt aantal 
chemicaliën zijn voorspellingen gebaseerd op omgekeerde dosimetrie voor de 
toxicologische eindpunten acute en herhaalde blootstellingstoxiciteit, 
neurotoxiciteit, genotoxiciteit en ontwikkelingstoxiciteit gemaakt (Punt et al., 2011). 
Omgekeerde‐dosimetrie‐benaderingen met behulp van PBK‐modellen worden ook 
gebruikt in het ToxCast‐programma van de ‘Environmental Protection 
Agency’ (EPA) van de Verenigde Staten en in de Europese 
kaderprogrammaprojecten ‘ESNATS’ en ‘ChemScreen’ om in vivo effectdoses te 
voorspellen op basis van in vitro effectconcentraties. Naarmate er meer voorbeelden 
van het ‘proof‐of‐principle’ voor andere chemicaliën en andere eindpunten zullen 
worden verstrekt, kan het worden overwogen om de aanpak toe te passen in 
teststrategieën voor toxicologische risico‐evaluaties. Des te meer omdat de aanpak 
goed binnen de toxiciteitsteststrategieën past zoals voorzien in het in 2007 
uitgebrachte rapport 'Toxiciteitstesten in de 21e eeuw: een visie en een strategie’ door 
de Amerikaanse ‘National Academy of Sciences’ (NAS) (NRC, 2007). Dit rapport 
voorziet een toekomst waarin alle routine toxiciteitstesten met behulp van in vitro 
testen zullen worden uitgevoerd, door het evalueren van cellulaire reacties op 
blootstelling aan chemicaliën. In de nieuw voorgestelde risico‐evaluatie‐strategie, 
zal op basis van in vitro modellen en PBK‐modelleren worden geschat bij welke 
blootstellingsniveaus schadelijke cellulaire verstoringen zullen optreden in de in 
vivo situatie (Andersen en Krewski, 2009). PBK‐modelleren met behulp van een 
omgekeerde‐dosimetrie‐aanpak kan een belangrijke bijdrage leveren aan deze 
schattingen. 
Dit proefschrift gebruikt omgekeerde dosimetrie door het vertalen van een 
complete in vitro concentratie‐respons curve naar een complete in vivo dosis‐
respons curve met PBK‐modellen die nauwkeurig de in vivo kinetiek beschrijven van 
de stof van interesse. De voorspelde dosis‐respons curves kunnen worden gebruikt 
om startpunten vast te stellen voor de risicobeoordeling om aanvaardbare dagelijkse 
inname (ADI)‐waarden te bepalen. De aanpak met behulp van complexe PBK‐
modellen kan echter te tijdrovend zijn om toe te passen voor alle chemicaliën die 
nog niet zijn geëvalueerd, en kan daarom niet geschikt zijn om te gebruiken voor alle 
chemicaliën. Daarom zou een voorselectie van chemicaliën kunnen worden gemaakt 
met behulp van eenvoudige algemene PBK‐modellen zoals gebruikt in ToxCast, om 
chemicaliën van de grootste zorg te identificeren die verder onderzocht moeten 
worden. Het ToxCast programma, geïnitieerd binnen de EPA, richt zich op de 
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ontwikkeling van methoden om (milieu‐)chemicaliën voor verdere screening en 
testen te prioriteren. In de gebruikte aanpak wordt de teststof getest in een batterij 
van meer dan 500 in vitro testen, waarna de potentie van de stof in elke positieve test 
wordt samengevat met behulp van de waarden voor de AC50 (concentratie op 50% 
van de maximale activiteit) of de laagste effectieve concentratie (LEC), afhankelijk 
van het type concentratie‐respons gegevens dat verzameld is in de test. Daarnaast 
worden in vitro testen uitgevoerd om hepatische metabole klaring en plasma‐
eiwitbinding bij mensen te schatten. Deze in vitro kinetische gegevens worden 
opgenomen in het algemene PBK‐model voor de in vitro‐in vivo extrapolaties om 
een dagelijkse humane orale toediening te berekenen die nodig zou zijn om een in 
vivo bloedspiegel van de stof te bereiken die gelijk is aan de in vitro AC50‐ of LEC‐
waarde, welke de orale equivalente dosis wordt genoemd (Rotroff et al., 2010; 
Wetmore et al., 2012). Indien gegevens over blootstelling beschikbaar zijn, wordt de 
geschatte orale equivalente dosis vergeleken met de geschatte menselijke orale 
blootstelling om te beoordelen of een in vivo effect kan worden verwacht (Rotroff et 
al., 2010; Wetmore et al., 2012). Als dat zo is, kunnen deze stoffen worden 
geprioriteerd voor verdere risicobeoordeling. 
De chemicaliën die zouden worden geprioriteerd voor verdere risico‐evaluatie, 
zouden in groter detail kunnen worden beoordeeld met behulp van omgekeerde 
dosimetrie met meer verfijnde in vitro toxiciteitstesten en PBK‐modellen, zoals 
beschreven in dit proefschrift. Deze PBK‐modellen kunnen worden gebruikt om 
nauwkeurig in vivo toxische doses te voorspellen voor de gevoelige individuen 
binnen de menselijke bevolking, door het beschrijven van interindividuele 
verschillen in kinetiek in het model met behulp van Monte Carlo‐simulaties 
(hoofdstuk 7). De voorspelde dosis‐respons curves kunnen worden gebruikt om 
startpunten vast te stellen om veilige blootstellingsniveaus te bepalen. Als PBK‐
modelleren met een omgekeerde‐dosimetrie‐aanpak, waarbij in vitro concentratie‐
respons curves worden vertaald naar in vivo dosis‐respons curves, zou worden 
gebruikt voor menselijke risico‐evaluaties, hoeven alleen PBK‐modellen voor de 
mens te worden ontwikkeld, wat impliceert dat er geen onzekerheidsfactor voor 
verschillen in kinetiek tussen soorten nodig zou zijn. Als de menselijke 
interindividuele verschillen in kinetiek worden opgenomen in het PBK‐model 
(hoofdstuk 7), zou er ook geen onzekerheidsfactor voor deze interindividuele 
verschillen in kinetiek hoeven worden toegepast. Als het in vitro model voor het 
bepalen van in vitro concentratie‐respons curves zou zijn gebaseerd op menselijke 
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cellen in plaats van muizencellen, zou bovendien geen onzekerheidsfactor voor 
verschillen in dynamiek tussen soorten nodig zijn, zodat alleen 
onzekerheidsfactoren voor menselijke interindividuele verschillen in dynamiek 
nodig zouden zijn. Aan de andere kant zou een onzekerheidsfactor kunnen worden 
ingevoerd voor onzekerheid in de nauwkeurigheid van voorspelde dosis‐respons 
effecten bij de omgekeerde‐dosimetrie‐benadering. Voor de chemicaliën die zijn 
gebruikt in dit proefschrift verschillen de voorspelde dosis‐respons‐effecten en de 
dosis‐respons effecten gemeten in gerapporteerde in vivo studies in ratten minder 
dan een orde van grootte, wat aangeeft dat een onzekerheidsfactor van 10 zou 
kunnen worden gebruikt voor onzekerheden in de voorspellingen. Er zijn echter 
meer gegevens nodig om een geschikte waarde voor deze onzekerheid te bepalen. 
Al met al toont dit proefschrift aan dat het haalbaar is om concentratie‐respons 
curves verkregen in in vitro toxiciteitstesten te vertalen naar voorspelde in vivo  
dosis‐respons curves, welke kunnen worden gebruikt in de risicobeoordeling. Het 
gepresenteerde werk in dit proefschrift levert het eerste bewijs dat in vivo 
ontwikkelingstoxiciteitsdoses nauwkeurig kunnen worden voorspeld door het 
combineren van enkel in vitro toxiciteitsgegevens en in silico PBK‐modellering, door 
gebruik te maken van een omgekeerde‐dosimetrie‐aanpak. Dit werk kan daarom 
bijdragen aan een verhoogde acceptatie en de toekomstige implementatie van in 
vitro toxiciteitsgegevens in de risicobeoordeling en kan zelfs worden beschouwd als 
de belangrijkste aanpak om de doelstellingen van de 3 V's van diergebruik in de 
toxicologische risicobeoordeling te bereiken. 
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